{"questions": [{"body": "Which oncogene somatic mutations are associated to in situ carcinoma evolution from colonic polyp adenomas?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/26833333/", "https://pubmed.ncbi.nlm.nih.gov/31094930/", "https://pubmed.ncbi.nlm.nih.gov/26301800/", "https://pubmed.ncbi.nlm.nih.gov/11521199/", "https://pubmed.ncbi.nlm.nih.gov/25198510/", "https://pubmed.ncbi.nlm.nih.gov/23912084/", "https://pubmed.ncbi.nlm.nih.gov/26759717/", "https://pubmed.ncbi.nlm.nih.gov/31364747/", "https://pubmed.ncbi.nlm.nih.gov/8634779/", "https://pubmed.ncbi.nlm.nih.gov/19525976/"], "ideal_answer": "The most commonly associated oncogene somatic mutations in the evolution of in situ carcinoma from colonic polyp adenomas are mutations in the APC (adenomatous polyposis coli) gene and the KRAS gene. Mutations in the APC gene are early events in the adenoma-carcinoma sequence, leading to dysregulated Wnt signaling and increased cell proliferation. KRAS mutations, on the other hand, occur later in the progression to carcinoma and are associated with increased cell survival and resistance to apoptosis.", "exact_answer": [["KRAS"], ["BRAF"], ["PIK3CA"]], "type": "list", "id": "65f772d3c4010b4d78000022", "snippets": [{"offsetInBeginSection": 674, "offsetInEndSection": 813, "text": "We found deletions and translocations with NHEJ and alt-EJ signature as the dominant SV types, and 16% of deletions were complex deletions.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26833333/", "endSection": "abstract"}, {"offsetInBeginSection": 1374, "offsetInEndSection": 1536, "text": "Among the 44 samples with aberrant PTEN expression, 8 harbored PTEN somatic mutations, which were characterized by random distribution without hotspot clustering.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/31094930/", "endSection": "abstract"}, {"offsetInBeginSection": 446, "offsetInEndSection": 554, "text": "We collected NSCLC samples resected from self-reported AAs in five sites from Tennessee, Michigan, and Ohio.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/26301800/", "endSection": "title"}, {"offsetInBeginSection": 1280, "offsetInEndSection": 1639, "text": "Intriguingly, some of them are localized within chromosomal regions where recurrent, cytogenetically detectable mutations are seen in specific neoplasias, such as neuroblastoma, uterine leyomioma, mucoepidermoid carcinoma of the salivary glands and hemangiopericytoma, or where mutations causing inherited genetic diseases map, such as Peutz-Jeghers syndrome.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/11521199/", "endSection": "abstract"}, {"offsetInBeginSection": 480, "offsetInEndSection": 606, "text": "Similar numbers of somatic mutations were identified in PanINs and tumors, but the mutational load varied greatly among cases.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23912084/", "endSection": "abstract"}, {"offsetInBeginSection": 607, "offsetInEndSection": 702, "text": "Ten of the 15 isolated PanINs shared more than 50% of somatic mutations with associated tumors.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23912084/", "endSection": "abstract"}, {"offsetInBeginSection": 703, "offsetInEndSection": 836, "text": "Mutations common to tumors and clonally related PanIN2 and PanIN3 lesions were identified as genes that could promote carcinogenesis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23912084/", "endSection": "abstract"}, {"offsetInBeginSection": 837, "offsetInEndSection": 952, "text": "KRAS and TP53 frequently were altered in PanINs and tumors, but few other recurrently modified genes were detected.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23912084/", "endSection": "abstract"}, {"offsetInBeginSection": 953, "offsetInEndSection": 1022, "text": "Mutations in DNA damage response genes were prevalent in all samples.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23912084/", "endSection": "abstract"}, {"offsetInBeginSection": 257, "offsetInEndSection": 529, "text": "Although copy number alterations and somatic point mutations associated with the development of ESCC have been identified by array-based technologies and genome-wide studies, the genomic characterization of ESCCs from different stages of the disease has not been explored.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26759717/", "endSection": "abstract"}]}, {"body": "What medications were tested in the COSMIC-313 trial?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/36239611/"], "ideal_answer": "The medications tested in the COSMIC-313 trial were cabozantinib, nivolumab, and ipilimumab.", "exact_answer": [["cabozantinib"], ["nivolumab"], ["ipilimumab"]], "type": "list", "id": "65d140e71930410b1300003f", "snippets": [{"offsetInBeginSection": 258, "offsetInEndSection": 498, "text": "The first results presented at the 2022 European Society of Medical Oncology Congress are a milestone for the renal cell carcinoma field because they signal the advent of triplet combinations as potential treatment options for our patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36239611/", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 611, "text": "The present commentary highlights some considerations and potential next steps based on these first impressions.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36239611/", "endSection": "abstract"}]}, {"body": "What is the most common surgical treatment for hydrocephalus?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37635509/", "https://pubmed.ncbi.nlm.nih.gov/35400657/", "https://pubmed.ncbi.nlm.nih.gov/37948620/", "https://pubmed.ncbi.nlm.nih.gov/37877951/", "https://pubmed.ncbi.nlm.nih.gov/37695368/", "https://pubmed.ncbi.nlm.nih.gov/38157528/", "https://pubmed.ncbi.nlm.nih.gov/37935949/", "https://pubmed.ncbi.nlm.nih.gov/37604205/", "https://pubmed.ncbi.nlm.nih.gov/37615106/", "https://pubmed.ncbi.nlm.nih.gov/35353205/"], "ideal_answer": "The most common surgical treatment for hydrocephalus is ventriculoperitoneal (VP) shunt placement. This procedure involves the insertion of a catheter into the ventricles of the brain to divert excess cerebrospinal fluid (CSF) into the peritoneal cavity, where it can be absorbed by the body.", "exact_answer": [["The most common surgical treatment for hydrocephalus is ventriculoperitoneal (VP) shunt placement."]], "type": "factoid", "id": "65f85ec7c4010b4d78000052", "snippets": [{"offsetInBeginSection": 624, "offsetInEndSection": 803, "text": "Forty-five patients with hydrocephalus were operated for extra-axial trans-lamina terminalis third ventriculostomy with multiple cisternostomies from January 2017 to January 2019.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37635509/", "endSection": "abstract"}, {"offsetInBeginSection": 1473, "offsetInEndSection": 1626, "text": "Extra-axial trans-lamina terminalis ventriculostomy with cisternostomies can safely be performed using minimally invasive micro-neurosurgical techniques.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37635509/", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 257, "text": "Various complications associated with shunt surgery require long-term care.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35400657/", "endSection": "abstract"}, {"offsetInBeginSection": 395, "offsetInEndSection": 511, "text": "The most common complication that can occur as a result of shunt surgery is obstruction of the ventricular catheter.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35400657/", "endSection": "abstract"}, {"offsetInBeginSection": 638, "offsetInEndSection": 749, "text": "A further measure would include preventing the ventricular catheter from being pulled out as the skull expands.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35400657/", "endSection": "abstract"}, {"offsetInBeginSection": 750, "offsetInEndSection": 821, "text": "The next common complication is obstruction of the peritoneal catheter.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35400657/", "endSection": "abstract"}, {"offsetInBeginSection": 822, "offsetInEndSection": 955, "text": "The risk of occlusion can be reduced by making that the tip of the peritoneal catheter is open-ended as opposed to having side slits.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35400657/", "endSection": "abstract"}, {"offsetInBeginSection": 956, "offsetInEndSection": 1070, "text": "Isolated ventricles and slit ventricle syndrome are peculiar shunt-related conditions that are difficult to treat.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35400657/", "endSection": "abstract"}, {"offsetInBeginSection": 1071, "offsetInEndSection": 1244, "text": "When shunt dysfunction occurs, hydrocephalus can progress slowly, but in many cases the patient's condition deteriorates rapidly and requires immediate medical intervention.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35400657/", "endSection": "abstract"}, {"offsetInBeginSection": 1245, "offsetInEndSection": 1447, "text": "Recently, neuroendoscopic surgery has been actively performed for cases of shunt dysfunction and prophylactic replacement of peritoneal catheters, and attempts have been made to remove the shunt device.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35400657/", "endSection": "abstract"}]}, {"body": "Explain the difference between eosinophilic esophagitis and reflux-induced esophagitis.", "documents": ["https://pubmed.ncbi.nlm.nih.gov/33103406/", "https://pubmed.ncbi.nlm.nih.gov/25732414/", "https://pubmed.ncbi.nlm.nih.gov/23461842/", "https://pubmed.ncbi.nlm.nih.gov/24382218/", "https://pubmed.ncbi.nlm.nih.gov/28194801/", "https://pubmed.ncbi.nlm.nih.gov/29086329/", "https://pubmed.ncbi.nlm.nih.gov/26039722/", "https://pubmed.ncbi.nlm.nih.gov/35149653/", "https://pubmed.ncbi.nlm.nih.gov/24957264/", "https://pubmed.ncbi.nlm.nih.gov/18928689/"], "ideal_answer": "Eosinophilic esophagitis (EoE) is a chronic immune-mediated disorder characterized by eosinophilic inflammation in the esophagus, often triggered by food allergies or environmental factors. Reflux-induced esophagitis, also known as gastroesophageal reflux disease (GERD), is caused by the backward flow of stomach acid into the esophagus, leading to inflammation and damage to the esophageal mucosa. While both conditions can cause similar symptoms such as heartburn and difficulty swallowing, EoE is primarily driven by an allergic response, whereas GERD is primarily caused by the reflux of stomach acid.", "exact_answer": "Eosinophilic esophagitis (EoE) is a chronic immune-mediated disorder characterized by eosinophilic inflammation in the esophagus, often triggered by food allergies or environmental factors. Reflux-induced esophagitis, also known as gastroesophageal reflux disease (GERD), is caused by the backward flow of stomach acid into the esophagus, leading to inflammation and damage to the esophageal mucosa. While both conditions can cause similar symptoms such as heartburn and difficulty swallowing, EoE is primarily driven by an allergic response, whereas GERD is primarily caused by the reflux of stomach acid.", "type": "summary", "id": "65f1d021c4010b4d78000004", "snippets": [{"offsetInBeginSection": 232, "offsetInEndSection": 452, "text": "Currently, in the clinical setting, GERD is defined by the presence of symptoms that, when endoscopic investigation is required, permit to distinguish between cases with or without associated esophageal mucosal injuries.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33103406/", "endSection": "abstract"}, {"offsetInBeginSection": 557, "offsetInEndSection": 609, "text": "The latter is the most common manifestation of GERD.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33103406/", "endSection": "abstract"}, {"offsetInBeginSection": 812, "offsetInEndSection": 1098, "text": "In this context, it is crucial for clinicians to investigate the presence of features of suspected malignancy, as unexplained weight loss, anemia, dysphagia, persistent vomiting, familiar history of cancer, long history of GERD, and beginning of GERD symptoms after the age of 50 years.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33103406/", "endSection": "abstract"}, {"offsetInBeginSection": 1186, "offsetInEndSection": 1377, "text": "Particular attention should be given to functional conditions that can mimic GERD, such as functional heartburn and hypersensitive esophagus as well as, more rarely, eosinophilic esophagitis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33103406/", "endSection": "abstract"}, {"offsetInBeginSection": 1378, "offsetInEndSection": 1500, "text": "The former ones have different pathophysiology and this explains the frequent non-response to proton pump inhibitor drugs.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33103406/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Eosinophilic oesophagitis has emerged as a common cause of oesophageal symptoms.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23461842/", "endSection": "abstract"}, {"offsetInBeginSection": 81, "offsetInEndSection": 224, "text": "To document practice variation in care provided to eosinophilic oesophagitis patients in Spain and to assess adherence to available guidelines.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23461842/", "endSection": "abstract"}, {"offsetInBeginSection": 66, "offsetInEndSection": 159, "text": "It has been debated whether pediatric EoE and adult EoE represent different disease entities.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28194801/", "endSection": "abstract"}, {"offsetInBeginSection": 694, "offsetInEndSection": 807, "text": "An eosinophil molecular pattern capable of distinguishing children with EoE from control children was identified.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28194801/", "endSection": "abstract"}, {"offsetInBeginSection": 1319, "offsetInEndSection": 1439, "text": "Children with EoE can be distinguished from healthy children based on the molecular patterns of their blood eosinophils.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28194801/", "endSection": "abstract"}]}, {"body": "Should men be immunized against Human Papilloma Virus?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/32154741/", "https://pubmed.ncbi.nlm.nih.gov/33603082/", "https://pubmed.ncbi.nlm.nih.gov/34971362/", "https://pubmed.ncbi.nlm.nih.gov/21051842/", "https://pubmed.ncbi.nlm.nih.gov/27858157/", "https://pubmed.ncbi.nlm.nih.gov/36305982/", "https://pubmed.ncbi.nlm.nih.gov/22123925/", "https://pubmed.ncbi.nlm.nih.gov/22021967/", "https://pubmed.ncbi.nlm.nih.gov/35358015/", "https://pubmed.ncbi.nlm.nih.gov/34463960/"], "ideal_answer": "Based on current guidelines and evidence, it is recommended to immunize men against Human Papilloma Virus (HPV). HPV vaccination in men has been shown to confer immunogenicity and protect against HPV-related diseases. Public HPV vaccination programs now include men up to a certain age range, and recent studies have highlighted the benefits of vaccinating men against HPV.", "exact_answer": "Based on current guidelines and evidence, it is recommended to immunize men against Human Papilloma Virus (HPV). HPV vaccination in men has been shown to confer immunogenicity and protect against HPV-related diseases. Public HPV vaccination programs now include men up to a certain age range, recognizing the risks posed by HPV infection beyond a certain age.", "type": "summary", "id": "65f8611dc4010b4d78000055", "snippets": [{"offsetInBeginSection": 390, "offsetInEndSection": 499, "text": "Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32154741/", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 599, "text": "Yet, only recently have guidelines begun to consider vaccination of men older than 26 years of age.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32154741/", "endSection": "abstract"}, {"offsetInBeginSection": 704, "offsetInEndSection": 1138, "text": "Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32154741/", "endSection": "abstract"}, {"offsetInBeginSection": 87, "offsetInEndSection": 124, "text": "Little is known about male infection.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33603082/", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 257, "text": "Nonavalent vaccine against types 6/11/16/18/31/33/45/52/58 was approved and neutral gender immunization programs have been proposed.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33603082/", "endSection": "abstract"}, {"offsetInBeginSection": 381, "offsetInEndSection": 460, "text": "58.7% of samples were HPV positive and forty-four types of HPV were identified.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33603082/", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 919, "text": "Low impact of the vaccine were calculated as the empirical probability of HPV genotypes 6/11/16/18/31/33/45/52/58 alone or in combination; the high impact as empirical probability of HPV6/11/16/18/31/33/45/52/58 genotypes alone or in association with other genotypes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33603082/", "endSection": "abstract"}, {"offsetInBeginSection": 1324, "offsetInEndSection": 1473, "text": "Nonavalent vaccine offers broader protection in men with HPV positive partners, who would have a potential role in the transmission of the infection.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33603082/", "endSection": "abstract"}, {"offsetInBeginSection": 818, "offsetInEndSection": 898, "text": "There were 200 unvaccinated men and 127 vaccinated men included in the analysis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34971362/", "endSection": "abstract"}, {"offsetInBeginSection": 1325, "offsetInEndSection": 1522, "text": "Among young MSM vaccinated with the quadrivalent HPV vaccine, antibody levels for HPV6, HPV11, HPV16, and HPV18 were significantly higher than those in unvaccinated MSM following natural infection.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34971362/", "endSection": "abstract"}]}, {"body": "What is the target of Selpercatinib?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/32493697/", "https://pubmed.ncbi.nlm.nih.gov/37274265/", "https://pubmed.ncbi.nlm.nih.gov/32416592/", "https://pubmed.ncbi.nlm.nih.gov/32703767/", "https://pubmed.ncbi.nlm.nih.gov/38288815/", "https://pubmed.ncbi.nlm.nih.gov/35582449/", "https://pubmed.ncbi.nlm.nih.gov/37265412/", "https://pubmed.ncbi.nlm.nih.gov/38144396/", "https://pubmed.ncbi.nlm.nih.gov/37317595/", "https://pubmed.ncbi.nlm.nih.gov/37425604/"], "ideal_answer": "Selpercatinib targets the rearranged during transfection (RET) receptor, which is implicated in various types of cancer.", "exact_answer": [["The target of Selpercatinib is the rearranged during transfection (RET) receptor."]], "type": "factoid", "id": "65cfa22b1930410b1300000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "The FDA has greenlighted selpercatinib, the first targeted therapy for", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32493697/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Blueprint Medicines entered into a strategic partnership with Roche to jointly develop and commercialize pralsetinib, a targeted agent for RET-driven malignancies.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32703767/", "endSection": "abstract"}, {"offsetInBeginSection": 164, "offsetInEndSection": 361, "text": "If pralsetinib is approved, Roche's vast commercial network and diagnostic abilities could help the drug compete against another RET inhibitor, Eli Lilly's selpercatinib, which was approved in May.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32703767/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "New drugs being established in the market every year produce specified structures for selective biological targeting.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38288815/", "endSection": "abstract"}, {"offsetInBeginSection": 1346, "offsetInEndSection": 1662, "text": "These drugs act as anticancer agents against various cancer types, especially non-small cell lung, lymphoma, breast, prostate, multiple myeloma, neuroendocrine tumor, cervical, bladder, cholangiocarcinoma, myeloid leukemia, gastrointestinal, neuroblastoma, thyroid, epithelioid and cutaneous squamous cell carcinoma.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38288815/", "endSection": "abstract"}, {"offsetInBeginSection": 716, "offsetInEndSection": 874, "text": "High response rates to these selective RET inhibitors across multiple forms of RET alterations in different types of cancers were observed in clinical trials.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35582449/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Despite the high activity of selective RET inhibitors in RET-driven NSCLC, resistance eventually develops and there is unmet need to better define therapeutic options for patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38144396/", "endSection": "abstract"}, {"offsetInBeginSection": 359, "offsetInEndSection": 454, "text": "She was treated initially with chemotherapy and immune therapy, then switched to selpercatinib.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38144396/", "endSection": "abstract"}]}, {"body": "What are the most commonly used pain scales for the measurement of pain in ICU?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/27833752/", "https://pubmed.ncbi.nlm.nih.gov/20843604/", "https://pubmed.ncbi.nlm.nih.gov/20045849/", "https://pubmed.ncbi.nlm.nih.gov/23311493/", "https://pubmed.ncbi.nlm.nih.gov/27275945/", "https://pubmed.ncbi.nlm.nih.gov/35756365/", "https://pubmed.ncbi.nlm.nih.gov/32114614/", "https://pubmed.ncbi.nlm.nih.gov/22092294/", "https://pubmed.ncbi.nlm.nih.gov/31536628/", "https://pubmed.ncbi.nlm.nih.gov/34744277/"], "ideal_answer": "The most commonly used pain scales for the measurement of pain in the ICU include the Critical Care Pain Observation Tool (CPOT), Behavioral Pain Scale (BPS), Visual Analog Scale (VAS), Verbal Descriptor Scale (VDS), Numeric Rating Scale (NRS), Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale, Glasgow composite pain scale, and Neonatal Pain, Agitation, and Sedation Scale (N-PASS) and Neonatal Infant Pain Scale (NIPS) for infants.", "exact_answer": [["Critical Care Pain Observation Tool (CPOT)"], ["Behavioral Pain Scale (BPS)"], ["Visual Analog Scale (VAS)"], ["Verbal Descriptor Scale (VDS)"], ["Numeric Rating Scale (NRS)"]], "type": "list", "id": "644108b157b1c7a315000053", "snippets": [{"offsetInBeginSection": 1801, "offsetInEndSection": 1912, "text": "The combination of both BPS and CPOT might result in improved accuracy to detect pain compared to scales alone.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27833752/", "endSection": "abstract"}, {"offsetInBeginSection": 544, "offsetInEndSection": 708, "text": "One hundred and eleven consecutive patients admitted into a medical-surgical ICU were included as soon as they became alert and were able to follow simple commands.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/20843604/", "endSection": "abstract"}, {"offsetInBeginSection": 1081, "offsetInEndSection": 1239, "text": "Pain intensity changed significantly between T1 and T2, showing a good validity and responsiveness for the 5 scales, which correlated well between each other.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/20843604/", "endSection": "abstract"}, {"offsetInBeginSection": 1382, "offsetInEndSection": 1580, "text": "In conclusion, the NRS-V should be the tool of choice for the ICU setting, because it is the most feasible and discriminative self-report scale for measuring critically ill patients' pain intensity.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/20843604/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Few investigators have evaluated pain assessment tools in the critical care setting.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/20045849/", "endSection": "abstract"}, {"offsetInBeginSection": 1155, "offsetInEndSection": 1249, "text": "Internal consistency was excellent; the Cronbach alpha was 0.882 when all items were included.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/20045849/", "endSection": "abstract"}, {"offsetInBeginSection": 1250, "offsetInEndSection": 1466, "text": "Although similar in content to other behavioral pain scales, the FLACC can be used across populations of patients and settings, and the scores are comparable to those of the commonly used 0-to-10 number rating scale.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/20045849/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "The purposes of this study were to determine the prevalence of pain in veterinary ICU patients, to determine if there are predictors for patients to be painful, and to relate 3 commonly used pain scoring systems with each other.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/23311493/", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "The purpose of this study was to determine differences in pediatric pain management by unit type in hospitals across the United States.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/27275945/", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Pain, agitation, and delirium are associated with negative outcomes in critically ill patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32114614/", "endSection": "abstract"}]}, {"body": "Can Ultrasonography be used to detect tumors in dogs and cats?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38275771/", "https://pubmed.ncbi.nlm.nih.gov/9698615/", "https://pubmed.ncbi.nlm.nih.gov/28879674/", "https://pubmed.ncbi.nlm.nih.gov/29530040/", "https://pubmed.ncbi.nlm.nih.gov/7358560/", "https://pubmed.ncbi.nlm.nih.gov/20973385/", "https://pubmed.ncbi.nlm.nih.gov/33476083/", "https://pubmed.ncbi.nlm.nih.gov/34617607/", "https://pubmed.ncbi.nlm.nih.gov/14703250/", "https://pubmed.ncbi.nlm.nih.gov/36038190/"], "ideal_answer": "Yes, ultrasonography can be used to detect tumors in dogs and cats. Ultrasonography is a non-invasive imaging modality that uses sound waves to create real-time images of internal structures. It can provide valuable information about the size, location, and characteristics of tumors in various organs and tissues. Ultrasonography is commonly used to evaluate the abdomen, including the liver, spleen, kidneys, and gastrointestinal tract, where tumors can often be visualized as abnormal masses or lesions. Additionally, ultrasonography can aid in the detection and characterization of tumors in other areas of the body, such as the urinary bladder, lymph nodes, and pleural or peritoneal cavities. However, it is important to note that definitive diagnosis of tumors usually requires cytology or histopathology, and ultrasonography is often used as a complementary tool in the diagnostic process.", "exact_answer": "yes", "type": "yesno", "id": "65f5a3efc4010b4d78000017", "snippets": [{"offsetInBeginSection": 281, "offsetInEndSection": 373, "text": "Studies on elastography are based on the elasticity and deformation of the evaluated tissue.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38275771/", "endSection": "abstract"}, {"offsetInBeginSection": 374, "offsetInEndSection": 520, "text": "The information obtained from the different types of elastography can aid in the detection and differentiation of malignant and benign structures.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38275771/", "endSection": "abstract"}, {"offsetInBeginSection": 772, "offsetInEndSection": 890, "text": "Contrast-enhanced ultrasonography is based on the intravenous injection of contrast media constituted by microbubbles.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38275771/", "endSection": "abstract"}, {"offsetInBeginSection": 891, "offsetInEndSection": 1061, "text": "This imaging modality can be performed in nonsedated animals and provides information on the tissue perfusion, allowing the investigation of macro- and micro-circulation.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38275771/", "endSection": "abstract"}, {"offsetInBeginSection": 227, "offsetInEndSection": 407, "text": "An updated summary of the clinical studies currently investigating the use of ultrasonography to detect and to characterize gastrointestinal neoplasia is presented in this article.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9698615/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Lymph node evaluation is an important component of oncology staging in dogs and cats, however diagnosis of malignancy currently requires cytology or histopathology.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28879674/", "endSection": "abstract"}, {"offsetInBeginSection": 1012, "offsetInEndSection": 1112, "text": "Fifty-one lymph nodes were included in the evaluation, 21 had benign and 30 had neoplastic cytology.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28879674/", "endSection": "abstract"}, {"offsetInBeginSection": 1469, "offsetInEndSection": 1706, "text": "Findings indicated that elastographic stiffness scores differed between benign and malignant lymph node groups; however overlapping scores for the two groups limited the use of this technique for routine clinical diagnosis of malignancy.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28879674/", "endSection": "abstract"}, {"offsetInBeginSection": 290, "offsetInEndSection": 382, "text": "The utility of contrast-enhanced ultrasonography in other applications is still under study.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/29530040/", "endSection": "abstract"}, {"offsetInBeginSection": 383, "offsetInEndSection": 643, "text": "The aim of this study was to develop diagnostic criteria by contrast-enhanced ultrasonography in 8 client-owned adult dogs affected by urinary bladder transitional cell carcinoma with definitive diagnosis made by cytopathologic evaluation after suction biopsy.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/29530040/", "endSection": "abstract"}]}, {"body": "Can Antioxidant curcumin kill tumor cells?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38192657/", "https://pubmed.ncbi.nlm.nih.gov/24453488/", "https://pubmed.ncbi.nlm.nih.gov/29642292/", "https://pubmed.ncbi.nlm.nih.gov/24256565/", "https://pubmed.ncbi.nlm.nih.gov/24063255/", "https://pubmed.ncbi.nlm.nih.gov/25964558/", "https://pubmed.ncbi.nlm.nih.gov/34904972/", "https://pubmed.ncbi.nlm.nih.gov/35646537/", "https://pubmed.ncbi.nlm.nih.gov/24495080/"], "ideal_answer": "Yes, curcumin, a potent antioxidant found in turmeric root, can kill tumor cells. Curcumin binds to several enzymes in tumors, inducing mitochondrial damage, increasing ROS production, and ultimately leading to tumor cell death.", "exact_answer": "yes", "type": "yesno", "id": "65f1dadac4010b4d78000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Curcumin is a plant polyphenol in turmeric root and a potent antioxidant.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38192657/", "endSection": "abstract"}, {"offsetInBeginSection": 370, "offsetInEndSection": 610, "text": "It binds to several enzymes in tumors, such as carbonyl reductases, glutathione S-transferase P1 and nicotinamide adenine dinucleotide phosphate to induce mitochondrial damage, increase ROS production and ultimately induce tumor cell death.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38192657/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Curcumin is a natural phenolic compound extracted from the plant Curcuma longa L.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/24453488/", "endSection": "abstract"}, {"offsetInBeginSection": 403, "offsetInEndSection": 645, "text": "Consequently, the viability of osteosarcoma cells was less than 50% at a concentration of 10 \u03bcM compared to the control sample without curcumin, but healthy osteoblast cells had at least 80% viability throughout all the concentrations tested.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/24453488/", "endSection": "abstract"}, {"offsetInBeginSection": 646, "offsetInEndSection": 874, "text": "The results demonstrated that MG-63 osteosarcoma cells were much more sensitive in terms of cytotoxicity to curcumin, while the healthy human osteoblasts exhibited a higher healthy viability after 24 hours of curcumin treatment.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/24453488/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Curcumin is known to possess various biological functions, including anti-inflammatory, antioxidative, and anti-cancer activities.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/29642292/", "endSection": "abstract"}, {"offsetInBeginSection": 212, "offsetInEndSection": 358, "text": "However, many aggressive cancers, including breast cancer, were reported to escape the successful killing of NK cells in a tumor microenvironment.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/29642292/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Certain phenolic phytochemicals can kill cancer cells.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/24256565/", "endSection": "abstract"}, {"offsetInBeginSection": 325, "offsetInEndSection": 379, "text": "EGCG and curcumin each caused DNA damage in the cells.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/24256565/", "endSection": "abstract"}, {"offsetInBeginSection": 380, "offsetInEndSection": 472, "text": "The DNA-damaging ability of EGCG, but not curcumin, was hindered by either ascorbate or NAC.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/24256565/", "endSection": "abstract"}]}, {"body": "What medication were tested in the PEMMELA trial?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38530960/", "https://pubmed.ncbi.nlm.nih.gov/38530346/", "https://pubmed.ncbi.nlm.nih.gov/38531105/", "https://pubmed.ncbi.nlm.nih.gov/38526663/", "https://pubmed.ncbi.nlm.nih.gov/38531532/", "https://pubmed.ncbi.nlm.nih.gov/38526661/", "https://pubmed.ncbi.nlm.nih.gov/38531023/", "https://pubmed.ncbi.nlm.nih.gov/38530321/", "https://pubmed.ncbi.nlm.nih.gov/38531077/", "https://pubmed.ncbi.nlm.nih.gov/38531167/"], "ideal_answer": "The PEMMELA trial tested the medication pembrolizumab.", "exact_answer": [["The medication tested in the PEMMELA trial was pembrolizumab."]], "type": "list", "id": "65d373e21930410b13000049", "snippets": [{"offsetInBeginSection": 380, "offsetInEndSection": 541, "text": "The survey collected the respondents' sociodemographic data and answers to five hypothetical clinical cases meeting Endocrine Society criteria for PHA screening.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38530960/", "endSection": "abstract"}, {"offsetInBeginSection": 597, "offsetInEndSection": 800, "text": "Endocrinologists were the specialists who most often chose PHA screening, although the screening rates were overall low, ranging from 36.5% to 92.9%, depending on the case and the respondents' specialty.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38530960/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Alcohol and other substance use disorders usually begin with substance use in adolescence.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38530346/", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 335, "text": "Pediatric primary care offices, where most adolescents receive health care, are a promising venue for early identification of substance use and for brief intervention to prevent associated problems and the development of substance use disorder.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38530346/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Delays in malaria diagnosis increase treatment failures and deaths.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38531105/", "endSection": "abstract"}, {"offsetInBeginSection": 1231, "offsetInEndSection": 1361, "text": "Of the 165 P. falciparum-positive samples screened for pfhrp2/pfhrp3 gene deletions, one gene deletion was detected in one sample.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38531105/", "endSection": "abstract"}, {"offsetInBeginSection": 1543, "offsetInEndSection": 1827, "text": "Thus, exclusive reliance on microscopy in endemic areas may impede control efforts resulting from false negatives, underscoring the necessity for enhanced training and advocating for high-throughput molecular testing such as RT-qPCR or qPCR at referral centers to address limitations.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38531105/", "endSection": "abstract"}, {"offsetInBeginSection": 1213, "offsetInEndSection": 1455, "text": "The antioxidant activity of the plant extract was evaluated using the DPPH, ABTS, phosphomolybdenum, FRAP, and superoxide radical scavenging activity assays, while the antibacterial potential was evaluated using the agar well diffusion assay.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38526661/", "endSection": "abstract"}, {"offsetInBeginSection": 1456, "offsetInEndSection": 1534, "text": "The ethanol extract of C. roseus was found to have the highest reducing power.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38526661/", "endSection": "abstract"}, {"offsetInBeginSection": 1535, "offsetInEndSection": 1669, "text": "In addition, a 4- to 21-mm-wide zone of inhibition was seen when the C. roseus extract was tested against bacterial and fungal stains.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38526661/", "endSection": "abstract"}]}, {"body": "Please summarize MuSK Antibody positive Myasthenia Gravis.", "documents": ["https://pubmed.ncbi.nlm.nih.gov/34494126/", "https://pubmed.ncbi.nlm.nih.gov/21802480/"], "ideal_answer": "MuSK Antibody positive Myasthenia Gravis is a subtype of Myasthenia Gravis (MG) characterized by the presence of antibodies against the muscle-specific kinase (MuSK). It is more commonly seen in females and is associated with a more severe form of MG, often presenting with bulbar and respiratory muscle weakness. Treatment options include immunosuppressive medications, such as corticosteroids and other immunosuppressants, as well as symptomatic management with acetylcholinesterase inhibitors.", "exact_answer": "MuSK Antibody positive Myasthenia Gravis is a subtype of Myasthenia Gravis (MG) characterized by the presence of antibodies against the muscle-specific kinase (MuSK). It is more commonly seen in females and is associated with severe muscle weakness, bulbar symptoms, and respiratory involvement. Treatment options include immunosuppressive medications, thymectomy, and supportive therapies.", "type": "summary", "id": "65f70915c4010b4d7800001a", "snippets": []}, {"body": "What proportion of risk is attributable to obesity in colorectal cancer women development?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/19207714/", "https://pubmed.ncbi.nlm.nih.gov/24448854/", "https://pubmed.ncbi.nlm.nih.gov/30282445/", "https://pubmed.ncbi.nlm.nih.gov/11169969/", "https://pubmed.ncbi.nlm.nih.gov/27196525/"], "ideal_answer": "The population attributable risk (PAR) for colorectal cancer development in women due to obesity is 29%. This means that approximately 29% of the risk of developing colorectal cancer in women can be attributed to obesity.", "exact_answer": [["The proportion of risk attributable to obesity in colorectal cancer development in women is 29%."]], "type": "factoid", "id": "65f7728fc4010b4d78000021", "snippets": [{"offsetInBeginSection": 1149, "offsetInEndSection": 1242, "text": "Study characteristics and adjustments accounted for only moderate variations of associations.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/19207714/", "endSection": "abstract"}, {"offsetInBeginSection": 1243, "offsetInEndSection": 1340, "text": "Increasing BMI is associated with a modest increased risk of developing colon and rectal cancers.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/19207714/", "endSection": "abstract"}, {"offsetInBeginSection": 486, "offsetInEndSection": 642, "text": "Overall and specific PAFs% were calculated for cancer sites and sex from known estimates of relative risk and national prevalence of overweight and obesity.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/24448854/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "There is growing evidence that excess body weight increases the risk of cancer at several sites, including kidney, endometrium, colon, prostate, gallbladder and breast in post-menopausal women.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/11169969/", "endSection": "abstract"}, {"offsetInBeginSection": 1010, "offsetInEndSection": 1115, "text": "Participants meeting all 4 of these criteria made up the low-risk group; all others, the high-risk group.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27196525/", "endSection": "abstract"}, {"offsetInBeginSection": 1770, "offsetInEndSection": 1946, "text": "For individual cancers, the respective PARs in women and men were 82% and 78% for lung, 29% and 20% for colon and rectum, 30% and 29% for pancreas, and 36% and 44% for bladder.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27196525/", "endSection": "abstract"}]}, {"body": "What is the mechanisms of action of Sotorasib?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/35842839/", "https://pubmed.ncbi.nlm.nih.gov/37190303/", "https://pubmed.ncbi.nlm.nih.gov/38288815/", "https://pubmed.ncbi.nlm.nih.gov/35412531/", "https://pubmed.ncbi.nlm.nih.gov/37005530/", "https://pubmed.ncbi.nlm.nih.gov/37627169/", "https://pubmed.ncbi.nlm.nih.gov/36082871/"], "ideal_answer": "Sotorasib is a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C mutation. It binds to the Switch II binding pocket and Cys12 residue of GDP-bound KRAS proteins in G12C mutants, keeping them in their inactive state.", "exact_answer": "Sotorasib is a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C mutation. It binds covalently to the mutant KRAS protein, locking it in an inactive state and preventing downstream signaling pathways that promote cancer cell growth and survival.", "type": "summary", "id": "65ce88be1930410b13000002", "snippets": [{"offsetInBeginSection": 558, "offsetInEndSection": 730, "text": "We found that the FDA-approved compounds, namely, azelastine, dihydrocodeine, paroxetine, and tramadol, are potential candidates to inhibit the action of G13D mutant K-Ras.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35842839/", "endSection": "abstract"}, {"offsetInBeginSection": 731, "offsetInEndSection": 872, "text": "All four compounds exhibited similar binding patterns of sotorasib, and a structural binding mechanism with significant hydrophobic contacts.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35842839/", "endSection": "abstract"}, {"offsetInBeginSection": 873, "offsetInEndSection": 991, "text": "The descriptor features from the QikProp of all four compounds are within allowable limits compared to sotorasib drug.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35842839/", "endSection": "abstract"}, {"offsetInBeginSection": 992, "offsetInEndSection": 1189, "text": "Consequently, a molecular simulation result emphasized that the dihydrocodeine and tramadol exhibited less fluctuation, minimal basin, significant h-bonds, and potent inhibition against G13D K-Ras.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35842839/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Colorectal cancer is one of the world's most prevalent and lethal cancers.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37190303/", "endSection": "abstract"}, {"offsetInBeginSection": 75, "offsetInEndSection": 149, "text": "Mutations of the KRAS gene occur in ~40% of metastatic colorectal cancers.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37190303/", "endSection": "abstract"}, {"offsetInBeginSection": 329, "offsetInEndSection": 503, "text": "Their foremost mechanism of action utilizes the Switch II binding pocket and Cys12 residue of GDP-bound KRAS proteins in G12C mutants, confining them to their inactive state.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37190303/", "endSection": "abstract"}, {"offsetInBeginSection": 794, "offsetInEndSection": 963, "text": "Treatment resistance remains an issue with combination treatment regimens including indirect pathway inhibition and immunotherapy providing possible ways to combat this.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37190303/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "New drugs being established in the market every year produce specified structures for selective biological targeting.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38288815/", "endSection": "abstract"}, {"offsetInBeginSection": 1346, "offsetInEndSection": 1662, "text": "These drugs act as anticancer agents against various cancer types, especially non-small cell lung, lymphoma, breast, prostate, multiple myeloma, neuroendocrine tumor, cervical, bladder, cholangiocarcinoma, myeloid leukemia, gastrointestinal, neuroblastoma, thyroid, epithelioid and cutaneous squamous cell carcinoma.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38288815/", "endSection": "abstract"}]}, {"body": "What is a spillover event?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38096175/", "https://pubmed.ncbi.nlm.nih.gov/38125528/", "https://pubmed.ncbi.nlm.nih.gov/38306202/", "https://pubmed.ncbi.nlm.nih.gov/38038916/", "https://pubmed.ncbi.nlm.nih.gov/38090144/", "https://pubmed.ncbi.nlm.nih.gov/38096228/", "https://pubmed.ncbi.nlm.nih.gov/38165992/", "https://pubmed.ncbi.nlm.nih.gov/38114703/", "https://pubmed.ncbi.nlm.nih.gov/38347527/", "https://pubmed.ncbi.nlm.nih.gov/38130434/"], "ideal_answer": "A spillover event refers to the transmission or transfer of a disease or risk factor from one population or system to another. In the context of infectious diseases, it specifically refers to the transmission of a pathogen from animals to humans, resulting in human infection and disease.", "exact_answer": "A spillover event refers to the transmission or transfer of a disease or risk factor from one population or system to another. In the context of infectious diseases, it specifically refers to the transmission of a pathogen from animals to humans, resulting in human infection and disease. Spillover events can occur due to various factors such as close contact with infected animals, environmental changes, or behavioral practices that increase the risk of exposure to zoonotic pathogens.", "type": "summary", "id": "65f843cbc4010b4d78000042", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Against the background of the global active pursuit of carbon neutrality, this paper uses the DY spillover index method to analyze the spillover network effects between carbon, fossil energy and financial markets.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38096175/", "endSection": "abstract"}, {"offsetInBeginSection": 214, "offsetInEndSection": 395, "text": "The research results show that the spillover effects between these three markets change over time, with an average spillover index of 25.30%, showing a significant mutual influence.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38096175/", "endSection": "abstract"}, {"offsetInBeginSection": 396, "offsetInEndSection": 490, "text": "Further analysis found that the EU carbon market plays an important role in spillover effects.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38096175/", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 663, "text": "At this time, the degree of mutual influence between markets is as high as 60.01%.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38096175/", "endSection": "abstract"}, {"offsetInBeginSection": 664, "offsetInEndSection": 921, "text": "In addition, during the COVID-19 epidemic, the spillover effect of the EU carbon market on other markets also reached its maximum, indicating that the epidemic increased the contagion of cross-market risks and caused the carbon market to bear greater risks.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38096175/", "endSection": "abstract"}, {"offsetInBeginSection": 568, "offsetInEndSection": 732, "text": "The findings indicate that the DJIA, Nasdaq, Small Cap 100, and MOEX are net receivers of spillovers, whereas the S&P 500 and PFTS are significant net transmitters.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38125528/", "endSection": "abstract"}, {"offsetInBeginSection": 951, "offsetInEndSection": 1215, "text": "This study contributes to a better understanding of the interdependency and transmission mechanisms among equity markets and highlights the importance of considering external factors and geopolitical events in formulating risk management and investment strategies.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38125528/", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 286, "text": "Despite efforts to detect and respond to such threats, surveillance and mitigation efforts have been criticized as ineffective.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38306202/", "endSection": "abstract"}, {"offsetInBeginSection": 214, "offsetInEndSection": 435, "text": "Leveraging sample data from January 3, 2017, to December 16, 2022, this study investigates the risk spillover effects among China's power, coal, and carbon markets via rolling window technology and the DY spillover index.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38038916/", "endSection": "abstract"}, {"offsetInBeginSection": 436, "offsetInEndSection": 547, "text": "The empirical results indicate a significant long-term two-way asymmetric spillover effect among these markets.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38038916/", "endSection": "abstract"}]}, {"body": "Cilta-cel was developed for treatment of which disease?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37403937/", "https://pubmed.ncbi.nlm.nih.gov/38369760/", "https://pubmed.ncbi.nlm.nih.gov/36811414/", "https://pubmed.ncbi.nlm.nih.gov/37497629/", "https://pubmed.ncbi.nlm.nih.gov/37272512/", "https://pubmed.ncbi.nlm.nih.gov/34175021/", "https://pubmed.ncbi.nlm.nih.gov/37716872/", "https://pubmed.ncbi.nlm.nih.gov/37958658/", "https://pubmed.ncbi.nlm.nih.gov/38331676/", "https://pubmed.ncbi.nlm.nih.gov/38369437/"], "ideal_answer": "Cilta-cel was developed for the treatment of multiple myeloma, a cancer that affects plasma cells.", "exact_answer": [["Cilta-cel was developed for the treatment of multiple myeloma."]], "type": "factoid", "id": "65cfd4b21930410b13000020", "snippets": [{"offsetInBeginSection": 792, "offsetInEndSection": 917, "text": "This article briefly reviews the history of the preclinical development of CAR T cells, with a particular focus on Cilta-cel.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38369760/", "endSection": "abstract"}, {"offsetInBeginSection": 918, "offsetInEndSection": 1061, "text": "Moreover, it summarizes the newest clinical data on Cilta-cel and discusses strategies to further improve its activity and reduce its toxicity.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38369760/", "endSection": "abstract"}, {"offsetInBeginSection": 1062, "offsetInEndSection": 1155, "text": "Modern next-generation immunotherapy is continuously transforming the MM treatment landscape.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38369760/", "endSection": "abstract"}, {"offsetInBeginSection": 595, "offsetInEndSection": 670, "text": "In this review we summarize the available clinical trial data for cilta-cel", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36811414/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 323, "text": "Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received \u22654 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37497629/", "endSection": "abstract"}, {"offsetInBeginSection": 324, "offsetInEndSection": 389, "text": "Approval in the EU followed for patients with \u22653 prior therapies.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37497629/", "endSection": "abstract"}, {"offsetInBeginSection": 825, "offsetInEndSection": 887, "text": "Patients received cilta-cel 5 to 7 days after lymphodepletion.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37716872/", "endSection": "abstract"}, {"offsetInBeginSection": 1330, "offsetInEndSection": 1448, "text": "One patient with prior alloSCT had grade 3 movement and neurocognitive treatment-emergent adverse events/parkinsonism.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37716872/", "endSection": "abstract"}, {"offsetInBeginSection": 1449, "offsetInEndSection": 1477, "text": "No GVHD cases were reported.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37716872/", "endSection": "abstract"}, {"offsetInBeginSection": 1577, "offsetInEndSection": 1683, "text": "Cilta-cel efficacy and safety were comparable between CARTITUDE-1 patients with and without prior alloSCT.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37716872/", "endSection": "abstract"}]}, {"body": "Is peritoneal dialysis the best option for infants with kidney failure?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/22972407/", "https://pubmed.ncbi.nlm.nih.gov/20526851/", "https://pubmed.ncbi.nlm.nih.gov/12172823/", "https://pubmed.ncbi.nlm.nih.gov/28741715/"], "ideal_answer": "Peritoneal dialysis can be a safe and effective option for infants with kidney failure. It has been shown to have a low rate of complications, such as peritonitis, and does not preclude the use of other indwelling devices like ventriculoperitoneal shunts. Continuous flow peritoneal dialysis (CFPD) has been described as a highly efficient and cost-effective method for phosphate removal. However, the choice of renal replacement therapy should be individualized based on the specific needs and circumstances of each infant, and consultation with a pediatric nephrologist is recommended.", "exact_answer": "yes", "type": "yesno", "id": "65f86e06c4010b4d7800005a", "snippets": [{"offsetInBeginSection": 470, "offsetInEndSection": 537, "text": "A total of 18 patients with a concurrent VPS and PDC were reported.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22972407/", "endSection": "abstract"}, {"offsetInBeginSection": 781, "offsetInEndSection": 937, "text": "There were 20 episodes of peritonitis observed in 11 of the 18 patients during a period of 392 months at risk, which is a peritonitis rate of 1/19.6 months.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22972407/", "endSection": "abstract"}, {"offsetInBeginSection": 938, "offsetInEndSection": 1060, "text": "Only one patient developed both a VPS infection and an episode of peritonitis, and these events were temporally unrelated.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22972407/", "endSection": "abstract"}, {"offsetInBeginSection": 1061, "offsetInEndSection": 1242, "text": "No episodes of an ascending shunt infection or meningitis occurred in association with any episode of peritonitis, and no other complications of catheter dysfunction were described.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22972407/", "endSection": "abstract"}, {"offsetInBeginSection": 1243, "offsetInEndSection": 1542, "text": "The rate of peritonitis, the absence of any documented ascending or descending infections and the lack of catheter dysfunction during the period of observation suggests that the presence of, or need for, a VPS should not preclude PD as a safe option for children requiring renal replacement therapy.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22972407/", "endSection": "abstract"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1109, "text": "The modality of PD described here has potential as an alternative management option as it is a highly efficient, methodologically simple, and low-cost method without any need for sophisticated equipment.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/20526851/", "endSection": "abstract"}]}, {"body": "What should you do if you find an individual that you suspect has overdosed?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37582355/", "https://pubmed.ncbi.nlm.nih.gov/34182238/", "https://pubmed.ncbi.nlm.nih.gov/37766723/", "https://pubmed.ncbi.nlm.nih.gov/37586329/", "https://pubmed.ncbi.nlm.nih.gov/34237678/", "https://pubmed.ncbi.nlm.nih.gov/37547204/", "https://pubmed.ncbi.nlm.nih.gov/38066140/", "https://pubmed.ncbi.nlm.nih.gov/37563799/", "https://pubmed.ncbi.nlm.nih.gov/37697715/", "https://pubmed.ncbi.nlm.nih.gov/37440537/"], "ideal_answer": "If you suspect that an individual has overdosed, it is important to take immediate action to ensure their safety. First, call emergency services or the local poison control center for assistance. While waiting for help to arrive, stay with the person and monitor their vital signs, such as their breathing and heart rate. If the person is unconscious but still breathing, place them in the recovery position to prevent choking. Do not try to induce vomiting unless instructed to do so by a healthcare professional. It is crucial to provide accurate information about the substance(s) involved and any known medical conditions or medications the person may have taken. Remember, time is of the essence in cases of overdose, so prompt medical attention is essential.", "exact_answer": [["Call for emergency medical assistance"], ["Stay with the individual and monitor their vital signs"], ["Do not leave the individual alone"], ["If the individual is unconscious but breathing, place them in the recovery position"], ["If the individual is not breathing, start CPR"]], "type": "list", "id": "65f85df3c4010b4d78000051", "snippets": []}, {"body": "Is Upadacitinib effective for Crohn\u2019s Disease?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/34968730/", "https://pubmed.ncbi.nlm.nih.gov/36272109/", "https://pubmed.ncbi.nlm.nih.gov/35695972/", "https://pubmed.ncbi.nlm.nih.gov/31594037/", "https://pubmed.ncbi.nlm.nih.gov/37224198/", "https://pubmed.ncbi.nlm.nih.gov/32044319/", "https://pubmed.ncbi.nlm.nih.gov/36898598/", "https://pubmed.ncbi.nlm.nih.gov/38294885/", "https://pubmed.ncbi.nlm.nih.gov/38362641/", "https://pubmed.ncbi.nlm.nih.gov/38134405/"], "ideal_answer": "Yes, Upadacitinib has been shown to be effective for Crohn's Disease. Clinical trials and studies have demonstrated that Upadacitinib induces endoscopic remission and maintains clinical remission in patients with moderate-to-severe Crohn's Disease. It has also shown sustained long-term benefit and further endoscopic improvements in patients. Upadacitinib is an orally administered selective Janus kinase (JAK) inhibitor and is considered an advanced therapy for Crohn's Disease.", "exact_answer": "yes", "type": "yesno", "id": "65d126471930410b1300002b", "snippets": [{"offsetInBeginSection": 829, "offsetInEndSection": 887, "text": "A total of 107 CELEST study completers entered CELEST OLE.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34968730/", "endSection": "abstract"}, {"offsetInBeginSection": 1062, "offsetInEndSection": 1111, "text": "Endoscopic response was maintained in all groups.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34968730/", "endSection": "abstract"}, {"offsetInBeginSection": 1366, "offsetInEndSection": 1525, "text": "Sustained long-term benefit at 30 months and further endoscopic improvements to month 24 were observed in patients with Crohn's disease receiving upadacitinib.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34968730/", "endSection": "abstract"}, {"offsetInBeginSection": 1526, "offsetInEndSection": 1609, "text": "Safety over 30 months was consistent with the known safety profile of upadacitinib.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34968730/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Upadacitinib is a selective JAK-1 inhibitor approved for the treatment of rheumatoid arthritis and more recently, ulcerative colitis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35695972/", "endSection": "abstract"}, {"offsetInBeginSection": 134, "offsetInEndSection": 262, "text": "Phase II trials demonstrated that upadacitinib induces endoscopic remission in patients with moderate-to-severe Crohn's disease.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35695972/", "endSection": "abstract"}, {"offsetInBeginSection": 415, "offsetInEndSection": 587, "text": "In this cohort of medically refractory patients with CD, treatment with upadacitinib resulted in subjective and objective responses in 25 and 42% of patients, respectively.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35695972/", "endSection": "abstract"}, {"offsetInBeginSection": 588, "offsetInEndSection": 734, "text": "Even at doses that are considered lower than currently being studied for CD, upadacitinib was associated with a favorable benefit-to-risk profile.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35695972/", "endSection": "abstract"}, {"offsetInBeginSection": 583, "offsetInEndSection": 746, "text": "Most trials assessing drug efficacy do not report efficacy by disease location, and robust data on efficacy of therapies in isolated small bowel Crohn's is sparse.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38294885/", "endSection": "abstract"}, {"offsetInBeginSection": 747, "offsetInEndSection": 914, "text": "Several studies indicate that small bowel disease is generally less responsive to biologics, and could require higher drug trough levels to achieve endoscopic healing.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38294885/", "endSection": "abstract"}]}, {"body": "Has MDMA(ecstasy) been successfully used to treat PTSD disorder?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/31308191/", "https://pubmed.ncbi.nlm.nih.gov/9315942/", "https://pubmed.ncbi.nlm.nih.gov/17165370/", "https://pubmed.ncbi.nlm.nih.gov/9163865/", "https://pubmed.ncbi.nlm.nih.gov/19015003/", "https://pubmed.ncbi.nlm.nih.gov/15904898/", "https://pubmed.ncbi.nlm.nih.gov/12352914/", "https://pubmed.ncbi.nlm.nih.gov/16362878/"], "ideal_answer": "Yes, MDMA (ecstasy) has shown promising results in the treatment of PTSD (Post-Traumatic Stress Disorder). Clinical trials have demonstrated that MDMA-assisted psychotherapy can be effective in reducing symptoms of PTSD and improving overall well-being in patients. The use of MDMA in therapy allows patients to access and process traumatic memories in a safe and controlled environment, leading to significant improvements in their condition. However, it is important to note that MDMA-assisted psychotherapy should only be administered under the supervision of trained professionals in specialized settings.", "exact_answer": "yes", "type": "yesno", "id": "65f490fac4010b4d78000010", "snippets": [{"offsetInBeginSection": 545, "offsetInEndSection": 660, "text": "Participant ratings in real time and in retrospect ranged from 36% to 100% similarity to a drug-induced experience.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17165370/", "endSection": "abstract"}, {"offsetInBeginSection": 1102, "offsetInEndSection": 1195, "text": "Applications for this technique as an adjunct to therapy and health treatments are discussed.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17165370/", "endSection": "abstract"}]}, {"body": "Which age group should never be tested for HIV infection?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/36729993/", "https://pubmed.ncbi.nlm.nih.gov/36377075/", "https://pubmed.ncbi.nlm.nih.gov/36457098/", "https://pubmed.ncbi.nlm.nih.gov/37467301/", "https://pubmed.ncbi.nlm.nih.gov/36562652/", "https://pubmed.ncbi.nlm.nih.gov/37977194/", "https://pubmed.ncbi.nlm.nih.gov/37749490/", "https://pubmed.ncbi.nlm.nih.gov/32428005/", "https://pubmed.ncbi.nlm.nih.gov/32453193/", "https://pubmed.ncbi.nlm.nih.gov/37344218/"], "ideal_answer": "There is no age group that should never be tested for HIV infection. HIV testing is recommended for all individuals, regardless of age, as early detection and treatment can improve outcomes and prevent transmission.", "exact_answer": [["There is no age group that should never be tested for HIV infection."]], "type": "factoid", "id": "65f86ba3c4010b4d78000059", "snippets": [{"offsetInBeginSection": 622, "offsetInEndSection": 679, "text": "An estimated 72.5% of US adults had never tested for HIV.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36729993/", "endSection": "abstract"}, {"offsetInBeginSection": 680, "offsetInEndSection": 766, "text": "Never testing was most prevalent among those aged 18 to 29 or those 50 years or older.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36729993/", "endSection": "abstract"}]}, {"body": "Should all babies diagnosed with spina bifida be operated within the first week of life?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38438690/", "https://pubmed.ncbi.nlm.nih.gov/15167834/", "https://pubmed.ncbi.nlm.nih.gov/16491001/", "https://pubmed.ncbi.nlm.nih.gov/4930541/", "https://pubmed.ncbi.nlm.nih.gov/17610175/", "https://pubmed.ncbi.nlm.nih.gov/32474814/", "https://pubmed.ncbi.nlm.nih.gov/4905059/"], "ideal_answer": "The timing of surgery for babies diagnosed with spina bifida should be determined based on clinical conditions. Urgent management is recommended for more compromised patients, usually infants, while elective treatment should be performed before severe deterioration in patients with less severe conditions. Surgical correction is typically performed between the ages of 2 to 12 months. However, it is important to note that all infants with cutaneous markers in the lumbo-sacral region should undergo spinal sonography to detect any occult spinal dysrhaphism or tethered cord. Early surgical correction, if necessary, can prevent neurological damage and should be performed by the end of the first year of life. The decision for surgical intervention should be made on an individual basis, taking into consideration the severity of the condition and the presence of any other associated malformations.", "exact_answer": "no", "type": "yesno", "id": "65f859b2c4010b4d78000050", "snippets": [{"offsetInBeginSection": 299, "offsetInEndSection": 455, "text": "Whereas the patch detached in the first case 3 weeks after the procedure, it covered the exposed neural tissue in the 2 other fetuses beyond their delivery.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/16491001/", "endSection": "abstract"}, {"offsetInBeginSection": 456, "offsetInEndSection": 567, "text": "Two of the three children survived, but 1 unexpectedly died from a ventilation problem in its 3rd week of life.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/16491001/", "endSection": "abstract"}, {"offsetInBeginSection": 643, "offsetInEndSection": 818, "text": "Percutaneous fetoscopic patch coverage of spina bifida aperta is feasible in human fetuses and offers a substantial reduction of maternal trauma compared to open fetal repair.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/16491001/", "endSection": "abstract"}, {"offsetInBeginSection": 819, "offsetInEndSection": 1029, "text": "Further clinical experience is now required before the efficacy of the new approach to protect the exposed neural tissue from mechanical and chemical damage and to improve hindbrain herniation can be evaluated.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/16491001/", "endSection": "abstract"}, {"offsetInBeginSection": 1137, "offsetInEndSection": 1303, "text": "All infants with cutaneous markers in the lumbo-sacral region should be investigated by spinal sonography as long as the vertebral arches are not completely ossified.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17610175/", "endSection": "abstract"}, {"offsetInBeginSection": 1304, "offsetInEndSection": 1487, "text": "Sonography of the spinal cord may detect occult spinal dysrhaphism and tethered cord and prevent neurological damage by early surgical correction at the end of the first year of life.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17610175/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Chiari malformation type II is present in almost all patients with myelomeningocele but usually remains asymptomatic.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/32474814/", "endSection": "title"}, {"offsetInBeginSection": 118, "offsetInEndSection": 195, "text": "Symptoms are generally more severe in neonates, who have the worst prognosis.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/32474814/", "endSection": "title"}, {"offsetInBeginSection": 1727, "offsetInEndSection": 1869, "text": "Early treatment of symptomatic Chiari II malformations may warrant satisfactory results in a significant number of patients, even in neonates.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/32474814/", "endSection": "title"}]}, {"body": "Which symptoms could indicate depression in young children?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37801270/", "https://pubmed.ncbi.nlm.nih.gov/37642920/", "https://pubmed.ncbi.nlm.nih.gov/38125276/", "https://pubmed.ncbi.nlm.nih.gov/36951690/", "https://pubmed.ncbi.nlm.nih.gov/37583326/", "https://pubmed.ncbi.nlm.nih.gov/37224886/", "https://pubmed.ncbi.nlm.nih.gov/37657816/", "https://pubmed.ncbi.nlm.nih.gov/38109174/", "https://pubmed.ncbi.nlm.nih.gov/36990979/", "https://pubmed.ncbi.nlm.nih.gov/33713764/"], "ideal_answer": "Symptoms that could indicate depression in young children include persistent sadness, irritability, loss of interest in activities, changes in appetite or sleep patterns, fatigue or low energy, difficulty concentrating, feelings of worthlessness or guilt, and thoughts of death or suicide.", "exact_answer": [["Anhedonic symptoms"], ["Depressive symptoms"], ["Negative self-evaluation"], ["Symptomatology and impairment"], ["Single symptoms"]], "type": "list", "id": "65f86f62c4010b4d7800005c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 255, "text": "Parental depression is a well-established risk factor for youth psychopathology; however, depression is highly heterogeneous, and different parental symptom profiles may be differentially associated with risk mechanisms and youth psychopathology outcomes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37801270/", "endSection": "abstract"}, {"offsetInBeginSection": 541, "offsetInEndSection": 846, "text": "Regression analyses indicated that parental self-reported anhedonic symptoms at baseline demonstrated relatively specific prospective associations with chronic parent-child stress assessed using contextual stress interview methods, as well as youth self-reported depressive symptoms at 18-month follow-up.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37801270/", "endSection": "abstract"}, {"offsetInBeginSection": 847, "offsetInEndSection": 1091, "text": "Findings also indicated concurrent associations between parental anhedonic symptoms and observed parental criticism, conflict, and responsiveness in the context of a 5-min discussion task, as well as parent self-reported monitoring/supervision.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37801270/", "endSection": "abstract"}, {"offsetInBeginSection": 1215, "offsetInEndSection": 1427, "text": "Findings suggest that parental anhedonic symptoms may contribute to relatively unique reductions in the quality of the parent-child relationship and may be a particularly salient risk factor for youth depression.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37801270/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Unique trajectories of adolescent depression symptoms have been identified, yet less is known about whether such patterns translate to real-world clinical settings.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37642920/", "endSection": "abstract"}, {"offsetInBeginSection": 165, "offsetInEndSection": 567, "text": "Because annual adolescent depression screening is becoming more prevalent in primary care, we examined whether longitudinal patterns of depression symptoms documented in the developmental psychopathology literature can also be detected via routine screening in primary care and explored how membership in the identified trajectories varied based on concurrent suicide risk and sociodemographic factors.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37642920/", "endSection": "abstract"}, {"offsetInBeginSection": 568, "offsetInEndSection": 679, "text": "A total of 1,359 adolescents aged 12-16 years old at the first timepoint were included in the current analyses.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37642920/", "endSection": "abstract"}, {"offsetInBeginSection": 680, "offsetInEndSection": 849, "text": "These adolescents completed three depression screeners during their well-visits in a large pediatric primary care network between November 15, 2017 and February 1, 2020.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37642920/", "endSection": "abstract"}, {"offsetInBeginSection": 850, "offsetInEndSection": 980, "text": "Retrospective electronic health record data were extracted, including sociodemographic variables and depression screening results.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37642920/", "endSection": "abstract"}, {"offsetInBeginSection": 981, "offsetInEndSection": 1081, "text": "Dynamic functional time series clustering results indicated the optimal number of clusters was five.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37642920/", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of Pegozafermin?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37889055/", "https://pubmed.ncbi.nlm.nih.gov/37356033/", "https://pubmed.ncbi.nlm.nih.gov/38301798/"], "ideal_answer": "Pegozafermin (PGZ) exerts its mechanism of action by promoting adiponectin levels, enhancing insulin sensitivity, increasing triglyceride uptake, and reducing de novo lipogenesis. It is a glycopegylated version of human fibroblast growth factor 21 (FGF21) and acts through FGF21 receptors, which are found in the liver, adipose, skeletal muscles, and pancreatic tissues. These receptors rely on the beta klotho (KLB) coreceptors.", "exact_answer": "Pegozafermin (PGZ) exerts its mechanism of action by promoting adiponectin levels, enhancing insulin sensitivity, increasing triglyceride uptake, and reducing de novo lipogenesis. It is a glycopegylated version of human fibroblast growth factor 21 (FGF21) and acts through FGF21 receptors, which rely on the beta klotho (KLB) coreceptors. PGZ has an extended half-life of 55 to 100 hours, allowing for sustained metabolic improvements.", "type": "summary", "id": "65cfab681930410b13000012", "snippets": [{"offsetInBeginSection": 270, "offsetInEndSection": 348, "text": "FGF21 is a naturally occurring peptide hormone primarily produced by the liver", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37889055/", "endSection": "abstract"}, {"offsetInBeginSection": 386, "offsetInEndSection": 457, "text": "It can influence metabolic processes through endocrine cellular effects", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37889055/", "endSection": "abstract"}, {"offsetInBeginSection": 459, "offsetInEndSection": 548, "text": "FGF21 receptors are found in the liver, adipose, skeletal muscles, and pancreatic tissues", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37889055/", "endSection": "abstract"}, {"offsetInBeginSection": 839, "offsetInEndSection": 997, "text": "Its mechanism of action includes promoting adiponectin levels, enhancing insulin sensitivity, increasing triglyceride uptake, and reducing de novo lipogenesis", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37889055/", "endSection": "abstract"}]}, {"body": "What is Oculopharyngeal Muscular Dystrophy (OPMD)?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37519616/", "https://pubmed.ncbi.nlm.nih.gov/33805441/", "https://pubmed.ncbi.nlm.nih.gov/17296297/", "https://pubmed.ncbi.nlm.nih.gov/34380753/", "https://pubmed.ncbi.nlm.nih.gov/18175083/", "https://pubmed.ncbi.nlm.nih.gov/35859342/", "https://pubmed.ncbi.nlm.nih.gov/32804098/", "https://pubmed.ncbi.nlm.nih.gov/35112761/", "https://pubmed.ncbi.nlm.nih.gov/34225694/", "https://pubmed.ncbi.nlm.nih.gov/36462961/"], "ideal_answer": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset myopathic genetic disorder characterized by chronic progressive dysphagia and ptosis with or without proximal limb weakness. It is caused by the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1 of the PABPN1 gene. OPMD can be inherited in an autosomal dominant or recessive manner, with the dominant form being more common. The disease is characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.", "exact_answer": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset myopathic genetic disorder characterized by chronic progressive dysphagia and ptosis with or without proximal limb weakness.", "type": "summary", "id": "6446884b57b1c7a31500006f", "snippets": [{"offsetInBeginSection": 184, "offsetInEndSection": 275, "text": "It is usually dominantly inherited; however, a rare recessive form has also been described.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17296297/", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 394, "text": "Here we report two siblings with recessive OPMD.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17296297/", "endSection": "abstract"}, {"offsetInBeginSection": 487, "offsetInEndSection": 592, "text": "They exhibit later onset and milder symptoms than is typical for patients with dominantly inherited OPMD.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17296297/", "endSection": "abstract"}]}, {"body": "What is the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/35924173/", "https://pubmed.ncbi.nlm.nih.gov/36113229/", "https://pubmed.ncbi.nlm.nih.gov/32564086/", "https://pubmed.ncbi.nlm.nih.gov/36158907/", "https://pubmed.ncbi.nlm.nih.gov/33610769/", "https://pubmed.ncbi.nlm.nih.gov/36735734/", "https://pubmed.ncbi.nlm.nih.gov/38176933/", "https://pubmed.ncbi.nlm.nih.gov/34500451/", "https://pubmed.ncbi.nlm.nih.gov/35166891/", "https://pubmed.ncbi.nlm.nih.gov/35895832/"], "ideal_answer": "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is not fully understood. However, dysbiosis in the gut microbiota, characterized by an imbalance in the composition and function of the microbial community, has been implicated in the development of colorectal cancer. Specific changes in the gut microbiome can lead to chronic inflammation, alteration of the intestinal barrier function, production of genotoxic metabolites, and modulation of the immune response, all of which contribute to the initiation and progression of malignant lesions in the colonic mucosa.", "exact_answer": "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is not fully understood. However, dysbiosis in the gut microbiota has been implicated in the pathogenesis of many diseases, including colorectal cancer. Specific changes in the gut microbiome have been associated with maintaining chronic inflammation, altering the gut barrier function, and producing metabolites that can influence host health and pathophysiological functions. Further research is needed to fully elucidate the mechanisms by which the microbiota contribute to the development of malignant lesions in the colonic mucosa.", "type": "summary", "id": "65f77328c4010b4d78000023", "snippets": [{"offsetInBeginSection": 357, "offsetInEndSection": 499, "text": "The gut microbiota is a complicated group that can largely be found in the intestine and has a dual role in cancer occurrence and progression.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35924173/", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 644, "text": "Previous research has focused on the crucial functions of the intestinal microflora as the main pathophysiological mechanism in HCC development.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35924173/", "endSection": "abstract"}, {"offsetInBeginSection": 645, "offsetInEndSection": 769, "text": "Intestinal bacteria produce a broad range of metabolites that exhibit a variety of pro- and anticarcinogenic effects on HCC.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35924173/", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 278, "text": "Gut microbiota plays a vital role in nutrient exchange, signaling transduction between intestinal epithelial cells, and resistance to pathogen invasion.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36113229/", "endSection": "abstract"}, {"offsetInBeginSection": 784, "offsetInEndSection": 980, "text": "In the intestinal micro-ecosystem, A.\u00a0muciniphila is non-pathogenic, and its colonization with suitable abundance contributes to the development of immune system, thus promoting intestinal health.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36113229/", "endSection": "abstract"}, {"offsetInBeginSection": 981, "offsetInEndSection": 1088, "text": "The mechanisms by which A.\u00a0muciniphila bears a protective role in the host intestine are currently unclear.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36113229/", "endSection": "abstract"}, {"offsetInBeginSection": 1089, "offsetInEndSection": 1366, "text": "In this review, we summarize the microenvironment for the colonization of A.\u00a0muciniphila, physiological characteristics and pathophysiological impact of A.\u00a0muciniphila on intestinal diseases, such as irritable bowel syndrome, inflammatory bowel diseases, and intestinal tumors.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36113229/", "endSection": "abstract"}, {"offsetInBeginSection": 1367, "offsetInEndSection": 1511, "text": "We also provided updates for current studies on signals that A.\u00a0muciniphila enhances intestinal barrier integrity and regulates immune response.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36113229/", "endSection": "abstract"}, {"offsetInBeginSection": 1028, "offsetInEndSection": 1106, "text": "Dysbiosis in the gut has been implicated in the pathogenesis of many diseases.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32564086/", "endSection": "abstract"}, {"offsetInBeginSection": 1535, "offsetInEndSection": 1674, "text": "It has been reported that secondary bile acids could also induce the differentiation of peripherally derived regulatory T cells in the gut.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32564086/", "endSection": "abstract"}]}, {"body": "Brunner's gland hamartoma (BGH) is often asymptomatic and so how is it usually diagnosed?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/27055413/", "https://pubmed.ncbi.nlm.nih.gov/28408987/", "https://pubmed.ncbi.nlm.nih.gov/38296695/"], "ideal_answer": "Brunner's gland hamartoma (BGH) is mostly asymptomatic and is usually diagnosed incidentally during routine esophagogastroduodenoscopy (EGD). However, in some cases, BGH may present with major complications such as anemia, bleeding, obstruction, or dysplasia, which require further management and resection of the lesions.", "exact_answer": "Brunner's gland hamartoma (BGH) is mostly asymptomatic and is usually found incidentally during routine esophagogastroduodenoscopy (EGD). However, some BGHs may present with major complications such as anemia, bleeding, obstruction, or dysplasia, which require management and resection of the lesions.", "type": "summary", "id": "65f59db8c4010b4d78000014", "snippets": [{"offsetInBeginSection": 234, "offsetInEndSection": 334, "text": "They are predominantly benign lesions, but instances of malignant transformation have been reported.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27055413/", "endSection": "abstract"}, {"offsetInBeginSection": 702, "offsetInEndSection": 812, "text": "Given the symptoms and findings upon investigations, we proceeded to pylorus-preserving pancreatoduodenectomy.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27055413/", "endSection": "abstract"}, {"offsetInBeginSection": 116, "offsetInEndSection": 265, "text": "Usually these lesions are asymptomatic, just only occasionally presenting with duodenal obstruction or bleeding signs and mimicking a tumoral lesion.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28408987/", "endSection": "abstract"}, {"offsetInBeginSection": 266, "offsetInEndSection": 428, "text": "A 72-year-old male, referred for recurrent vomiting and epigastralgia, was investigated and all preoperative findings were suggestive of a tumour of the duodenum.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28408987/", "endSection": "abstract"}, {"offsetInBeginSection": 429, "offsetInEndSection": 683, "text": "During the scheduled pancreaticoduodenectomy a mass, resultant to a polyp, was palpatory felt inside the duodenum and then successfully and completely resected through a duodenotomy avoiding surgical overtreatment and connected postoperative morbidities.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28408987/", "endSection": "abstract"}, {"offsetInBeginSection": 791, "offsetInEndSection": 1008, "text": "BGH was undiagnosed before surgery, due to its particular sub-mucosal growth simulating an expanding process starting from the duodenum, and secondly due to unsuccessful biopsies performed during endoscopic procedure.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28408987/", "endSection": "abstract"}, {"offsetInBeginSection": 1009, "offsetInEndSection": 1092, "text": "BGH is a rare lesion featuring, when symptomatic, obstructive or bleeding symptoms.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28408987/", "endSection": "abstract"}, {"offsetInBeginSection": 1093, "offsetInEndSection": 1262, "text": "Surgical treatment represents the gold standard approach in case of lesions that are technically impossible to remove endoscopically or in case of an undiagnosed lesion.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28408987/", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 334, "text": "However, some BGHs present with major complications including anemia, bleeding, obstruction, or dysplasia, requiring management and resection of these lesions.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38296695/", "endSection": "abstract"}]}, {"body": "Please list the Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD)", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38199885/", "https://pubmed.ncbi.nlm.nih.gov/30704246/", "https://pubmed.ncbi.nlm.nih.gov/30626911/", "https://pubmed.ncbi.nlm.nih.gov/30582430/", "https://pubmed.ncbi.nlm.nih.gov/38075635/", "https://pubmed.ncbi.nlm.nih.gov/38074503/", "https://pubmed.ncbi.nlm.nih.gov/38035145/", "https://pubmed.ncbi.nlm.nih.gov/38078574/", "https://pubmed.ncbi.nlm.nih.gov/38078584/", "https://pubmed.ncbi.nlm.nih.gov/37208098/"], "ideal_answer": "The Janus Kinase (JAK) inhibitors used to treat Inflammatory Bowel Disease (IBD) include Tofacitinib and Upadacitinib.", "exact_answer": [["Tofacitinib"], ["Upadacitinib"], ["Filgotinib"]], "type": "list", "id": "65f1d234c4010b4d78000005", "snippets": [{"offsetInBeginSection": 145, "offsetInEndSection": 245, "text": "Several clinical studies have demonstrated the effectiveness of acupuncture and moxibustion for IBS.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38199885/", "endSection": "abstract"}, {"offsetInBeginSection": 393, "offsetInEndSection": 518, "text": "To evaluate the methodological, reporting, and evidence quality of systematic reviews of acupuncture and moxibustion for IBS.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38199885/", "endSection": "abstract"}, {"offsetInBeginSection": 962, "offsetInEndSection": 1084, "text": "Systematic reviews and meta-analyses of randomized controlled trials of acupuncture and moxibustion for IBS were included.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38199885/", "endSection": "abstract"}, {"offsetInBeginSection": 1565, "offsetInEndSection": 1700, "text": "The results of AMSTAR 2 showed low methodological quality in 2 studies and very low methodological quality in the remaining 13 studies.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38199885/", "endSection": "abstract"}, {"offsetInBeginSection": 1942, "offsetInEndSection": 2133, "text": "The results of PRISMA 2020 showed seriously deficient reporting quality of 2 studies, somewhat deficient reporting quality of 12 studies, and relatively complete reporting quality of 1 study.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38199885/", "endSection": "abstract"}, {"offsetInBeginSection": 2423, "offsetInEndSection": 2503, "text": "The results of GRADE showed that the quality of the evidence is low or very low.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38199885/", "endSection": "abstract"}, {"offsetInBeginSection": 2504, "offsetInEndSection": 2624, "text": "Most included systematic reviews interpreted findings to suggest that acupuncture and moxibustion have benefits for IBS.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38199885/", "endSection": "abstract"}, {"offsetInBeginSection": 2739, "offsetInEndSection": 2889, "text": "Larger, multicenter, rigorously designed randomized controlled trials and high-quality systematic reviews are required to obtain more robust evidence.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38199885/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30626911/", "endSection": "abstract"}, {"offsetInBeginSection": 83, "offsetInEndSection": 161, "text": "This trial evaluated oral NSI-189 as monotherapy in major depressive disorder.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30626911/", "endSection": "abstract"}]}, {"body": "Which neurotransmitters are thought to play a role in obsessive compulsive disorder?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/9322235/", "https://pubmed.ncbi.nlm.nih.gov/38040286/", "https://pubmed.ncbi.nlm.nih.gov/8580116/", "https://pubmed.ncbi.nlm.nih.gov/2463450/", "https://pubmed.ncbi.nlm.nih.gov/21401876/", "https://pubmed.ncbi.nlm.nih.gov/12218715/", "https://pubmed.ncbi.nlm.nih.gov/7906530/", "https://pubmed.ncbi.nlm.nih.gov/19740366/", "https://pubmed.ncbi.nlm.nih.gov/12215871/", "https://pubmed.ncbi.nlm.nih.gov/15080439/"], "ideal_answer": "Serotonin (5-HT) is thought to play a pivotal role in obsessive-compulsive disorder (OCD).", "exact_answer": [["Serotonin (5-HT)"], ["Glutamate"], ["Dopamine"]], "type": "list", "id": "65f8721ec4010b4d7800005d", "snippets": [{"offsetInBeginSection": 379, "offsetInEndSection": 501, "text": "The successful use of SRIs in OCD has led to the hypothesis that 5-HTT may play a pivotal role in the pathogenesis of OCD.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9322235/", "endSection": "abstract"}, {"offsetInBeginSection": 502, "offsetInEndSection": 654, "text": "We decided to study this hypothesis from a genetic perspective, because family and twin studies suggest that there is a strong genetic component to OCD.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9322235/", "endSection": "abstract"}, {"offsetInBeginSection": 815, "offsetInEndSection": 901, "text": "There is evidence that this polymorphism alters expression of the transporter protein.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9322235/", "endSection": "abstract"}, {"offsetInBeginSection": 712, "offsetInEndSection": 834, "text": "We found that acute treatment with 5\u00a0mg/kg RU-24969 induced stereotyped hyperlocomotion in vehicle- and CORT-treated mice.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38040286/", "endSection": "abstract"}, {"offsetInBeginSection": 835, "offsetInEndSection": 1051, "text": "Furthermore, pre-treatment with CORT in adolescence produced subtle anxiety-like behaviour in adult mice, and also resulted in an impairment to late-stage discrimination learning and alterations to reversal learning.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38040286/", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 630, "text": "This study used research done on OCD as a template to interpret the available research findings in ED and their possible meaning in terms of neurochemical origin of cognitions in ED.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/8580116/", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 740, "text": "This paper suggests that the neurochemical and behavioral expression of both ED and OCD occur on a continuum.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/8580116/", "endSection": "abstract"}, {"offsetInBeginSection": 1078, "offsetInEndSection": 1184, "text": "It is suggested that these levels of 5-HT generate cognitions that may in turn promote specific behaviors.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/8580116/", "endSection": "abstract"}, {"offsetInBeginSection": 325, "offsetInEndSection": 485, "text": "We describe a 42-year-old woman who experienced isolated obsessive thoughts about killing her neighbor 10 years after the onset of her genetically confirmed HD.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/12218715/", "endSection": "abstract"}, {"offsetInBeginSection": 486, "offsetInEndSection": 611, "text": "Sertraline was prescribed at a daily dose of 150 mg with a complete remission of obsessive ideas within 4 weeks of treatment.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/12218715/", "endSection": "abstract"}]}, {"body": "Is Marburg virus a member of the family of the Ebola virus (Filoviridae)?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/26426036/", "https://pubmed.ncbi.nlm.nih.gov/31021739/", "https://pubmed.ncbi.nlm.nih.gov/16355872/", "https://pubmed.ncbi.nlm.nih.gov/30332733/", "https://pubmed.ncbi.nlm.nih.gov/30215737/", "https://pubmed.ncbi.nlm.nih.gov/26656687/", "https://pubmed.ncbi.nlm.nih.gov/16026254/", "https://pubmed.ncbi.nlm.nih.gov/15588056/", "https://pubmed.ncbi.nlm.nih.gov/27338448/", "https://pubmed.ncbi.nlm.nih.gov/32320678/"], "ideal_answer": "Yes, Marburg virus is a member of the family Filoviridae, which also includes the Ebola virus.", "exact_answer": "no", "type": "yesno", "id": "65f86f03c4010b4d7800005b", "snippets": [{"offsetInBeginSection": 372, "offsetInEndSection": 521, "text": "Many of these, including Marburgviruses and Ebolaviruses other than EBOV, are also highly virulent and fully capable of causing widespread epidemics.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26426036/", "endSection": "abstract"}, {"offsetInBeginSection": 850, "offsetInEndSection": 1103, "text": "It is evident that much research is yet to be done in order to bring the non-EBOV filovirus field to the forefront of current research and, importantly, to the development of more effective vaccines and therapeutics to combat potential future outbreaks.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26426036/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Members of the family Filoviridae produce variously shaped, often filamentous, enveloped virions containing linear non-segmented, negative-sense RNA genomes of 15-19\u2009kb.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/31021739/", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The family Filoviridae is comprised of two genera: Marburgvirus and Ebolavirus.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/16355872/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Filoviruses are among the most pathogenic infectious agents known to human, with high destructive potential, as evidenced by the recent Ebola virus epidemic in West Africa.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30215737/", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 298, "text": "As members of the filovirus family, marburgviruses have caused similar devastating outbreaks, albeit with lower case numbers.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30215737/", "endSection": "abstract"}, {"offsetInBeginSection": 530, "offsetInEndSection": 654, "text": "Our results reveal the most pathogenic MARV strain to be Angola, followed by Musoke, whereas Ozolin is the least pathogenic.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30215737/", "endSection": "abstract"}, {"offsetInBeginSection": 655, "offsetInEndSection": 768, "text": "We also demonstrate that RAVV is highly pathogenic in cynomolgus macaques but less pathogenic in rhesus macaques.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30215737/", "endSection": "abstract"}, {"offsetInBeginSection": 311, "offsetInEndSection": 476, "text": "We found that MARV VP40 forms a dimer in solution, mediated by N-terminal domains, and that formation of this dimer is essential for budding of virus-like particles.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26656687/", "endSection": "abstract"}, {"offsetInBeginSection": 477, "offsetInEndSection": 566, "text": "We also found the N-terminal domain to be necessary and sufficient for immune antagonism.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26656687/", "endSection": "abstract"}]}, {"body": "Is sectoral Heterochromia associated with Crohn's disease?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/1736874/", "https://pubmed.ncbi.nlm.nih.gov/34189344/", "https://pubmed.ncbi.nlm.nih.gov/3792843/", "https://pubmed.ncbi.nlm.nih.gov/32232994/", "https://pubmed.ncbi.nlm.nih.gov/17933676/"], "ideal_answer": "There is no known association between sectoral heterochromia and Crohn's disease. Sectoral heterochromia is a condition characterized by different colors within the iris, while Crohn's disease is a chronic inflammatory bowel disease. The association between sectoral heterochromia and Hirschsprung's disease has been reported, but not with Crohn's disease.", "exact_answer": "yes", "type": "yesno", "id": "65cfd68a1930410b13000021", "snippets": [{"offsetInBeginSection": 121, "offsetInEndSection": 285, "text": "The association between sector heterochromia and Hirschsprung's disease has been previously reported and both conditions have been ascribed to neural crest defects.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/1736874/", "endSection": "abstract"}, {"offsetInBeginSection": 392, "offsetInEndSection": 582, "text": "Histopathologic examination of the globes revealed decreased iris stroma, decreased pigmentation in the anterior stroma, and reduced numbers of pigment-producing cells in the affected areas.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/1736874/", "endSection": "abstract"}]}, {"body": "Is it advisable to bring the fever down when it is supposedly meant to assist in the fight of disease?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/29664899/", "https://pubmed.ncbi.nlm.nih.gov/35080441/", "https://pubmed.ncbi.nlm.nih.gov/6837852/", "https://pubmed.ncbi.nlm.nih.gov/11276761/", "https://pubmed.ncbi.nlm.nih.gov/19481042/", "https://pubmed.ncbi.nlm.nih.gov/8488153/", "https://pubmed.ncbi.nlm.nih.gov/28575919/", "https://pubmed.ncbi.nlm.nih.gov/3991351/", "https://pubmed.ncbi.nlm.nih.gov/32375712/"], "ideal_answer": "Bringing down a fever is advisable in certain situations to provide comfort and prevent complications. However, fever is a natural defense mechanism that helps the body fight off infections, so it is not always necessary to lower it. The decision to treat a fever should be based on the underlying cause, severity of symptoms, and individual patient factors.", "exact_answer": "Bringing down a fever is advisable in certain situations to provide comfort and prevent complications. However, fever is a natural defense mechanism of the body and can help in fighting off infections. Therefore, the decision to bring down a fever should be based on the individual's overall health condition and the severity of symptoms.", "type": "summary", "id": "65f8418fc4010b4d78000041", "snippets": [{"offsetInBeginSection": 133, "offsetInEndSection": 391, "text": "This number included 56 operations in children under 16 years of age, which formed the basis of this report of the risk of infection in young splenectomized patients and provided guidelines for the role of splenectomy under emergency and elective conditions.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/6837852/", "endSection": "abstract"}, {"offsetInBeginSection": 662, "offsetInEndSection": 798, "text": "It is emphasized, however, that the development of serious postsplenectomy sepsis in our series resulted in a 25 percent mortality rate.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/6837852/", "endSection": "abstract"}, {"offsetInBeginSection": 799, "offsetInEndSection": 976, "text": "The risk of postsplenectomy sepsis is much greater in those individuals who are immunologically compromised, such as those who undergo staging splenectomy for Hodgkin's disease.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/6837852/", "endSection": "abstract"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1147, "text": "If splenectomy is indicated for a hematologic disorder, it is wise to defer operation for as long as possible, especially if the acute episodes are self-limiting or mild.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/6837852/", "endSection": "abstract"}, {"offsetInBeginSection": 1148, "offsetInEndSection": 1442, "text": "Rather than the promiscuous use of polyvalent serum and antibiotic therapy after splenectomy in children, it is recommended that parents be advised to bring the child to the hospital anytime an illness or fever develops that might require an immediate loading dose of an appropriate antibiotic.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/6837852/", "endSection": "abstract"}, {"offsetInBeginSection": 889, "offsetInEndSection": 1006, "text": "It is helpful for the patients to bring all medications to the office for review at the time of the dental procedure.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/11276761/", "endSection": "abstract"}, {"offsetInBeginSection": 2190, "offsetInEndSection": 2242, "text": "Consultation with patient's cardiologist is advised.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/11276761/", "endSection": "abstract"}, {"offsetInBeginSection": 2243, "offsetInEndSection": 2320, "text": "Anticoagulation with coumadin is not a contraindication to dental procedures.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/11276761/", "endSection": "abstract"}, {"offsetInBeginSection": 2485, "offsetInEndSection": 2580, "text": "Aspirin therapy is not a problem unless the patient is on very high doses for severe arthritis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/11276761/", "endSection": "abstract"}, {"offsetInBeginSection": 1026, "offsetInEndSection": 1145, "text": "The most frequent clinical variables are rash, febrile state, non-purulent conjunctivitis and arthralgia, among others.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28575919/", "endSection": "abstract"}]}, {"body": "Are only babies and young children at risk of severe malaria in endemic areas?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/31752891/", "https://pubmed.ncbi.nlm.nih.gov/32660434/", "https://pubmed.ncbi.nlm.nih.gov/10081156/", "https://pubmed.ncbi.nlm.nih.gov/30730633/", "https://pubmed.ncbi.nlm.nih.gov/9093619/", "https://pubmed.ncbi.nlm.nih.gov/28291790/", "https://pubmed.ncbi.nlm.nih.gov/30061962/", "https://pubmed.ncbi.nlm.nih.gov/9827117/", "https://pubmed.ncbi.nlm.nih.gov/25652127/", "https://pubmed.ncbi.nlm.nih.gov/25913272/"], "ideal_answer": "No, severe malaria can affect individuals of all ages in endemic areas. However, it is more commonly observed in babies and young children. The prevalence of severe malaria among children under 5 years is higher compared to other age groups. Factors such as age and parasitaemia contribute to the high prevalence of severe malaria in young children, even in areas of low endemicity.", "exact_answer": "no", "type": "yesno", "id": "65f83281c4010b4d78000040", "snippets": [{"offsetInBeginSection": 1615, "offsetInEndSection": 1730, "text": "Across all sites, except Kabale, malaria admissions were concentrated among young children, 74% were under 5 years.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32660434/", "endSection": "abstract"}, {"offsetInBeginSection": 889, "offsetInEndSection": 1042, "text": "In these trials, three injections of the malaria vaccine one month apart did not reduce overall mortality or malaria mortality in low-mortality settings.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/30730633/", "endSection": "title"}, {"offsetInBeginSection": 1535, "offsetInEndSection": 1682, "text": "Febrile seizures during the days following vaccination were 2 to 5 times more frequent with the malaria vaccine among children aged 5 to 17 months.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/30730633/", "endSection": "title"}, {"offsetInBeginSection": 1683, "offsetInEndSection": 1821, "text": "The malaria vaccine may also carry a risk of meningitis, as well as a risk of pneumonia among HIV-infected children and premature infants.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/30730633/", "endSection": "title"}, {"offsetInBeginSection": 347, "offsetInEndSection": 452, "text": "They lived in Dakar and its suburbs, a region of Senegal where the malaria transmission rate is very low.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9093619/", "endSection": "abstract"}, {"offsetInBeginSection": 1344, "offsetInEndSection": 1534, "text": "The results suggest that the high prevalence of severe anaemia in young children, even in an area of very low endemicity, depends more on age and parasitaemia than on the transmission level.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9093619/", "endSection": "abstract"}, {"offsetInBeginSection": 239, "offsetInEndSection": 431, "text": "The aim of this study was to estimate the prevalence of anaemia, and to determine the risk factors of anaemia and change in haemoglobin value in Adami Tullu district in south-central Ethiopia.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28291790/", "endSection": "abstract"}, {"offsetInBeginSection": 673, "offsetInEndSection": 783, "text": "Anaemia was diagnosed using HemoCue Hb 301, and children with haemoglobin <11 g/dl were classified as anaemic.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28291790/", "endSection": "abstract"}, {"offsetInBeginSection": 910, "offsetInEndSection": 952, "text": "Death was noted in the evolution in 28.32%", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30061962/", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of Peresolimab?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37195941/"], "ideal_answer": "Peresolimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on immune cells. By binding to PD-1, Peresolimab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and other immune cells. This blockade enhances the activation of T cells and promotes an anti-tumor immune response.", "exact_answer": "Peresolimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on immune cells. By binding to PD-1, Peresolimab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and other immune cells. This blockade enhances the activation of T cells and promotes an anti-tumor immune response.", "type": "summary", "id": "65d128f81930410b1300002d", "snippets": []}, {"body": "Which dietary compounds are associated with colorectal cancer incidence?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/8850441/", "https://pubmed.ncbi.nlm.nih.gov/34189071/", "https://pubmed.ncbi.nlm.nih.gov/33389861/", "https://pubmed.ncbi.nlm.nih.gov/31289520/", "https://pubmed.ncbi.nlm.nih.gov/25785727/", "https://pubmed.ncbi.nlm.nih.gov/34579010/", "https://pubmed.ncbi.nlm.nih.gov/31300834/", "https://pubmed.ncbi.nlm.nih.gov/26771634/", "https://pubmed.ncbi.nlm.nih.gov/30551667/", "https://pubmed.ncbi.nlm.nih.gov/29873077/"], "ideal_answer": "The association between dietary compounds and colorectal cancer incidence is complex and multifactorial. However, several studies have suggested that certain dietary factors may be associated with an increased or decreased risk of colorectal cancer. These include:\n\n1. Red and processed meat: High consumption of red and processed meat has been consistently associated with an increased risk of colorectal cancer. This may be due to the presence of mutagenic compounds, such as heterocyclic amines, formed during the cooking process.\n\n2. Fiber: While the role of fiber in colorectal cancer prevention is still debated, some studies suggest that a high intake of dietary fiber, particularly from whole grains, fruits, and vegetables, may be associated with a lower risk of colorectal cancer.\n\n3. Phytochemicals: Certain phytochemicals found in fruits, vegetables, and other plant-based foods have been associated with a reduced risk of colorectal cancer. Examples include cruciferous vegetables (e.g., broccoli, cauliflower), citrus fruits, garlic, tomatoes, and nuts.\n\n4. Choline and betaine: Higher intake of choline, particularly from sources like phosphatidylcholine, glycerophosphocholine, and sphingomyelin, has been inversely associated with colorectal cancer risk.\n\n5. Seaweed: Some studies have shown an inverse association between the intake of seaweed and colorectal cancer risk.\n\n6. Coffee: Coffee consumption has been suggested to have a protective effect against colorectal cancer, possibly due to its bioactive compounds.\n\nIt is important to note that the evidence regarding the association between dietary compounds and colorectal cancer is still evolving, and further research is needed to establish more definitive conclusions. Additionally, individual dietary patterns and other lifestyle factors should be considered in the context of overall colorectal cancer risk.", "exact_answer": [["vegetables"], ["fiber"], ["meat"], ["folate"], ["calcium"]], "type": "list", "id": "65f7725ec4010b4d78000020", "snippets": [{"offsetInBeginSection": 92, "offsetInEndSection": 150, "text": "Colon cancer varies approximately 20-fold internationally.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/8850441/", "endSection": "abstract"}, {"offsetInBeginSection": 306, "offsetInEndSection": 442, "text": "At present, the data suggest that vegetables are associated with lower risk, and that fiber alone does not account for this association.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/8850441/", "endSection": "abstract"}, {"offsetInBeginSection": 443, "offsetInEndSection": 561, "text": "Further, meat consumption is associated with increased risk but this, too, is not explained solely by its fat content.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/8850441/", "endSection": "abstract"}, {"offsetInBeginSection": 562, "offsetInEndSection": 717, "text": "Several microconstituents of the diet may be associated with reduced risk--including folate and calcium--but phytochemicals of other sorts may be relevant.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/8850441/", "endSection": "abstract"}, {"offsetInBeginSection": 718, "offsetInEndSection": 845, "text": "Mutagenic compounds, particularly heterocyclic amines, produced when protein is cooked, plausibly explain the meat association.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/8850441/", "endSection": "abstract"}, {"offsetInBeginSection": 846, "offsetInEndSection": 912, "text": "The most consistent inverse association is with physical activity.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/8850441/", "endSection": "abstract"}, {"offsetInBeginSection": 913, "offsetInEndSection": 979, "text": "Alcohol is associated, though inconsistently, with increased risk.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/8850441/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Personalized nutrition and protective diets and lifestyles represent a key cancer research priority.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34189071/", "endSection": "abstract"}, {"offsetInBeginSection": 616, "offsetInEndSection": 745, "text": "To investigate the independent impact of increased intake of specific dietary constituents on CRC risk in the general population.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34189071/", "endSection": "abstract"}, {"offsetInBeginSection": 1402, "offsetInEndSection": 1436, "text": "Forty-six studies were identified.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34189071/", "endSection": "abstract"}]}, {"body": "What is prurigo nodularis?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37987710/", "https://pubmed.ncbi.nlm.nih.gov/35340735/", "https://pubmed.ncbi.nlm.nih.gov/38281092/", "https://pubmed.ncbi.nlm.nih.gov/35283533/", "https://pubmed.ncbi.nlm.nih.gov/38291823/", "https://pubmed.ncbi.nlm.nih.gov/38051855/", "https://pubmed.ncbi.nlm.nih.gov/38051854/", "https://pubmed.ncbi.nlm.nih.gov/38016088/", "https://pubmed.ncbi.nlm.nih.gov/38078642/", "https://pubmed.ncbi.nlm.nih.gov/35417906/"], "ideal_answer": "Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. It is a debilitating disease that is often associated with mental health disorders and chronic medical comorbidities.", "exact_answer": "Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. It is a complex disease that causes severe itching and can significantly impact a patient's quality of life. Treatment for prurigo nodularis often involves a multimodal approach to target both the immune and neural aspects of the disease.", "type": "summary", "id": "65f1eb84c4010b4d78000008", "snippets": [{"offsetInBeginSection": 120, "offsetInEndSection": 175, "text": "The goal of therapy is to break the scratch-itch cycle.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37987710/", "endSection": "abstract"}, {"offsetInBeginSection": 176, "offsetInEndSection": 295, "text": "Treatment varies and often requires a multimodal approach to target both immune and neural mediated aspects of disease.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37987710/", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 358, "text": "To review the efficacy of systemic treatment used to treat PN.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37987710/", "endSection": "abstract"}, {"offsetInBeginSection": 737, "offsetInEndSection": 898, "text": "The search resulted in 1153 articles; 382 were duplicates, 643 were irrelevant, 19 were not retrieved, 21 were abstract only, and 88 are included in this review.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37987710/", "endSection": "abstract"}, {"offsetInBeginSection": 241, "offsetInEndSection": 357, "text": "We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35340735/", "endSection": "abstract"}, {"offsetInBeginSection": 358, "offsetInEndSection": 503, "text": "This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35340735/", "endSection": "abstract"}, {"offsetInBeginSection": 504, "offsetInEndSection": 561, "text": "Cytokines may be an important cause of prurigo nodularis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35340735/", "endSection": "abstract"}, {"offsetInBeginSection": 562, "offsetInEndSection": 711, "text": "JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35340735/", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 185, "text": "PN is often associated with mental health disorders and chronic medical comorbidities.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38281092/", "endSection": "abstract"}, {"offsetInBeginSection": 93, "offsetInEndSection": 158, "text": "Treatment consists of systemic and non-systemic modes of therapy.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38291823/", "endSection": "abstract"}]}, {"body": "Is melatonin beneficial in the treatment of in cerebral ischemia-reperfusion injury:", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38375039/", "https://pubmed.ncbi.nlm.nih.gov/15673559/", "https://pubmed.ncbi.nlm.nih.gov/12853293/", "https://pubmed.ncbi.nlm.nih.gov/33993861/", "https://pubmed.ncbi.nlm.nih.gov/35572137/", "https://pubmed.ncbi.nlm.nih.gov/27620136/", "https://pubmed.ncbi.nlm.nih.gov/24646622/", "https://pubmed.ncbi.nlm.nih.gov/33557283/", "https://pubmed.ncbi.nlm.nih.gov/12390506/", "https://pubmed.ncbi.nlm.nih.gov/12074104/"], "ideal_answer": "Yes, melatonin has been found to be beneficial in the treatment of cerebral ischemia-reperfusion injury. It has been shown to reduce infarct volume, decrease brain edema, improve neurological functions, and attenuate blood-brain barrier breakdown. Melatonin exerts its protective effects by inhibiting oxidative stress, neuroinflammation, apoptosis, excessive autophagy, glutamate excitotoxicity, and mitochondrial dysfunction. Clinical studies have also reported the predictive and therapeutic implications of melatonin in ischemic stroke. Overall, melatonin's efficacy in curtailing neural damage under conditions of interrupted blood supply to the brain makes it a promising treatment option for cerebral ischemia-reperfusion injury.", "exact_answer": "yes", "type": "yesno", "id": "65f0369bc4010b4d78000001", "snippets": [{"offsetInBeginSection": 239, "offsetInEndSection": 343, "text": "Melatonin, an endogenous hormone, was found to be valid in preventing I/R injury in a variety of organs.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38375039/", "endSection": "abstract"}, {"offsetInBeginSection": 699, "offsetInEndSection": 1195, "text": "In this systematic review, we outline the extensive scientific studies and summarize the beneficial functions of melatonin, including reducing infarct volume, decreasing brain edema, improving neurological functions and attenuating blood-brain barrier breakdown, as well as its key protective mechanisms on almost every aspect of cerebral I/R injury, including inhibiting oxidative stress, neuroinflammation, apoptosis, excessive autophagy, glutamate excitotoxicity and mitochondrial dysfunction.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38375039/", "endSection": "abstract"}, {"offsetInBeginSection": 273, "offsetInEndSection": 463, "text": "Melatonin's efficacy in curtailing neural damage under conditions of transitory interruption of the blood supply to the brain has been documented in models of both focal and global ischemia.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/15673559/", "endSection": "abstract"}, {"offsetInBeginSection": 566, "offsetInEndSection": 826, "text": "For example, when given at the time of ischemia or reperfusion onset, melatonin reduces neurophysiological deficits, infarct volume, the degree of neural edema, lipid peroxidation, protein carbonyls, DNA damage, neuron and glial loss, and death of the animals.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/15673559/", "endSection": "abstract"}, {"offsetInBeginSection": 827, "offsetInEndSection": 1111, "text": "Melatonin's protective actions against these adverse changes are believed to stem from its direct free radical scavenging and indirect antioxidant activities, possibly from its ability to limit free radical generation at the mitochondrial level and because of yet-undefined functions.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/15673559/", "endSection": "abstract"}, {"offsetInBeginSection": 1112, "offsetInEndSection": 1373, "text": "Considering its high efficacy in overcoming much of the damage associated with ischemia/reperfusion injury, not only in the brain but in other organs as well, its use in clinical trials for the purpose of improving stroke outcome should be seriously considered.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/15673559/", "endSection": "abstract"}, {"offsetInBeginSection": 1059, "offsetInEndSection": 1162, "text": "Under no circumstances did melatonin exacerbate the damage associated with ischemia/reperfusion injury.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/12853293/", "endSection": "title"}, {"offsetInBeginSection": 1163, "offsetInEndSection": 1453, "text": "As well as the beneficial pharmacologic actions of melatonin, several studies show that a relative deficiency of endogenous melatonin exaggerates neural damage due to stroke; this suggests that even physiologic concentrations of melatonin normally serve to protect the brain against damage.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/12853293/", "endSection": "title"}, {"offsetInBeginSection": 762, "offsetInEndSection": 906, "text": "Activities of the membrane-bound enzyme, brain malondialdehyde levels, and brain matter ultrastructure were examined in frontoparietal cortices.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33993861/", "endSection": "abstract"}, {"offsetInBeginSection": 907, "offsetInEndSection": 977, "text": "Melatonin lowered production of malondialdehyde in a dose-dependently.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33993861/", "endSection": "abstract"}]}, {"body": "Explain the action of Domperidone.", "documents": ["https://pubmed.ncbi.nlm.nih.gov/3236935/", "https://pubmed.ncbi.nlm.nih.gov/36500360/", "https://pubmed.ncbi.nlm.nih.gov/17157291/", "https://pubmed.ncbi.nlm.nih.gov/4087563/", "https://pubmed.ncbi.nlm.nih.gov/6151826/", "https://pubmed.ncbi.nlm.nih.gov/19391150/", "https://pubmed.ncbi.nlm.nih.gov/2565360/", "https://pubmed.ncbi.nlm.nih.gov/6617741/", "https://pubmed.ncbi.nlm.nih.gov/4051640/", "https://pubmed.ncbi.nlm.nih.gov/11463772/"], "ideal_answer": "Domperidone is a medication that acts as a dopamine antagonist in the gastrointestinal tract. It antagonizes the inhibitory effects of dopamine on gastric relaxation, leading to enhanced gastric contractions and improved antroduodenal coordination. Additionally, Domperidone has a direct relaxatory effect on gastric tone.", "exact_answer": "Domperidone is a dopaminergic antagonist that acts primarily on the peripheral dopamine receptors in the gastrointestinal tract. It enhances gastric contractions, reduces contractile frequency, and improves antroduodenal coordination. Domperidone also has antiemetic properties and is used to treat nausea and vomiting.", "type": "summary", "id": "65f492bbc4010b4d78000011", "snippets": [{"offsetInBeginSection": 389, "offsetInEndSection": 461, "text": "The XRD and DSC show no interaction between the drug and Na-attapulgite.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36500360/", "endSection": "abstract"}, {"offsetInBeginSection": 462, "offsetInEndSection": 677, "text": "The FTIR spectrum indicates a shift in the absorption of N-H in the drug molecule, which can be explained by the hydrogen bonding interaction between the N-H in the DOM molecule and the -OH on the surface of Na-ATP.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36500360/", "endSection": "abstract"}, {"offsetInBeginSection": 678, "offsetInEndSection": 838, "text": "The diameter, hardness, friability and drug content of the tablets were measured, and they all met the relevant requirements of the United States Pharmacopoeia.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36500360/", "endSection": "abstract"}, {"offsetInBeginSection": 808, "offsetInEndSection": 888, "text": "Trimebutine reduced gastric spontaneous activity and antroduodenal coordination.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/4087563/", "endSection": "abstract"}, {"offsetInBeginSection": 541, "offsetInEndSection": 653, "text": "Domperidone did not counteract the apomorphine effect, indicating a central mechanism of action for apomorphine.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/2565360/", "endSection": "abstract"}, {"offsetInBeginSection": 654, "offsetInEndSection": 771, "text": "Metoclopramide did not counteract the apomorphine effect and, in higher doses, water intake was even further reduced.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/2565360/", "endSection": "abstract"}, {"offsetInBeginSection": 772, "offsetInEndSection": 889, "text": "Sulpiride completely counteracted the apomorphine effect but, in higher doses, did not by itself reduce water intake.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/2565360/", "endSection": "abstract"}, {"offsetInBeginSection": 890, "offsetInEndSection": 1036, "text": "Haloperidol counteracted the apomorphine effect in a small dose-range and caused a further reduction in the water intake when given in high doses.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/2565360/", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 224, "text": "Our results confirm that the bradycardic effect of tabernanthine is not inhibited by vagotomy, atropine or propranolol.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/4051640/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Bromocriptine, a dopamine agonist, is known to lower cardiovascular mortality in L-dopa-treated patients with Parkinson's disease, probably by reducing the cardiac sympathetic activity.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/11463772/", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of sparsentan?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38041499/", "https://pubmed.ncbi.nlm.nih.gov/37706310/", "https://pubmed.ncbi.nlm.nih.gov/37180506/", "https://pubmed.ncbi.nlm.nih.gov/35514086/", "https://pubmed.ncbi.nlm.nih.gov/37015244/", "https://pubmed.ncbi.nlm.nih.gov/30361325/", "https://pubmed.ncbi.nlm.nih.gov/29947527/", "https://pubmed.ncbi.nlm.nih.gov/37931634/", "https://pubmed.ncbi.nlm.nih.gov/37762309/", "https://pubmed.ncbi.nlm.nih.gov/37921461/"], "ideal_answer": "Sparsentan is a dual endothelin/angiotensin II receptor antagonist. It works by blocking the action of both endothelin and angiotensin II, which are involved in the regulation of blood pressure and kidney function. By inhibiting these receptors, sparsentan helps reduce proteinuria in patients with primary IgA nephropathy at high risk of disease progression.", "exact_answer": "Sparsentan is a dual endothelin/angiotensin II receptor antagonist. It works by blocking the action of both endothelin and angiotensin II, which are involved in the regulation of blood pressure and inflammation. By inhibiting these receptors, sparsentan helps reduce proteinuria in patients with primary IgA nephropathy at high risk of disease progression.", "type": "summary", "id": "65cebf371930410b13000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Sparsentan is a dual endothelin/angiotensin II receptor antagonist indicated to reduce proteinuria in patients with primary IgA nephropathy at high risk of disease progression.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38041499/", "endSection": "abstract"}, {"offsetInBeginSection": 713, "offsetInEndSection": 894, "text": "The model was verified using clinical PK data from healthy adult volunteers administered single and multiple doses in the fasted and fed states for a wide range of sparsentan doses.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38041499/", "endSection": "abstract"}, {"offsetInBeginSection": 895, "offsetInEndSection": 965, "text": "The model was also verified by simulation of clinically observed DDIs.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38041499/", "endSection": "abstract"}, {"offsetInBeginSection": 966, "offsetInEndSection": 1153, "text": "The verified model was then used to test various DDI simulations of sparsentan as a perpetrator and victim of CYP3A4 using an expanded set of inducers and inhibitors with varying potency.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38041499/", "endSection": "abstract"}, {"offsetInBeginSection": 1154, "offsetInEndSection": 1255, "text": "Additional perpetrator and victim DDI simulations were performed using probes for CYP2C9 and CYP2C19.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38041499/", "endSection": "abstract"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1386, "text": "Simulations were conducted to predict the effect of complete inhibition of P-gp inhibition on sparsentan absorption and clearance.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38041499/", "endSection": "abstract"}, {"offsetInBeginSection": 1387, "offsetInEndSection": 1561, "text": "The predictive simulations indicated that exposure of sparsentan could increase greater than two-fold if co-administered with a strong CYP3A4 inhibitor, such as itraconazole.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38041499/", "endSection": "abstract"}, {"offsetInBeginSection": 1562, "offsetInEndSection": 1656, "text": "Other potential DDI interactions as victim or perpetrator were all within two-fold of control.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38041499/", "endSection": "abstract"}, {"offsetInBeginSection": 1657, "offsetInEndSection": 1728, "text": "The effect of complete P-gp inhibition on sparsentan PK was negligible.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38041499/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37180506/", "endSection": "abstract"}]}, {"body": "Please list the congenital fibrinogen disorders.", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37465444/"], "ideal_answer": "Congenital fibrinogen disorders include afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia.", "exact_answer": [["Afibrinogenemia"], ["Hypofibrinogenemia"], ["Dysfibrinogenemia"]], "type": "list", "id": "65f70a55c4010b4d7800001b", "snippets": []}, {"body": "What is the first line treatment for severe Plasmodium falciparum malaria?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/30885541/", "https://pubmed.ncbi.nlm.nih.gov/35916842/", "https://pubmed.ncbi.nlm.nih.gov/9784674/", "https://pubmed.ncbi.nlm.nih.gov/27986683/", "https://pubmed.ncbi.nlm.nih.gov/28039388/", "https://pubmed.ncbi.nlm.nih.gov/33685888/", "https://pubmed.ncbi.nlm.nih.gov/31843017/", "https://pubmed.ncbi.nlm.nih.gov/9763721/", "https://pubmed.ncbi.nlm.nih.gov/10528960/", "https://pubmed.ncbi.nlm.nih.gov/11037785/"], "ideal_answer": "The first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate, which is more effective than quinine in endemic areas.", "exact_answer": [["The first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate."]], "type": "factoid", "id": "65f82058c4010b4d7800003d", "snippets": [{"offsetInBeginSection": 1195, "offsetInEndSection": 1322, "text": "The first-line treatment of severe malaria is now intravenous artesunate which is more effective than quinine in endemic areas.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30885541/", "endSection": "abstract"}, {"offsetInBeginSection": 452, "offsetInEndSection": 547, "text": "For severe tropical malaria, or if parasitaemia exceeds 2%, quinine remains the drug of choice.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9784674/", "endSection": "abstract"}, {"offsetInBeginSection": 794, "offsetInEndSection": 874, "text": "Five late treatment failures were detected after AL and one slow response to AP.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27986683/", "endSection": "abstract"}, {"offsetInBeginSection": 561, "offsetInEndSection": 702, "text": "Due primarily to the presence of measurement bias in the selected studies, the quality of the evidence was considered predominantly moderate.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28039388/", "endSection": "abstract"}, {"offsetInBeginSection": 703, "offsetInEndSection": 845, "text": "Statistically significant associations were not observed when ASMQ was compared to artemether-lumefentrine and dihydroartemisinin-piperaquine.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28039388/", "endSection": "abstract"}, {"offsetInBeginSection": 846, "offsetInEndSection": 1039, "text": "The results of studies performed in areas with a history of use of ASMQ, regardless of the intensity of transmission, were not statistically different from those presented in the meta-analyses.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28039388/", "endSection": "abstract"}, {"offsetInBeginSection": 1163, "offsetInEndSection": 1298, "text": "No deaths were attributed to ASMQ, severe adverse events were rare and some studies indicate a higher frequency of mild adverse events.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28039388/", "endSection": "abstract"}, {"offsetInBeginSection": 1299, "offsetInEndSection": 1409, "text": "The use of ASMQ it is recommended to Brazil as first line treatment of uncomplicated P. falciparum infections.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28039388/", "endSection": "abstract"}, {"offsetInBeginSection": 619, "offsetInEndSection": 770, "text": "The benefits of artenimol-piperaquine in children have been validated in endemic countries but experience remains limited in cases of imported malaria.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/31843017/", "endSection": "abstract"}, {"offsetInBeginSection": 1299, "offsetInEndSection": 1403, "text": "None of the adverse events were severe and all were considered mild with no significant clinical impact.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/31843017/", "endSection": "abstract"}]}, {"body": "Can denosumab cause jaw necrosis?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/35606457/", "https://pubmed.ncbi.nlm.nih.gov/37559413/", "https://pubmed.ncbi.nlm.nih.gov/37219080/", "https://pubmed.ncbi.nlm.nih.gov/36151778/", "https://pubmed.ncbi.nlm.nih.gov/35277242/", "https://pubmed.ncbi.nlm.nih.gov/36742414/", "https://pubmed.ncbi.nlm.nih.gov/27956123/", "https://pubmed.ncbi.nlm.nih.gov/36464958/", "https://pubmed.ncbi.nlm.nih.gov/37496231/", "https://pubmed.ncbi.nlm.nih.gov/35225806/"], "ideal_answer": "Yes, denosumab has been associated with medication-related osteonecrosis of the jaw (MRONJ). MRONJ is a rare but severe bone disorder in the jawbone region. Although the incidence is low, cases of MRONJ have been reported in patients receiving denosumab, even without invasive dental treatment. It is important to evaluate the risk factors and consider preventive measures before any invasive dental procedure in patients receiving denosumab.", "exact_answer": "yes", "type": "yesno", "id": "65d126d21930410b1300002c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Denosumab has been suggested as a first-line therapy for osteoporotic patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35606457/", "endSection": "abstract"}, {"offsetInBeginSection": 501, "offsetInEndSection": 575, "text": "Four of the 98 patients developed MRONJ before and after tooth extraction.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35606457/", "endSection": "abstract"}, {"offsetInBeginSection": 856, "offsetInEndSection": 958, "text": "Two out of 4 patients developed MRONJ regardless of invasive treatment after denosumab administration.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35606457/", "endSection": "abstract"}, {"offsetInBeginSection": 1210, "offsetInEndSection": 1331, "text": "MRONJ cases reported in this study show that MRONJ can develop as chronic inflammation without invasive dental treatment.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35606457/", "endSection": "abstract"}, {"offsetInBeginSection": 548, "offsetInEndSection": 635, "text": "A total of 42\u00a0003 patients with various solid tumors reported in 23 RCTs were included.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37219080/", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 587, "text": "The purpose of this study was to evaluate the incidence and risk factors for MRONJ related to BPs or denosumab in cancer patients in real-world clinical settings using data from the OneFlorida Clinical Research Consortium.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36151778/", "endSection": "abstract"}, {"offsetInBeginSection": 1182, "offsetInEndSection": 1341, "text": "The overall rate of MRONJ was 0.73%, 0.86%, and 3.50% in the cancer patients treated with IV BPs, denosumab, and sequential IV BPs and denosumab, respectively.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36151778/", "endSection": "abstract"}, {"offsetInBeginSection": 1501, "offsetInEndSection": 1659, "text": "Patients with sequential prescription of IV BP and denosumab were at much higher risk for MRONJ, with an adjusted HR of 4.49, 95% CI of 1.96-10.28, p\u00a0=\u2009.0004.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36151778/", "endSection": "abstract"}, {"offsetInBeginSection": 345, "offsetInEndSection": 511, "text": "In addition, the authors hand searched the bibliographies of all relevant articles, the gray literature, textbooks, and guidelines in association position statements.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35277242/", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 1289, "text": "The following information for MRONJ risk should be evaluated before any invasive dental procedure: metastatic carcinoma has a higher risk than osteoporosis; parenterally administered bisphosphonates and denosumab have a higher risk than orally administered bisphosphonates or antiangiogenic agents; dose and duration of medication received; adjunctive medications or combination of antiresorptive agents also may increase the risk of MRONJ; additive factors and comorbidities such as diabetes, autoimmune disease, immunosuppression, or any condition that might affect healing negatively would result in potentially higher risk of developing MRONJ; angiogenic inhibitors as part of a cancer treatment regimen, with or without antiresorptive medication, are considered high risk.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35277242/", "endSection": "abstract"}]}, {"body": "What are the most common symptoms of fibroids?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/36436959/", "https://pubmed.ncbi.nlm.nih.gov/37937278/", "https://pubmed.ncbi.nlm.nih.gov/36471219/", "https://pubmed.ncbi.nlm.nih.gov/37867928/", "https://pubmed.ncbi.nlm.nih.gov/37958957/", "https://pubmed.ncbi.nlm.nih.gov/38046766/", "https://pubmed.ncbi.nlm.nih.gov/38370330/", "https://pubmed.ncbi.nlm.nih.gov/38110820/", "https://pubmed.ncbi.nlm.nih.gov/37937024/", "https://pubmed.ncbi.nlm.nih.gov/38068842/"], "ideal_answer": "The most common symptoms of fibroids include heavy menstrual bleeding (menorrhagia), pelvic pressure or pain, bulk symptoms (such as a feeling of fullness in the abdomen), and infertility. Other less frequent symptoms may include deep vein thrombosis, bowel obstruction, and pain during pregnancy.", "exact_answer": [["Menorrhagia"], ["Heavy vaginal bleeding"], ["Pelvic pressure/pain"], ["Bulk symptoms"], ["Paresthesia"]], "type": "list", "id": "65f84aa5c4010b4d78000047", "snippets": [{"offsetInBeginSection": 421, "offsetInEndSection": 484, "text": "Fibroid symptoms are protean, and menorrhagia is most frequent.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36436959/", "endSection": "abstract"}, {"offsetInBeginSection": 115, "offsetInEndSection": 244, "text": "Symptoms can range from heavy vaginal bleeding and bulk symptoms to, less frequently, deep vein thrombosis and bowel obstruction.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37937278/", "endSection": "abstract"}, {"offsetInBeginSection": 245, "offsetInEndSection": 357, "text": "A 32-year-old female patient presented with acute-onset of right groin and knee pain, and difficulty ambulating.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37937278/", "endSection": "abstract"}, {"offsetInBeginSection": 639, "offsetInEndSection": 735, "text": "She continued physical therapy for residual mild paresthesia and pain with prolonged ambulation.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37937278/", "endSection": "abstract"}, {"offsetInBeginSection": 71, "offsetInEndSection": 176, "text": "It is imperative to comprehend UFs' associated risk factors to facilitate early detection and prevention.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37958957/", "endSection": "abstract"}, {"offsetInBeginSection": 537, "offsetInEndSection": 676, "text": "Furthermore, after myomectomy, the recurrence rate of UFs is extremely high with the need for additional surgeries and other interventions.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37958957/", "endSection": "abstract"}, {"offsetInBeginSection": 784, "offsetInEndSection": 896, "text": "Secondary prevention is the management of early disease to slow down its progression or even halt it completely.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37958957/", "endSection": "abstract"}, {"offsetInBeginSection": 149, "offsetInEndSection": 219, "text": "The prevalence is around 20-40% women in the age group of 14-45 years.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38046766/", "endSection": "abstract"}, {"offsetInBeginSection": 815, "offsetInEndSection": 990, "text": "During the decision-making process, factors such as the patient's age, desire for fertility preservation, and impact of fibroids on her quality of life are taken into account.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38046766/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Uterine leiomyomas are common benign smooth muscle tumors that often occur during the reproductive years.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38370330/", "endSection": "abstract"}]}, {"body": "How can Emery-Dreifuss Muscular Dystrophy (EDMD) be inherited?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/10711990/", "https://pubmed.ncbi.nlm.nih.gov/37257496/", "https://pubmed.ncbi.nlm.nih.gov/35922275/", "https://pubmed.ncbi.nlm.nih.gov/22480903/", "https://pubmed.ncbi.nlm.nih.gov/27179216/", "https://pubmed.ncbi.nlm.nih.gov/34026875/", "https://pubmed.ncbi.nlm.nih.gov/21496632/", "https://pubmed.ncbi.nlm.nih.gov/31574358/", "https://pubmed.ncbi.nlm.nih.gov/16550925/", "https://pubmed.ncbi.nlm.nih.gov/12424964/"], "ideal_answer": "Emery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in different ways, including X-linked recessive, autosomal dominant, and autosomal recessive patterns. The majority of EDMD cases are of the X-linked recessive type, caused by mutations in the EMD gene on the X chromosome. Autosomal dominant forms of EDMD are caused by mutations in the LMNA gene on chromosome 1, while autosomal recessive forms can be caused by mutations in other genes associated with EDMD.", "exact_answer": [["Emery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in different patterns, including:"], ["1. X-linked recessive inheritance: The majority of EDMD cases are inherited in an X-linked recessive manner. This means that the mutated gene is located on the X chromosome. Males are more commonly affected because they have only one X chromosome, while females have two X chromosomes and can be carriers of the disease without showing symptoms."], ["2. Autosomal dominant inheritance: A rare form of EDMD, known as autosomal dominant EDMD (AD-EDMD), can be inherited in an autosomal dominant manner. This means that a single copy of the mutated gene from one parent is sufficient to cause the disease. Both males and females can be affected, and there is a 50% chance of passing the condition to each child."], ["3. Autosomal recessive inheritance: In some rare cases, EDMD can be inherited in an autosomal recessive manner. This means that both copies of the gene, one from each parent, must be mutated to cause the disease. Both males and females can be affected, and there is a 25% chance of inheriting the condition if both parents are carriers."], ["It is important to note that the specific gene mutations associated with EDMD can vary, and different genes are responsible for different subtypes of the disease."]], "type": "list", "id": "64467f8657b1c7a31500006d", "snippets": [{"offsetInBeginSection": 499, "offsetInEndSection": 573, "text": "The mutated gene in EDMD is localized to the long arm of the X chromosome.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/10711990/", "endSection": "abstract"}, {"offsetInBeginSection": 574, "offsetInEndSection": 652, "text": "Mutations in the gene lead to abolished synthesis of the gene product, emerin.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/10711990/", "endSection": "abstract"}, {"offsetInBeginSection": 152, "offsetInEndSection": 292, "text": "Different subtypes of EDMD have been described, with the two most common forms represented by the X-linked EDMD1, caused by mutations in the", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37257496/", "endSection": "abstract"}, {"offsetInBeginSection": 202, "offsetInEndSection": 234, "text": "It can be X-linked or autosomal.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22480903/", "endSection": "abstract"}, {"offsetInBeginSection": 235, "offsetInEndSection": 371, "text": "There are at least six types of EDMD known so far, of which five have been associated with mutations in genes encoding nuclear proteins.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27179216/", "endSection": "abstract"}, {"offsetInBeginSection": 430, "offsetInEndSection": 574, "text": "Mutations in the EMD gene, which encodes emerin, a transmembrane protein found at the inner nuclear membrane, are responsible for X-linked EDMD.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/21496632/", "endSection": "abstract"}, {"offsetInBeginSection": 575, "offsetInEndSection": 793, "text": "The most common etiology of autosomal dominant EDMD is an LMNA gene mutation; LMNA encodes the intermediate filament protein lamins A and C, which constitute the major scaffolding protein of the inner nuclear membrane.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/21496632/", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 323, "text": "To date at least seven genes have been associated to EDMD with different inheritance patterns, being emerin gene responsible for the X-linked form of the disease.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/31574358/", "endSection": "abstract"}, {"offsetInBeginSection": 235, "offsetInEndSection": 316, "text": "Autosomal dominant and recessive forms are caused by mutations in lamin A/C gene.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/16550925/", "endSection": "abstract"}, {"offsetInBeginSection": 309, "offsetInEndSection": 460, "text": "Most of families with EDMD show X-linked recessive inheritance with mutations in the STA gene on chromosome Xq28, which encodes a protein named emerin.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/12424964/", "endSection": "abstract"}]}, {"body": "Is there an approved vaccine against Helicobacter pylori?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/11443556/", "https://pubmed.ncbi.nlm.nih.gov/9395760/", "https://pubmed.ncbi.nlm.nih.gov/36641984/", "https://pubmed.ncbi.nlm.nih.gov/32562830/", "https://pubmed.ncbi.nlm.nih.gov/14742550/", "https://pubmed.ncbi.nlm.nih.gov/34435515/", "https://pubmed.ncbi.nlm.nih.gov/25572939/"], "ideal_answer": "Currently, there is no approved vaccine against Helicobacter pylori. However, vaccine prototypes have been developed and tested for their efficacy in targeting multi-strains of H. pylori in patients.", "exact_answer": "yes", "type": "yesno", "id": "65f86a90c4010b4d78000057", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Helicobacter pylori is a Gram-negative spiral-shaped bacterium that infects half of the human population worldwide and causes chronic inflammation.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32562830/", "endSection": "abstract"}, {"offsetInBeginSection": 319, "offsetInEndSection": 535, "text": "For drug target identification, we used different tools and softwares to identify human non-homologous but pathogen essential proteins, with virulent properties and involved in unique metabolic pathways of H. pylori.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32562830/", "endSection": "abstract"}, {"offsetInBeginSection": 1748, "offsetInEndSection": 1851, "text": "Vaccine design may also prove useful in the quest for targeting multi-strains of H. pylori in patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32562830/", "endSection": "abstract"}, {"offsetInBeginSection": 755, "offsetInEndSection": 833, "text": "Despite the wide use of PPIs, their development lags behind the clinical need.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34435515/", "endSection": "abstract"}, {"offsetInBeginSection": 970, "offsetInEndSection": 1042, "text": "Regarding the antibiotic resistance crisis, including those used against", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34435515/", "endSection": "abstract"}, {"offsetInBeginSection": 429, "offsetInEndSection": 749, "text": "The state of the art comprises ten vaccine prototypes against Measles virus, Hepatitis B virus, Human immunodeficiency virus, Yersinia pestis, Chlamydia trachomatis, Mycobacterium tuberculosis, enterotoxigenic Escherichia coli, Corynebacterium diphtheria/Clostridium tetani/Bordetella pertussis, and Helicobacter pylori;", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/25572939/", "endSection": "abstract"}]}, {"body": "Can fingolimod be used during pregnancy?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/23961604/", "https://pubmed.ncbi.nlm.nih.gov/32538681/", "https://pubmed.ncbi.nlm.nih.gov/35908450/", "https://pubmed.ncbi.nlm.nih.gov/34494237/", "https://pubmed.ncbi.nlm.nih.gov/32892670/", "https://pubmed.ncbi.nlm.nih.gov/32169556/", "https://pubmed.ncbi.nlm.nih.gov/23448215/", "https://pubmed.ncbi.nlm.nih.gov/34310364/", "https://pubmed.ncbi.nlm.nih.gov/33443836/", "https://pubmed.ncbi.nlm.nih.gov/32564333/"], "ideal_answer": "No, fingolimod is contraindicated during pregnancy due to the suspected risk of congenital malformations. It is recommended to switch to a different disease-modifying drug (DMD) that is considered safe during pregnancy.", "exact_answer": "no", "type": "yesno", "id": "65d12ae11930410b13000030", "snippets": [{"offsetInBeginSection": 136, "offsetInEndSection": 226, "text": "Pregnancy outcomes of 63 fingolimod and 62 interferon-\u03b2-exposed pregnancies were compared.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32538681/", "endSection": "abstract"}, {"offsetInBeginSection": 696, "offsetInEndSection": 787, "text": "Fetal brain and lung and placenta samples were collected for histopathological examination.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32892670/", "endSection": "abstract"}, {"offsetInBeginSection": 1374, "offsetInEndSection": 1662, "text": "The findings of the present study confirm the neuroprotective effects of antenatally administered fingolimod, which also significantly improved preterm fetal lung injury and placental inflammation in LPS-exposed preterm pregnancies by possible antiapoptotic and anti-inflammatory effects.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32892670/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Patient safety during pregnancy is an important concern.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32169556/", "endSection": "abstract"}, {"offsetInBeginSection": 386, "offsetInEndSection": 603, "text": "The aim of PRIM was to enhance the process of pregnancy data collection and improve data quality, and in particular to enable estimation of the proportion of major congenital malformation and other pregnancy outcomes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32169556/", "endSection": "abstract"}, {"offsetInBeginSection": 1346, "offsetInEndSection": 1435, "text": "The number of reported pregnancies was significantly higher in PRIM than in the registry.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32169556/", "endSection": "abstract"}, {"offsetInBeginSection": 426, "offsetInEndSection": 680, "text": "The authors provide a brief summary of existing animal and human data with current recommendations regarding the safety of IFN-\u03b2, glatiramer acetate, natalizumab, mitoxantrone, fingolimod and teriflunomide during pregnancy and lactation in women with MS.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23448215/", "endSection": "abstract"}, {"offsetInBeginSection": 1197, "offsetInEndSection": 1327, "text": "Future pharmacovigilance studies should continue to pursue multicenter collaboration with an emphasis on appropriate study design.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23448215/", "endSection": "abstract"}, {"offsetInBeginSection": 454, "offsetInEndSection": 670, "text": "Drugs with a known potential of teratogenicity such as fingolimod or teriflunomide should be avoided and recommended wash-out times for medications such as cladribine, alemtuzumab or ocrelizumab should be considered.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34310364/", "endSection": "abstract"}, {"offsetInBeginSection": 363, "offsetInEndSection": 465, "text": "Where possible, a patient planning pregnancy can be switched to a DMD considered safe in this setting.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32564333/", "endSection": "abstract"}]}, {"body": "Which are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis)?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/33949288/", "https://pubmed.ncbi.nlm.nih.gov/35060618/", "https://pubmed.ncbi.nlm.nih.gov/33241922/", "https://pubmed.ncbi.nlm.nih.gov/15915477/", "https://pubmed.ncbi.nlm.nih.gov/36911822/", "https://pubmed.ncbi.nlm.nih.gov/33945856/", "https://pubmed.ncbi.nlm.nih.gov/34014982/", "https://pubmed.ncbi.nlm.nih.gov/36289303/", "https://pubmed.ncbi.nlm.nih.gov/32377229/", "https://pubmed.ncbi.nlm.nih.gov/31265958/"], "ideal_answer": "The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC).", "exact_answer": [["The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)."]], "type": "list", "id": "65f85231c4010b4d7800004d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Although combination formulas containing antihistamines, decongestants, and/or analgesics are sold over-the-counter in large quantities for the common cold, the evidence for their effectiveness is limited.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35060618/", "endSection": "abstract"}, {"offsetInBeginSection": 601, "offsetInEndSection": 718, "text": "We searched CENTRAL, MEDLINE via EBSCOhost, Embase, CINAHL via EBSCOhost, LILACS, and Web of Science to 10 June 2021.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35060618/", "endSection": "abstract"}, {"offsetInBeginSection": 1031, "offsetInEndSection": 1095, "text": "We used standard methodological procedures expected by Cochrane.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35060618/", "endSection": "abstract"}, {"offsetInBeginSection": 1096, "offsetInEndSection": 1163, "text": "We assessed the certainty of the evidence using the GRADE approach.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35060618/", "endSection": "abstract"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1235, "text": "We categorised the included trials according to the active ingredients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35060618/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Pyralid moths, Ephestia kuehniella and Plodia interpunctella, are prevalent stored product pests.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33241922/", "endSection": "abstract"}, {"offsetInBeginSection": 98, "offsetInEndSection": 170, "text": "The insecticides are the main tool to control these moths in the stores.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33241922/", "endSection": "abstract"}, {"offsetInBeginSection": 171, "offsetInEndSection": 246, "text": "The data describing the response of these moths to insecticides are scarce.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33241922/", "endSection": "abstract"}, {"offsetInBeginSection": 375, "offsetInEndSection": 532, "text": "The hypothesis was that the very polyphagous P. interpunctella would have generally higher insecticide tolerance than that of the stenophagous E. kuehniella.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33241922/", "endSection": "abstract"}, {"offsetInBeginSection": 533, "offsetInEndSection": 626, "text": "Different insecticide concentrations were applied onto the inner surface of glass tube vials.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33241922/", "endSection": "abstract"}]}, {"body": "What proportion of alteration in NTRK genes are attributable to colorectal cancer?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/30171197/", "https://pubmed.ncbi.nlm.nih.gov/37729688/", "https://pubmed.ncbi.nlm.nih.gov/36535760/", "https://pubmed.ncbi.nlm.nih.gov/38472412/", "https://pubmed.ncbi.nlm.nih.gov/34944796/", "https://pubmed.ncbi.nlm.nih.gov/33807876/", "https://pubmed.ncbi.nlm.nih.gov/35785159/"], "ideal_answer": "The proportion of NTRK gene alterations in colorectal cancer is approximately 1%.", "exact_answer": [["The proportion of NTRK gene alterations in colorectal cancer is not mentioned in the given context."]], "type": "factoid", "id": "65f77397c4010b4d78000025", "snippets": [{"offsetInBeginSection": 815, "offsetInEndSection": 991, "text": "Seventeen non-glioma cases with NTRK fusions included carcinomas of the lungs, thyroid, breast, cervix, colon, nasal cavity, cancer of unknown primary and soft tissue sarcomas.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30171197/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Thyroid carcinomas exhibit various genetic alterations, including the RET and NTRK fusion genes that are targets for molecular therapies.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38472412/", "endSection": "abstract"}, {"offsetInBeginSection": 218, "offsetInEndSection": 353, "text": "This study characterized the pathological findings associated with these genes to identify the specimens suitable for genetic analysis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38472412/", "endSection": "abstract"}, {"offsetInBeginSection": 511, "offsetInEndSection": 579, "text": "Among the 74 patients tested, 8 had RET and 1 had NTRK3 fusion gene.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38472412/", "endSection": "abstract"}, {"offsetInBeginSection": 877, "offsetInEndSection": 986, "text": "Primary tumors showed varied structural patterns and exhibited a high proportion of non-papillary structures.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38472412/", "endSection": "abstract"}, {"offsetInBeginSection": 987, "offsetInEndSection": 1035, "text": "Dysmorphic clear cells were frequently observed.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38472412/", "endSection": "abstract"}, {"offsetInBeginSection": 1036, "offsetInEndSection": 1090, "text": "BRAF V600E immunoreactivity was negative in all cases.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38472412/", "endSection": "abstract"}, {"offsetInBeginSection": 1091, "offsetInEndSection": 1193, "text": "Interestingly, some cases exhibited similarities to diffuse sclerosing variant of PTC characteristics.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38472412/", "endSection": "abstract"}, {"offsetInBeginSection": 1194, "offsetInEndSection": 1346, "text": "While calcification in lymph node metastases was mild, primary tumors typically required hydrochloric acid-based decalcification for tissue preparation.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38472412/", "endSection": "abstract"}, {"offsetInBeginSection": 410, "offsetInEndSection": 603, "text": "Both cALCLs and BI-ALCLs differ in their gene expression profiles compared to PTCLs; however, a direct comparison of the genomic alterations and transcriptomes of these two entities is lacking.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34944796/", "endSection": "abstract"}]}, {"body": "What are active ingredients of Trikafta?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/35440408/"], "ideal_answer": "The active ingredients of Trikafta are elexacaftor, tezacaftor, and ivacaftor.", "exact_answer": [["elexacaftor"], ["tezacaftor"], ["ivacaftor"]], "type": "list", "id": "65d137871930410b1300003e", "snippets": [{"offsetInBeginSection": 494, "offsetInEndSection": 710, "text": "Minimum costs of production for CFTR modulators were estimated via an algorithm validated in previous literature and identification of cost-limiting key starting materials from published routes of chemical synthesis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35440408/", "endSection": "abstract"}, {"offsetInBeginSection": 828, "offsetInEndSection": 920, "text": "Estimated production costs were compared with published list prices in a range of countries.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35440408/", "endSection": "abstract"}]}, {"body": "When was Havana Syndrome first recognized?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/10785939/"], "ideal_answer": "Havana Syndrome was first recognized in late 2016 when several U.S. diplomats stationed in Havana, Cuba, reported experiencing a range of unexplained neurological symptoms.", "exact_answer": [["Havana Syndrome was first recognized in late 2016."]], "type": "factoid", "id": "65f856a1c4010b4d7800004e", "snippets": []}, {"body": "Is GC1118 effective for glioblastoma?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/33142709/"], "ideal_answer": "Yes, GC1118 has shown comparable growth inhibitory effects on glioblastoma tumors in patient-derived xenograft (PDX) models. It has been confirmed that GC1118 can cross the blood-brain barrier and accumulate within the tumor. Additionally, GC1118 has demonstrated a survival benefit in intracranial models of glioblastoma.", "exact_answer": "yes", "type": "yesno", "id": "65d131451930410b13000034", "snippets": [{"offsetInBeginSection": 572, "offsetInEndSection": 683, "text": "Compared to cetuximab, GC1118 exerted comparable growth inhibitory effects on the GBM tumors in the PDX models.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33142709/", "endSection": "abstract"}, {"offsetInBeginSection": 684, "offsetInEndSection": 867, "text": "We confirmed that GC1118 accumulated within the tumor by crossing the blood-brain barrier in in vivo specimens and observed the survival benefit in GC1118-treated intracranial models.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33142709/", "endSection": "abstract"}]}, {"body": "Can syphilis cause proctitis?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/30516724/", "https://pubmed.ncbi.nlm.nih.gov/879137/", "https://pubmed.ncbi.nlm.nih.gov/33370929/", "https://pubmed.ncbi.nlm.nih.gov/31545062/", "https://pubmed.ncbi.nlm.nih.gov/27780947/", "https://pubmed.ncbi.nlm.nih.gov/26317454/", "https://pubmed.ncbi.nlm.nih.gov/34057249/", "https://pubmed.ncbi.nlm.nih.gov/38331484/", "https://pubmed.ncbi.nlm.nih.gov/29680458/", "https://pubmed.ncbi.nlm.nih.gov/7025620/"], "ideal_answer": "Yes, syphilis can cause proctitis. Syphilitic proctitis involves inflammation of the rectal mucosa and can present with symptoms such as pain on defecation, rectal bleeding, or ulceration. It is important for physicians to consider syphilis as a potential cause of proctitis, especially in individuals with a history of sexual contact or high-risk sexual behavior.", "exact_answer": "yes", "type": "yesno", "id": "65cfd13f1930410b1300001d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 40, "text": "The incidence of syphilis is increasing.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30516724/", "endSection": "abstract"}, {"offsetInBeginSection": 41, "offsetInEndSection": 161, "text": "Syphilitic proctitis involving the rectal mucosa often presents with pain on defecation, rectal bleeding, or ulceration.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30516724/", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 264, "text": "We present a case of asymptomatic syphilitic proctitis diagnosed upon a routine screening colonoscopy.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30516724/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Two adult male homosexuals with syphilitic proctitis and without any detectable anal lesions are reported.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/879137/", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 297, "text": "Of note, one had extensive rectal involvement of the first 20 cm and the other had multiple sites involved.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/879137/", "endSection": "abstract"}, {"offsetInBeginSection": 298, "offsetInEndSection": 431, "text": "One patient developed severe rectal bleeding following biopsy and a Jarisch-Herxheimer reaction after the first penicillin injection.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/879137/", "endSection": "abstract"}, {"offsetInBeginSection": 432, "offsetInEndSection": 494, "text": "Salient features of the literature are reviewed and discussed.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/879137/", "endSection": "abstract"}, {"offsetInBeginSection": 186, "offsetInEndSection": 356, "text": "We report a case of a 66-year-old male patient with a background of HIV infection presenting with obstructive bowel symptoms and initial diagnosis of rectal cancer on CT.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33370929/", "endSection": "abstract"}, {"offsetInBeginSection": 357, "offsetInEndSection": 410, "text": "Sigmoidoscopy and histopathology were non-diagnostic.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33370929/", "endSection": "abstract"}, {"offsetInBeginSection": 411, "offsetInEndSection": 554, "text": "A diagnosis of secondary syphilis was suspected after obtaining sexual history and diagnostic serology, avoiding planned surgical intervention.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33370929/", "endSection": "abstract"}]}, {"body": "List the most effective treatment methods for Madelung disease.", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38508835/", "https://pubmed.ncbi.nlm.nih.gov/38437855/", "https://pubmed.ncbi.nlm.nih.gov/38454410/", "https://pubmed.ncbi.nlm.nih.gov/38498057/", "https://pubmed.ncbi.nlm.nih.gov/38453592/", "https://pubmed.ncbi.nlm.nih.gov/38492790/", "https://pubmed.ncbi.nlm.nih.gov/38432750/", "https://pubmed.ncbi.nlm.nih.gov/38471489/", "https://pubmed.ncbi.nlm.nih.gov/38163560/", "https://pubmed.ncbi.nlm.nih.gov/38491514/"], "ideal_answer": "The most effective treatment methods for Madelung disease include surgical intervention, liposuction, and conservative management with physical therapy and supportive measures.", "exact_answer": [["Surgical intervention"], ["Liposuction"], ["Physical therapy"], ["Orthopedic devices"], ["Pain management"]], "type": "list", "id": "65f377d5c4010b4d78000009", "snippets": [{"offsetInBeginSection": 125, "offsetInEndSection": 240, "text": "Previous evidence has shown that acupuncture may be an effective complementary alternative therapy for stable COPD.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38454410/", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 650, "text": "This study aims to evaluate the efficacy and safety of acupuncture for stable COPD and further investigate the dose-effect relationship of acupuncture.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38454410/", "endSection": "abstract"}, {"offsetInBeginSection": 1519, "offsetInEndSection": 1582, "text": "The primary outcome is the proportion of responders at week 12.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38454410/", "endSection": "abstract"}, {"offsetInBeginSection": 241, "offsetInEndSection": 337, "text": "Our previous study confirmed their synergistic effect on neurogenesis against cerebral ischemia.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38492790/", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 645, "text": "The study was designed to explore the synergic mechanism between LCH and BO in promoting astrocyte-mediated neurogenesis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38492790/", "endSection": "abstract"}, {"offsetInBeginSection": 1558, "offsetInEndSection": 1757, "text": "The moderate OGD environment induced NSCs proliferation, migration, astrogenesis, and neurogenesis, increased the secretions of CNTF and VEGF from ACs, and upregulated the expressions of C3 and PTX3.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38492790/", "endSection": "abstract"}, {"offsetInBeginSection": 2032, "offsetInEndSection": 2209, "text": "LCH markedly enhanced the Nissl score and neurogenesis, and decreased astrogenesis which was accompanied by downregulations of C3, p-p65, and p-p65/p65 and upregulation of PTX3.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38492790/", "endSection": "abstract"}, {"offsetInBeginSection": 2210, "offsetInEndSection": 2337, "text": "BO not only decreased the expression of C3 in ACs both in vitro and in vivo but also downregulated p-p65 and p-p65/p65 in vivo.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38492790/", "endSection": "abstract"}, {"offsetInBeginSection": 2338, "offsetInEndSection": 2411, "text": "Additionally, BO promoted the therapeutic effect of LCH for most indices.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38492790/", "endSection": "abstract"}, {"offsetInBeginSection": 1173, "offsetInEndSection": 1239, "text": "Firstly, the chemical components of DHF were analyzed by UHPLC-MS.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38163560/", "endSection": "abstract"}]}, {"body": "What are active ingredients of Paxlovid?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38258119/", "https://pubmed.ncbi.nlm.nih.gov/37252346/", "https://pubmed.ncbi.nlm.nih.gov/35233163/", "https://pubmed.ncbi.nlm.nih.gov/36465589/", "https://pubmed.ncbi.nlm.nih.gov/35982654/", "https://pubmed.ncbi.nlm.nih.gov/36213093/", "https://pubmed.ncbi.nlm.nih.gov/38139391/", "https://pubmed.ncbi.nlm.nih.gov/37199464/", "https://pubmed.ncbi.nlm.nih.gov/35982652/", "https://pubmed.ncbi.nlm.nih.gov/37482021/"], "ideal_answer": "The active ingredients of Paxlovid are nirmatrelvir and ritonavir.", "exact_answer": [["nirmatrelvir"], ["ritonavir"]], "type": "list", "id": "65d136bc1930410b1300003c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 8, "text": "Paxlovid", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38258119/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "The advancement of nirmatrelvir, the active ingredient in Paxlovid, from discovery to emergency use authorization was achieved in just 17 months, requiring an unprecedented rate of chemical process development.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37252346/", "endSection": "abstract"}, {"offsetInBeginSection": 132, "offsetInEndSection": 359, "text": "COVID-19 are directly associated with hyper-activation of innate immune response that excessively produce pro-inflammatory cytokines and induce cytokine storm, leading to multi-organ-failure and significant morbidity/mortality.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35233163/", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 266, "text": "Worldwide demand is projected to be in the hundreds of metric tons per year, to be produced by several generic drug manufacturers.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36465589/", "endSection": "abstract"}, {"offsetInBeginSection": 267, "offsetInEndSection": 388, "text": "Here we show a 7-step, 3-pot synthesis of the antiviral nirmatrelvir, arriving at the targeted drug in 70% overall yield.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36465589/", "endSection": "abstract"}, {"offsetInBeginSection": 389, "offsetInEndSection": 556, "text": "Critical amide bond-forming steps utilize new green technology that completely avoids traditional peptide coupling reagents, as well as epimerization of stereocenters.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36465589/", "endSection": "abstract"}, {"offsetInBeginSection": 704, "offsetInEndSection": 870, "text": "DFT calculations for various conformers of nirmatrelvir predict that two rotamers about the tertiary amide would be present with an unusually high rotational barrier.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36465589/", "endSection": "abstract"}, {"offsetInBeginSection": 871, "offsetInEndSection": 1033, "text": "Direct comparisons with the original literature procedures highlight both the anticipated decrease in cost and environmental footprint associated with this route.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36465589/", "endSection": "abstract"}, {"offsetInBeginSection": 843, "offsetInEndSection": 1071, "text": "Our data suggest that the mutation significantly weakens the S1 pocket interactions with the N-terminus and perturbs the conformation of the oxyanion loop, leading to a decrease in the thermal stability and catalytic efficiency.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37199464/", "endSection": "abstract"}, {"offsetInBeginSection": 1072, "offsetInEndSection": 1235, "text": "Importantly, the perturbed S1 pocket dynamics weaken the nirmatrelvir binding in the P1 position, which explains the decreased inhibitory activity of nirmatrelvir.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37199464/", "endSection": "abstract"}]}, {"body": "What does capnography measure?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37507472/", "https://pubmed.ncbi.nlm.nih.gov/32369822/", "https://pubmed.ncbi.nlm.nih.gov/37862390/", "https://pubmed.ncbi.nlm.nih.gov/37184945/", "https://pubmed.ncbi.nlm.nih.gov/37178234/", "https://pubmed.ncbi.nlm.nih.gov/37698697/", "https://pubmed.ncbi.nlm.nih.gov/38091592/", "https://pubmed.ncbi.nlm.nih.gov/37792139/", "https://pubmed.ncbi.nlm.nih.gov/37447945/", "https://pubmed.ncbi.nlm.nih.gov/37365127/"], "ideal_answer": "Capnography measures the amount of carbon dioxide (CO2) in exhaled breath.", "exact_answer": [["Capnography measures the amount of carbon dioxide (CO2) in exhaled breath."]], "type": "factoid", "id": "65f38059c4010b4d7800000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Capnovolumetry is of interest as a method for the diagnosis of obstructive airway diseases, requiring little cooperation from the patient.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32369822/", "endSection": "abstract"}, {"offsetInBeginSection": 139, "offsetInEndSection": 280, "text": "To help in the interpretation of capnovolumetric parameters, we aimed to identify their correspondence to conventional lung function indices.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32369822/", "endSection": "abstract"}, {"offsetInBeginSection": 1059, "offsetInEndSection": 1204, "text": "The four capnovolumetric parameters were related to COPD and obstruction via both direct and indirect influences, but only two of them to asthma.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32369822/", "endSection": "abstract"}, {"offsetInBeginSection": 1205, "offsetInEndSection": 1576, "text": "Regarding the correspondence to lung function parameters, the slope of expiratory phase 3 corresponded best to the ratio of residual volume to total lung capacity, the ratio of slopes of phases 3 and 2 to forced expiratory volume in 1 s, the volume of phase 2 to forced expired flow at 50% of vital capacity, and the ratio area/volume of phase 3 to forced vital capacity.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32369822/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "Capnography is an essential tool used in the monitoring of patients during anesthesia and in critical care which, while required in most high-income countries, is unavailable in many low- and middle-income countries.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37862390/", "endSection": "abstract"}, {"offsetInBeginSection": 95, "offsetInEndSection": 274, "text": "The current methods for RR measurement such as capnography, pneumography, and plethysmography require patient contact, are cumbersome, or not accurate for widespread clinical use.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37698697/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Capnography aids assessment of the adequacy of mechanical patient ventilation.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38091592/", "endSection": "abstract"}, {"offsetInBeginSection": 361, "offsetInEndSection": 584, "text": "In 12 resting subjects breathing air at 284 kPa, we recorded ETCO Across all measurements there was a difference of about 0.1 kPa between the EMMA and sidestream capnographs indicating a very slight over-estimation of ETCO ", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38091592/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Non-contact continuous respiratory rate monitoring is preferred for early detection of patient deterioration.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37792139/", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 217, "text": "However, this technique is under development; a gold standard respiratory monitor has not been established.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37792139/", "endSection": "abstract"}]}, {"body": "Methotrexate is an antifolate medication.", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37677820/", "https://pubmed.ncbi.nlm.nih.gov/38429876/", "https://pubmed.ncbi.nlm.nih.gov/37683291/", "https://pubmed.ncbi.nlm.nih.gov/38311638/", "https://pubmed.ncbi.nlm.nih.gov/38364740/", "https://pubmed.ncbi.nlm.nih.gov/38251524/", "https://pubmed.ncbi.nlm.nih.gov/38334147/", "https://pubmed.ncbi.nlm.nih.gov/38475789/", "https://pubmed.ncbi.nlm.nih.gov/38245672/", "https://pubmed.ncbi.nlm.nih.gov/37661402/"], "ideal_answer": "Yes, methotrexate is an antifolate medication. It works by inhibiting the enzyme dihydrofolate reductase, which is involved in the synthesis of DNA, RNA, and proteins. By blocking this enzyme, methotrexate interferes with the production of essential components needed for cell division and growth, leading to its antifolate effects.", "exact_answer": "yes", "type": "yesno", "id": "65f82fe1c4010b4d7800003f", "snippets": [{"offsetInBeginSection": 105, "offsetInEndSection": 226, "text": "It requires appropriate monitoring and supportive care because delayed elimination of MTX can lead to serious toxicities.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37677820/", "endSection": "abstract"}, {"offsetInBeginSection": 572, "offsetInEndSection": 698, "text": "A review of published literature and guidelines was performed to evaluate nursing considerations for patients receiving HDMTX.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37677820/", "endSection": "abstract"}, {"offsetInBeginSection": 699, "offsetInEndSection": 822, "text": "Using existing and novel tools, nurses can closely monitor patients and provide supportive care to mitigate HDMTX toxicity.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37677820/", "endSection": "abstract"}, {"offsetInBeginSection": 823, "offsetInEndSection": 1048, "text": "Early identification of delayed MTX elimination and subsequent treatment with glucarpidase, if appropriate, has been associated with shorter length of hospital stay and decreased incidence of grade 4 toxicities and mortality.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37677820/", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 388, "text": "The low-doses of MTX are commonly used in children for the treatment of many inflammatory and autoimmune conditions, including inflammatory skin diseases, due to its anti-inflammatory and immunomodulatory effects.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38429876/", "endSection": "abstract"}, {"offsetInBeginSection": 566, "offsetInEndSection": 858, "text": "The testes of MTX-treated animals showed thickened tunica albuginea, distortion of seminiferous tubules with a marked reduction of germinal lining, a few primary spermatocytes with no spermatozoa, apoptotic cells, congested sub-capsular and interstitial blood vessels, and interstitial edema.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38364740/", "endSection": "abstract"}, {"offsetInBeginSection": 859, "offsetInEndSection": 1004, "text": "Reduction of reproductive hormones and increased oxidative, inflammatory, and apoptotic biomarkers levels were also seen in the MTX-treated rats.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38364740/", "endSection": "abstract"}, {"offsetInBeginSection": 1445, "offsetInEndSection": 1612, "text": "CoQ10 enhanced MTX-induced downregulation of Nrf2 and PPAR-\u03b3 signaling and modulated its downstream targets, the inducible nitric oxide synthase, NF-\u03baB, Bax, and Bcl2.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38364740/", "endSection": "abstract"}, {"offsetInBeginSection": 1120, "offsetInEndSection": 1307, "text": "Methotrexate administration resulted in increased levels of TNF-\u03b1, MPO, GATA3, caspase-3, and pulmonary edema indices, while reducing the levels of TAC, SOD, Gpx, IL-10, T-bet, and FOXP3.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38245672/", "endSection": "abstract"}, {"offsetInBeginSection": 143, "offsetInEndSection": 438, "text": "One of the unmet medical needs in the treatment of RA is to effectively prevent the structural destruction of joints, especially bone, which progresses because of resistance to conventional drugs that mainly have anti-inflammatory effects, and directly leads to a decline in the QOL of patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37661402/", "endSection": "abstract"}]}, {"body": "What are the transmission mechanisms of the human Ebola infection?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/30381349/", "https://pubmed.ncbi.nlm.nih.gov/25392221/", "https://pubmed.ncbi.nlm.nih.gov/37515275/", "https://pubmed.ncbi.nlm.nih.gov/33493959/", "https://pubmed.ncbi.nlm.nih.gov/28662754/", "https://pubmed.ncbi.nlm.nih.gov/38279760/", "https://pubmed.ncbi.nlm.nih.gov/24575870/", "https://pubmed.ncbi.nlm.nih.gov/31052499/", "https://pubmed.ncbi.nlm.nih.gov/29941593/", "https://pubmed.ncbi.nlm.nih.gov/32498080/"], "ideal_answer": "The transmission of human Ebola infection occurs through direct contact with infected bodily fluids, such as blood, semen, saliva, urine, and breast milk. It can also be transmitted through indirect contact with contaminated surfaces or objects. Sexual transmission has been documented, as the virus can persist in the testes. Additionally, Ebola virus can be transmitted from animals to humans through contact with infected animals or consumption of their meat. The virus is not transmitted through the air or by casual contact.", "exact_answer": [["Ebola virus (EBOV) has been responsible for sporadic outbreaks in Central Africa since 1976 and has the potential of causing social disruption and public panic as illustrated by the 2013-2016 epidemic in West Africa."], ["Transmission of EBOV has been described to occur via contact with infected bodily fluids, supported by data indicating that infectious EBOV could be cultured from blood, semen, saliva, urine, and breast milk."], ["EBOV transmission via indirect contact was frequently observed in this model but resulted in less-severe disease compared to direct contact."], ["EBOV sexual transmission has been a concern since the 2014-2016 outbreak in Africa, as persistent infection in the testis and transmission to women was demonstrated."], ["Zoonotic and human-to-human transmission have been well documented."]], "type": "list", "id": "65f84535c4010b4d78000044", "snippets": [{"offsetInBeginSection": 217, "offsetInEndSection": 425, "text": "Transmission of EBOV has been described to occur via contact with infected bodily fluids, supported by data indicating that infectious EBOV could be cultured from blood, semen, saliva, urine, and breast milk.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30381349/", "endSection": "abstract"}, {"offsetInBeginSection": 903, "offsetInEndSection": 1006, "text": "All challenged animals, male direct contacts, and one male indirect contact developed disease and died.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30381349/", "endSection": "abstract"}, {"offsetInBeginSection": 1007, "offsetInEndSection": 1172, "text": "The remaining animals were not viremic and remained asymptomatic but developed EBOV-glycoprotein IgM and/or IgG specific antibodies-indicative of virus transmission.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30381349/", "endSection": "abstract"}, {"offsetInBeginSection": 1173, "offsetInEndSection": 1313, "text": "EBOV transmission via indirect contact was frequently observed in this model but resulted in less-severe disease compared to direct contact.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30381349/", "endSection": "abstract"}, {"offsetInBeginSection": 134, "offsetInEndSection": 299, "text": "EBOV sexual transmission has been a concern since the 2014-2016 outbreak in Africa, as persistent infection in the testis and transmission to women was demonstrated.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37515275/", "endSection": "abstract"}, {"offsetInBeginSection": 300, "offsetInEndSection": 416, "text": "The only study related to establishing an intravaginal small animal infection model was recently documented in IFNAR", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37515275/", "endSection": "abstract"}, {"offsetInBeginSection": 123, "offsetInEndSection": 190, "text": "Zoonotic and human-to-human transmission have been well documented.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33493959/", "endSection": "abstract"}, {"offsetInBeginSection": 422, "offsetInEndSection": 492, "text": "It resulted in 28,646 suspected and confirmed cases and 11,323 deaths.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33493959/", "endSection": "abstract"}, {"offsetInBeginSection": 493, "offsetInEndSection": 585, "text": "There are 5 species within the genus Ebolavirus with 4 of them being clinically significant.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33493959/", "endSection": "abstract"}, {"offsetInBeginSection": 586, "offsetInEndSection": 743, "text": "In patients with EVD, neurologic manifestations range from mild symptoms such as confusion to severe neurologic diseases such as meningitis and encephalitis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33493959/", "endSection": "abstract"}]}, {"body": "Gantenerumab was developed for treatment of which disease?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/22583155/", "https://pubmed.ncbi.nlm.nih.gov/36447240/", "https://pubmed.ncbi.nlm.nih.gov/21987394/", "https://pubmed.ncbi.nlm.nih.gov/29221491/", "https://pubmed.ncbi.nlm.nih.gov/28754630/", "https://pubmed.ncbi.nlm.nih.gov/35100444/", "https://pubmed.ncbi.nlm.nih.gov/38220210/", "https://pubmed.ncbi.nlm.nih.gov/35493943/", "https://pubmed.ncbi.nlm.nih.gov/34110536/", "https://pubmed.ncbi.nlm.nih.gov/26433971/"], "ideal_answer": "Gantenerumab was developed for the treatment of Alzheimer's disease.", "exact_answer": [["Alzheimer's disease"]], "type": "factoid", "id": "65cfa37c1930410b1300000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Alzheimer's disease is the leading cause of dementia in the elderly, and there is no disease-modifying therapy yet available.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22583155/", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 237, "text": "Immunotherapy directed against the \u03b2-amyloid peptide may be capable of slowing the rate of disease progression.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22583155/", "endSection": "abstract"}, {"offsetInBeginSection": 238, "offsetInEndSection": 311, "text": "Gantenerumab is the first fully human anti-\u03b2-amyloid monoclonal antibody.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22583155/", "endSection": "abstract"}, {"offsetInBeginSection": 312, "offsetInEndSection": 430, "text": "To review the efficacy and safety of immunotherapy drugs and in particular gantenerumab, we used the database MEDLINE.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22583155/", "endSection": "abstract"}, {"offsetInBeginSection": 803, "offsetInEndSection": 919, "text": "Gantenerumab appears capable of reducing the cerebral \u03b2-amyloid peptide burden in patients with Alzheimer's disease.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/22583155/", "endSection": "abstract"}, {"offsetInBeginSection": 208, "offsetInEndSection": 383, "text": "Anti-amyloid monoclonal antibodies can substantially reverse amyloid plaque pathology and may modify the course of the disease by slowing or stopping its clinical progression.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36447240/", "endSection": "abstract"}, {"offsetInBeginSection": 676, "offsetInEndSection": 892, "text": "The US Food and Drug Administration's approval of aducanumab, an anti-amyloid monoclonal antibody as the first potential disease-modifying therapy for AD, signaled the value of more than 20 years of drug development.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36447240/", "endSection": "abstract"}, {"offsetInBeginSection": 1020, "offsetInEndSection": 1144, "text": "Here, we review over 2 decades of gantenerumab development in the context of scientific discoveries in the broader AD field.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36447240/", "endSection": "abstract"}, {"offsetInBeginSection": 1655, "offsetInEndSection": 1842, "text": "The results from the gantenerumab phase 3 programs are expected by the end of 2022 and will add critical information to the collective knowledge on the search for effective AD treatments.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36447240/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Gantenerumab is intended for the treatment of Alzheimer's disease.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/28754630/", "endSection": "title"}]}, {"body": "What is the administration route of zavegepant?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38517862/", "https://pubmed.ncbi.nlm.nih.gov/38514425/", "https://pubmed.ncbi.nlm.nih.gov/38444043/", "https://pubmed.ncbi.nlm.nih.gov/38523198/", "https://pubmed.ncbi.nlm.nih.gov/38511529/", "https://pubmed.ncbi.nlm.nih.gov/38512441/", "https://pubmed.ncbi.nlm.nih.gov/38443085/", "https://pubmed.ncbi.nlm.nih.gov/38443635/", "https://pubmed.ncbi.nlm.nih.gov/38510253/", "https://pubmed.ncbi.nlm.nih.gov/38524879/"], "ideal_answer": "Zavegepant is administered orally.", "exact_answer": [["Zavegepant is administered orally."]], "type": "factoid", "id": "65d1357c1930410b13000039", "snippets": [{"offsetInBeginSection": 1228, "offsetInEndSection": 1340, "text": "XBJ was physically incompatible with 27 of the 53 intravenous drugs tested, 26 were compatible with XBJ for 4 h.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38517862/", "endSection": "abstract"}, {"offsetInBeginSection": 1561, "offsetInEndSection": 1842, "text": "Assessment included visual inspection, Tyndall beam, turbidity measurement, particle counts, pH measurement, chromacity value measurement and absorption of A550 nm were proved to be valid and robust for the quality control of infusion and compatibility of Chinese herbal injection.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38517862/", "endSection": "abstract"}, {"offsetInBeginSection": 880, "offsetInEndSection": 989, "text": "About 4 months after the procedure, a new assessment with the same initial acquisition pattern was performed.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38514425/", "endSection": "abstract"}, {"offsetInBeginSection": 1432, "offsetInEndSection": 1624, "text": "In RA patients who have failed the initial treatment with MTX, the stepwise increase in MTX doses is associated with a higher ACR20 response and sustained remission rate than other strategies.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38444043/", "endSection": "abstract"}, {"offsetInBeginSection": 1625, "offsetInEndSection": 1766, "text": "In MTX non-responders, optimisation to SC MTX was associated with improvements in ACR20 and ACR50 rates with similar toxicity between groups.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38444043/", "endSection": "abstract"}, {"offsetInBeginSection": 2039, "offsetInEndSection": 2244, "text": "Higher starting doses of MTX and initial subcutaneous MTX made better performance in improving the ACR20 response, although the clinical effectiveness and safety of other MTX start regimens are comparable.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38444043/", "endSection": "abstract"}, {"offsetInBeginSection": 624, "offsetInEndSection": 669, "text": "The study included 31 lesions in 29 patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38523198/", "endSection": "abstract"}, {"offsetInBeginSection": 670, "offsetInEndSection": 705, "text": "The mean follow-up was 23.6 months.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38523198/", "endSection": "abstract"}, {"offsetInBeginSection": 706, "offsetInEndSection": 765, "text": "25 lesions out of 31 healed totally without any remissions.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38523198/", "endSection": "abstract"}, {"offsetInBeginSection": 766, "offsetInEndSection": 905, "text": "The outcomes were not affected by any variables such as gender, age, type of pharmacological treatment, lesion location, and MRONJ staging.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38523198/", "endSection": "abstract"}]}, {"body": "What is the relationship between  Electroporation (EP) and DNA vaccines?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/30027768/", "https://pubmed.ncbi.nlm.nih.gov/19619001/", "https://pubmed.ncbi.nlm.nih.gov/10812219/", "https://pubmed.ncbi.nlm.nih.gov/34851148/", "https://pubmed.ncbi.nlm.nih.gov/23684840/", "https://pubmed.ncbi.nlm.nih.gov/29026141/", "https://pubmed.ncbi.nlm.nih.gov/27697302/", "https://pubmed.ncbi.nlm.nih.gov/36935288/", "https://pubmed.ncbi.nlm.nih.gov/26125521/", "https://pubmed.ncbi.nlm.nih.gov/35428500/"], "ideal_answer": "Electroporation (EP) is a technique used to enhance the delivery of DNA vaccines. It involves the application of electrical pulses to cells or tissues, creating temporary pores in the cell membrane and allowing for increased uptake of DNA. EP has been shown to improve the immunogenicity of DNA vaccines by enhancing both cellular and humoral immune responses. Studies have demonstrated that DNA vaccines delivered with EP can induce stronger antibody responses, cytotoxic T lymphocyte responses, and provide protection against infectious diseases. EP is considered a promising method to optimize the efficacy of DNA vaccines in both preclinical and clinical settings.", "exact_answer": [["Electroporation (EP) is a technique used to enhance the delivery and immunogenicity of DNA vaccines. It involves the application of electrical pulses to cells or tissues, which creates temporary pores in the cell membrane, allowing for increased uptake of DNA. EP has been shown to improve the immune response generated by DNA vaccines, leading to higher antibody and cellular immune responses. It has been used in various studies to deliver DNA vaccines against HIV, malaria, and other infectious diseases."]], "type": "factoid", "id": "65f494d7c4010b4d78000013", "snippets": [{"offsetInBeginSection": 179, "offsetInEndSection": 515, "text": "This Phase I randomized controlled clinical trial in human immunodeficiency virus type 1-negative volunteers investigated whether the site and mode of DNA vaccination influences the quality of induced cellular and humoral immune responses following the DNA priming phase and subsequent protein boost with recombinant clade C CN54 gp140.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30027768/", "endSection": "abstract"}, {"offsetInBeginSection": 516, "offsetInEndSection": 617, "text": "A strategy of concurrent i.d. and i.m. DNA immunizations administered with or without EP was adopted.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30027768/", "endSection": "abstract"}, {"offsetInBeginSection": 973, "offsetInEndSection": 1026, "text": "EP did not appear to add toxicity to the vaccination.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/19619001/", "endSection": "abstract"}, {"offsetInBeginSection": 1066, "offsetInEndSection": 1164, "text": "Low anti-DOM IgG antibody responses were observed after intramuscular injection of DNA without EP.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/19619001/", "endSection": "abstract"}, {"offsetInBeginSection": 1398, "offsetInEndSection": 1444, "text": "Responses persisted to 18 months of follow-up.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/19619001/", "endSection": "abstract"}, {"offsetInBeginSection": 766, "offsetInEndSection": 866, "text": "These immune responses were sufficient to provide efficient protection against the lethal infection.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/10812219/", "endSection": "abstract"}, {"offsetInBeginSection": 1352, "offsetInEndSection": 1540, "text": "The intranasal administration of cholera toxin before HA-DNA immunization by electroporation enhanced the nasal IgA Ab production together with enhancement of the efficiency of protection.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/10812219/", "endSection": "abstract"}, {"offsetInBeginSection": 745, "offsetInEndSection": 948, "text": "We found that 4pox-vaccinated rabbits developed immunogen-specific antibodies, including neutralizing antibodies, and did not develop any clinical disease, indicating protection against aerosolized RPXV.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34851148/", "endSection": "abstract"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1062, "text": "In contrast, unvaccinated animals developed significant signs of disease, including lesions, and were euthanized.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34851148/", "endSection": "abstract"}, {"offsetInBeginSection": 188, "offsetInEndSection": 286, "text": "Our laboratory has been evaluating DNA plasmid based Pfs25 vaccine in mice and non-human primates.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23684840/", "endSection": "abstract"}]}, {"body": "What disease can be treated with Tebentafusp?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37595494/", "https://pubmed.ncbi.nlm.nih.gov/37444540/", "https://pubmed.ncbi.nlm.nih.gov/36847626/", "https://pubmed.ncbi.nlm.nih.gov/36102132/", "https://pubmed.ncbi.nlm.nih.gov/35172589/", "https://pubmed.ncbi.nlm.nih.gov/35060440/", "https://pubmed.ncbi.nlm.nih.gov/37141553/", "https://pubmed.ncbi.nlm.nih.gov/38262306/", "https://pubmed.ncbi.nlm.nih.gov/32816891/", "https://pubmed.ncbi.nlm.nih.gov/31336704/"], "ideal_answer": "Tebentafusp is approved for the treatment of metastatic uveal melanoma (mUM), a rare and aggressive form of melanoma that affects the eye.", "exact_answer": [["Metastatic uveal melanoma"]], "type": "factoid", "id": "65cec1fb1930410b13000005", "snippets": [{"offsetInBeginSection": 157, "offsetInEndSection": 275, "text": "This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37444540/", "endSection": "abstract"}, {"offsetInBeginSection": 493, "offsetInEndSection": 603, "text": "Tebentafusp is administered to patients via intravenous infusion daily or weekly, depending on the indication.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36847626/", "endSection": "abstract"}, {"offsetInBeginSection": 604, "offsetInEndSection": 670, "text": "Phase III trials have documented a 1-year overall survival of 73%.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36847626/", "endSection": "abstract"}, {"offsetInBeginSection": 766, "offsetInEndSection": 946, "text": "Common adverse events reported are cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache and vomiting.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36847626/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Metastatic uveal melanoma is associated with poor prognosis and few treatment options.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36102132/", "endSection": "abstract"}, {"offsetInBeginSection": 87, "offsetInEndSection": 174, "text": "Tebentafusp recently became the first FDA-approved agent for metastatic uveal melanoma.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36102132/", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 313, "text": "In this review, we describe the mechanism of action of tebentafusp as well as preclinical data showing high tumor specificity of the drug.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36102132/", "endSection": "abstract"}, {"offsetInBeginSection": 314, "offsetInEndSection": 475, "text": "We also review promising early-phase trials in which tebentafusp demonstrated activity in metastatic uveal melanoma patients with an acceptable toxicity profile.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36102132/", "endSection": "abstract"}, {"offsetInBeginSection": 564, "offsetInEndSection": 762, "text": "Finally, we summarize findings from a pivotal phase III randomized trial in which tebentafusp demonstrated significant improvement in overall survival in comparison with investigator choice therapy.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36102132/", "endSection": "abstract"}, {"offsetInBeginSection": 1033, "offsetInEndSection": 1191, "text": "Areas of future study should focus on its role in the adjuvant setting as well as strategies to improve the efficacy of tebentafusp in the metastatic setting.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36102132/", "endSection": "abstract"}]}, {"body": "What is the mechanisms of action of Dersimelagon?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/36050717/"], "ideal_answer": "Dersimelagon is a medication that works by blocking the action of certain receptors in the brain called orexin receptors. By blocking these receptors, Dersimelagon helps to regulate sleep-wake cycles and promote sleep in patients with insomnia.", "exact_answer": "Dersimelagon is a medication that works by blocking the action of certain receptors in the brain called melanocortin-4 receptors. By blocking these receptors, Dersimelagon helps to reduce appetite and promote weight loss in individuals with obesity.", "type": "summary", "id": "65d144731930410b13000040", "snippets": []}, {"body": "What are the current indications for thalidomide?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/14713870/", "https://pubmed.ncbi.nlm.nih.gov/23830554/", "https://pubmed.ncbi.nlm.nih.gov/12921515/", "https://pubmed.ncbi.nlm.nih.gov/12952752/", "https://pubmed.ncbi.nlm.nih.gov/15710258/", "https://pubmed.ncbi.nlm.nih.gov/25828060/", "https://pubmed.ncbi.nlm.nih.gov/22786781/", "https://pubmed.ncbi.nlm.nih.gov/25573527/", "https://pubmed.ncbi.nlm.nih.gov/26806146/", "https://pubmed.ncbi.nlm.nih.gov/32760161/"], "ideal_answer": "The current indications for thalidomide include lepromatous nodular erythema, severe aphthosis, Jessner-Kanoff's cutaneous lymphocyte infiltration, discoid lupus erythematosus, chronic graft-versus-host reactions, and relapsed and/or refractory multiple myeloma (after the failure of standard therapies). Thalidomide is also used off-label for conditions such as aphthous stomatitis, Beh\u00e7et disease, pyoderma gangrenosus, chronic discoid lupus erythematosus, systemic lupus erythematosus, lichen planus, prurigo nodularis, and sarcoidosis.", "exact_answer": [["lepromatous nodular erythema"], ["severe aphtosis"], ["Jessner-Kanoff's cutaneous lymphocyte infiltration"], ["discoid lupus erythematosis"], ["chronic graft-versus-host reactions"]], "type": "list", "id": "65f82218c4010b4d7800003e", "snippets": [{"offsetInBeginSection": 124, "offsetInEndSection": 393, "text": "It was thought to be one of the safest sedatives ever produced as it was effective in small doses, was not addictive, and did not have acute side-effects such as motor impairment, but was quickly removed from market after it was linked to cases of severe birth defects.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23830554/", "endSection": "abstract"}, {"offsetInBeginSection": 487, "offsetInEndSection": 905, "text": "Further, it was shown its effectiveness in unresponsive dermatological conditions such as actinic prurigo, adult Langerhans cell hystiocytosis, aphthous stomatitis, Beh\u00e7et syndrome, graft-versus-host disease, cutaneous sarcoidosis, erythema multiforme, Jessner-Kanof lymphocytic infiltration of the skin, Kaposi sarcoma, lichen planus, lupus erythematosus, melanoma, prurigo nodularis, pyoderma gangrenosum and others.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23830554/", "endSection": "abstract"}, {"offsetInBeginSection": 970, "offsetInEndSection": 1045, "text": "New thalidomide analogues have been developed but lack clinical experience.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23830554/", "endSection": "abstract"}, {"offsetInBeginSection": 872, "offsetInEndSection": 969, "text": "Thalidomide has hypnosedative, antiangiogenic, antiinflammatory, and immunomodulatory properties.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/12921515/", "endSection": "abstract"}, {"offsetInBeginSection": 1203, "offsetInEndSection": 1422, "text": "Controlled trials demonstrated the efficacy of thalidomide in a number of diseases, including erythema nodosum leprosum, lupus erythematosus, aphthosis, graft-versus-host disease, prurigo nodularis, and actinic prurigo.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/12921515/", "endSection": "abstract"}, {"offsetInBeginSection": 1423, "offsetInEndSection": 1583, "text": "Single case reports or studies in small series have also suggested a possible role for thalidomide in numerous other dermatologic and nondermatologic disorders.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/12921515/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Thalidomide causes congenital defects in children, such as limb reduction defects.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/25828060/", "endSection": "abstract"}, {"offsetInBeginSection": 230, "offsetInEndSection": 346, "text": "Recently, the prognosis of POEMS was substantially improved by introduction of therapeutic intervention for myeloma.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/25573527/", "endSection": "abstract"}, {"offsetInBeginSection": 144, "offsetInEndSection": 277, "text": "The choice of adequate treatment modality is complicated and depends dominantly on the risk stratification of these fragile patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26806146/", "endSection": "abstract"}, {"offsetInBeginSection": 539, "offsetInEndSection": 607, "text": "Thalidomide is the most ancient representative, effective but toxic.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26806146/", "endSection": "abstract"}]}, {"body": "Do black race patients have worse survival in colorectal cancer?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/35078631/", "https://pubmed.ncbi.nlm.nih.gov/36586755/", "https://pubmed.ncbi.nlm.nih.gov/31600666/", "https://pubmed.ncbi.nlm.nih.gov/36636091/", "https://pubmed.ncbi.nlm.nih.gov/21997132/", "https://pubmed.ncbi.nlm.nih.gov/32621260/", "https://pubmed.ncbi.nlm.nih.gov/23093413/", "https://pubmed.ncbi.nlm.nih.gov/34288237/", "https://pubmed.ncbi.nlm.nih.gov/33234793/", "https://pubmed.ncbi.nlm.nih.gov/35905109/"], "ideal_answer": "Yes, black race patients have been found to have worse survival in colorectal cancer compared to other racial groups. Several studies have shown that black patients with colorectal cancer have lower overall survival rates and poorer outcomes compared to Hispanics and whites. Racial disparities in prognosis and survival outcomes are evident, with black patients experiencing worse outcomes. Factors such as socioeconomic status and health-related quality of life also contribute to these disparities.", "exact_answer": "yes", "type": "yesno", "id": "65f77236c4010b4d7800001f", "snippets": [{"offsetInBeginSection": 72, "offsetInEndSection": 144, "text": "Minority populations with CRC are known to have worse survival outcomes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/31600666/", "endSection": "abstract"}, {"offsetInBeginSection": 1268, "offsetInEndSection": 1370, "text": "Black patients who reported poor Physical and Mental HR-QoL showed significant risk of a poor outcome.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32621260/", "endSection": "abstract"}, {"offsetInBeginSection": 612, "offsetInEndSection": 699, "text": "The study cohort consisted of 38 % Whites, 37 % Asians, 22 % Hispanics, and 4 % Blacks.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23093413/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "We sought to examine the impact of racial residential segregation on Black-White disparities in colorectal cancer diagnosis, surgical resection, and cancer-specific survival.", "beginSection": "title", "document": "https://pubmed.ncbi.nlm.nih.gov/33234793/", "endSection": "title"}]}, {"body": "Is COACH syndrome a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37965976/"], "ideal_answer": "Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension.", "exact_answer": "yes", "type": "yesno", "id": "65f70d71c4010b4d7800001e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37965976/", "endSection": "abstract"}, {"offsetInBeginSection": 459, "offsetInEndSection": 543, "text": "All four patients in our institute were female, and three received living donors LT.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37965976/", "endSection": "abstract"}, {"offsetInBeginSection": 544, "offsetInEndSection": 611, "text": "All patients were diagnosed with COACH syndrome by genetic testing.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37965976/", "endSection": "abstract"}, {"offsetInBeginSection": 677, "offsetInEndSection": 758, "text": "The indication for LT was varices related to portal hypertension in all patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37965976/", "endSection": "abstract"}, {"offsetInBeginSection": 759, "offsetInEndSection": 794, "text": "One showed an intrapulmonary shunt.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37965976/", "endSection": "abstract"}, {"offsetInBeginSection": 795, "offsetInEndSection": 923, "text": "Blood tests revealed renal impairment due to nephronophthisis in three patients, and one developed renal insufficiency after LT.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37965976/", "endSection": "abstract"}, {"offsetInBeginSection": 924, "offsetInEndSection": 974, "text": "The liver function was maintained in all patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37965976/", "endSection": "abstract"}, {"offsetInBeginSection": 975, "offsetInEndSection": 1049, "text": "A literature review revealed detailed information for three more patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37965976/", "endSection": "abstract"}, {"offsetInBeginSection": 1050, "offsetInEndSection": 1159, "text": "The indication for LT in these three cases was portal hypertension, such as bleeding from esophageal varices.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37965976/", "endSection": "abstract"}, {"offsetInBeginSection": 1160, "offsetInEndSection": 1276, "text": "One patient had chronic renal failure on hemodialysis at LT and underwent combined liver and kidney transplantation.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37965976/", "endSection": "abstract"}]}, {"body": "Is Lecanemab approved for Alzheimer\u2019s Disease?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37334596/", "https://pubmed.ncbi.nlm.nih.gov/37357276/", "https://pubmed.ncbi.nlm.nih.gov/37479527/", "https://pubmed.ncbi.nlm.nih.gov/36749830/", "https://pubmed.ncbi.nlm.nih.gov/36931947/", "https://pubmed.ncbi.nlm.nih.gov/37389302/", "https://pubmed.ncbi.nlm.nih.gov/36336488/", "https://pubmed.ncbi.nlm.nih.gov/37045461/", "https://pubmed.ncbi.nlm.nih.gov/35493943/", "https://pubmed.ncbi.nlm.nih.gov/35290498/"], "ideal_answer": "Yes, Lecanemab has received accelerated approval from the Food and Drug Administration (FDA) for the treatment of Alzheimer's Disease.", "exact_answer": "yes", "type": "yesno", "id": "65ce88b71930410b13000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "After the CLARITY-AD clinical trial results of lecanemab were interpreted as positive, and supporting the amyloid hypothesis, the drug received accelerated Food and Drug Administration approval.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37334596/", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 362, "text": "However, we argue that benefits of lecanemab treatment are uncertain and may yield net harm for some patients, and that the data do not support the amyloid hypothesis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37334596/", "endSection": "abstract"}, {"offsetInBeginSection": 486, "offsetInEndSection": 541, "text": "Lecanemab is currently being studied in phase 3 trials.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36749830/", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 345, "text": "Due to the effects of AD, pharmaceutical medications and anticholinesterases have been vigorously promoted and approved by the FDA as a form of AD therapy.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36931947/", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 543, "text": "However, it was progressively found that these drugs did not address the underlying causes of AD pathogenesis; rather, they focused on the symptoms in order to enhance patients' cognitive outcomes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36931947/", "endSection": "abstract"}, {"offsetInBeginSection": 544, "offsetInEndSection": 616, "text": "Consequently, a hunt for superior disease-modifying options is launched.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36931947/", "endSection": "abstract"}, {"offsetInBeginSection": 617, "offsetInEndSection": 783, "text": "Designing new therapeutic agents requires a thorough understanding of the neuroprotective processes and varied functions carried out by certain genes, and antibodies.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36931947/", "endSection": "abstract"}, {"offsetInBeginSection": 784, "offsetInEndSection": 1173, "text": "In this comprehensive review article, we give an overview of the history of Alzheimer's disease, the significance of the blood-brain barrier in determining the scope of treatment options, as well as the advantages and disadvantages of the current therapeutic treatment options for stem cell therapy, immunotherapy, regenerative therapy, and improved Alzheimer's disease care and diagnosis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36931947/", "endSection": "abstract"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1328, "text": "We have also included a discussion on the potential role of aducanumab and Lecanemab as a cutting-edge therapy in refractory Alzheimer's disease patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36931947/", "endSection": "abstract"}, {"offsetInBeginSection": 1329, "offsetInEndSection": 1418, "text": "Lecanemab has been recently approved by the FDA for the treatment of Alzheimer's disease.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36931947/", "endSection": "abstract"}]}, {"body": "What type of extracolonic tumors does the PMS2 germline mutation cause?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/10480359/"], "ideal_answer": "The PMS2 germline mutation can cause various types of extracolonic tumors.", "exact_answer": [["The PMS2 germline mutation can cause various types of extracolonic tumors."]], "type": "factoid", "id": "65f7736fc4010b4d78000024", "snippets": [{"offsetInBeginSection": 1028, "offsetInEndSection": 1171, "text": "We have detected 26 pathogenic germline mutations of the hMLH1 and hMSH2 genes and several novel variants of the hPMS1, hPMS2, and hMSH6 genes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/10480359/", "endSection": "abstract"}]}, {"body": "What disorder is considered off label use for domperidone?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/30361080/"], "ideal_answer": "Domperidone is considered off-label for the treatment of functional dyspepsia.", "exact_answer": [["Functional dyspepsia"]], "type": "factoid", "id": "65f493cac4010b4d78000012", "snippets": [{"offsetInBeginSection": 1063, "offsetInEndSection": 1227, "text": "The primary endpoint was overall satisfactory relief of global dyspepsia symptoms at 12 weeks, via patient-reported assessment in the intention-to-treat population.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30361080/", "endSection": "abstract"}, {"offsetInBeginSection": 2063, "offsetInEndSection": 2276, "text": "Low-dose imipramine should be considered as a possible therapy for patients with functional dyspepsia refractory to both PPIs and prokinetics, although patients should be cautioned about the adverse event profile.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30361080/", "endSection": "abstract"}]}, {"body": "Are Hemoglobin-Based Oxygen Carriers approved for human use?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/17591302/", "https://pubmed.ncbi.nlm.nih.gov/28054978/", "https://pubmed.ncbi.nlm.nih.gov/36443351/", "https://pubmed.ncbi.nlm.nih.gov/28685464/", "https://pubmed.ncbi.nlm.nih.gov/36837597/", "https://pubmed.ncbi.nlm.nih.gov/11336435/", "https://pubmed.ncbi.nlm.nih.gov/31836032/", "https://pubmed.ncbi.nlm.nih.gov/11805546/", "https://pubmed.ncbi.nlm.nih.gov/7635553/", "https://pubmed.ncbi.nlm.nih.gov/16999656/"], "ideal_answer": "No, Hemoglobin-Based Oxygen Carriers are not currently approved for human use in the United States. However, Hemopure has been approved for use in South Africa, and companies producing Hemopure and PolyHem have filed a Biologic License Application in the United States.", "exact_answer": "no", "type": "yesno", "id": "65f84b5ec4010b4d78000048", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Artificial oxygen carriers are not blood substitutes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17591302/", "endSection": "abstract"}, {"offsetInBeginSection": 54, "offsetInEndSection": 149, "text": "They serve to carry oxygen to tissues and are either hemoglobin based or perfluorocarbon based.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17591302/", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 276, "text": "Driving the development of artificial oxygen carriers are concerns involving both the safety and quantity of the blood supply.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17591302/", "endSection": "abstract"}, {"offsetInBeginSection": 277, "offsetInEndSection": 368, "text": "No artificial oxygen carriers are currently approved for clinical use in the United States.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17591302/", "endSection": "abstract"}, {"offsetInBeginSection": 369, "offsetInEndSection": 420, "text": "Hemopure has been approved for use in South Africa.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17591302/", "endSection": "abstract"}, {"offsetInBeginSection": 584, "offsetInEndSection": 634, "text": "Phase III trials have been completed for Hemopure.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17591302/", "endSection": "abstract"}, {"offsetInBeginSection": 128, "offsetInEndSection": 248, "text": "Side-effects such as vasoconstriction, oxidative injury, and cardiac toxicity have prevented clinical approval of HBOCs.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36443351/", "endSection": "abstract"}, {"offsetInBeginSection": 422, "offsetInEndSection": 474, "text": "This included the early trauma trials with HemAssist", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28685464/", "endSection": "abstract"}, {"offsetInBeginSection": 324, "offsetInEndSection": 431, "text": "There are two major categories of oxygen therapeutics, hemoglobin-based and perfluorocarbon-based products.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36837597/", "endSection": "abstract"}, {"offsetInBeginSection": 600, "offsetInEndSection": 738, "text": "Among all of the discussed hemoglobin-based oxygen therapeutics, HemAssist, PolyHeme, Hemolink, Hemospan, and Hemoximer were discontinued.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36837597/", "endSection": "abstract"}]}, {"body": "Do stroke patients have a lower risk of Obstructive Sleep Apnea?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/12800780/", "https://pubmed.ncbi.nlm.nih.gov/32948418/", "https://pubmed.ncbi.nlm.nih.gov/34718272/", "https://pubmed.ncbi.nlm.nih.gov/33688287/", "https://pubmed.ncbi.nlm.nih.gov/31722335/", "https://pubmed.ncbi.nlm.nih.gov/34930802/", "https://pubmed.ncbi.nlm.nih.gov/36516602/", "https://pubmed.ncbi.nlm.nih.gov/31301263/", "https://pubmed.ncbi.nlm.nih.gov/36158070/", "https://pubmed.ncbi.nlm.nih.gov/11775822/"], "ideal_answer": "No, stroke patients do not have a lower risk of Obstructive Sleep Apnea (OSA). In fact, OSA is commonly seen in stroke patients, and it is considered an important risk factor for stroke recurrence and mortality. Studies have shown that OSA is associated with a higher risk of stroke and recurrent stroke in ischemic stroke patients. Additionally, the treatment of OSA with interventions such as continuous positive airway pressure (CPAP) has been shown to improve functional prognosis and lower the risk of cerebral ischemic events in stroke patients.", "exact_answer": "no", "type": "yesno", "id": "65f7080fc4010b4d78000019", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Sleep-related breathing disorders are strongly associated with increased risk of stroke independent of known risk factors.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/12800780/", "endSection": "abstract"}, {"offsetInBeginSection": 487, "offsetInEndSection": 710, "text": "The relationship between sleep-disordered breathing and stroke risk factors is complex, and likely part of the risk for cerebrovascular events is because of higher cardiovascular risk factors in patients with increased RDI.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/12800780/", "endSection": "abstract"}, {"offsetInBeginSection": 1343, "offsetInEndSection": 1545, "text": "Treatment of sleep apnea has been shown to improve quality of life, lower blood pressure, improve sleep quality, improve neurocognitive functioning, and decrease symptoms of excessive daytime sleepiness", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/12800780/", "endSection": "abstract"}, {"offsetInBeginSection": 814, "offsetInEndSection": 931, "text": "Participants with CSA were more likely to be male, and had lower prevalence of obesity than participants without CSA.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32948418/", "endSection": "abstract"}, {"offsetInBeginSection": 995, "offsetInEndSection": 1073, "text": "CSA was uncommon in this large cohort of patients with recent ischemic stroke.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32948418/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Sleep apnea is described as an isolated risk factor for stroke or recurrent stroke which could be cause of death.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34718272/", "endSection": "abstract"}, {"offsetInBeginSection": 114, "offsetInEndSection": 212, "text": "In our study, the aim was to determine whether sleep apnea affects the outcome of stroke patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34718272/", "endSection": "abstract"}, {"offsetInBeginSection": 259, "offsetInEndSection": 388, "text": "The study recruited 232 ischemic stroke patients with moderate-to-severe OSA admitted for inpatient rehabilitation consecutively.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33688287/", "endSection": "abstract"}, {"offsetInBeginSection": 1353, "offsetInEndSection": 1585, "text": "Severe OSA is an independent risk factor for a poor functional prognosis in patients with acute ischemic stroke, and quantitative EEG during sleep showed a significant slow wave enhancement, suggesting more severe brain dysfunction.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36516602/", "endSection": "abstract"}, {"offsetInBeginSection": 1586, "offsetInEndSection": 1647, "text": "The treatment of severe OSA may improve functional prognosis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36516602/", "endSection": "abstract"}]}, {"body": "Should we treat all patients with glaucoma?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38421290/", "https://pubmed.ncbi.nlm.nih.gov/38478513/", "https://pubmed.ncbi.nlm.nih.gov/38419142/", "https://pubmed.ncbi.nlm.nih.gov/38099577/", "https://pubmed.ncbi.nlm.nih.gov/38410906/", "https://pubmed.ncbi.nlm.nih.gov/38112386/", "https://pubmed.ncbi.nlm.nih.gov/38418957/", "https://pubmed.ncbi.nlm.nih.gov/38399328/", "https://pubmed.ncbi.nlm.nih.gov/38430227/", "https://pubmed.ncbi.nlm.nih.gov/38109951/"], "ideal_answer": "The treatment of glaucoma should be individualized based on the specific characteristics and needs of each patient. While glaucoma is a chronic and progressive condition that requires management to prevent vision loss, not all patients with glaucoma may require immediate treatment. The decision to initiate treatment depends on factors such as the severity of the disease, the presence of risk factors, the rate of disease progression, and the patient's overall health and preferences. Regular monitoring and assessment of intraocular pressure, optic nerve health, and visual field are essential in determining the need for treatment and adjusting the treatment plan accordingly.", "exact_answer": "no", "type": "yesno", "id": "65f85f77c4010b4d78000053", "snippets": [{"offsetInBeginSection": 177, "offsetInEndSection": 354, "text": "By offering SLT as an initial drug-free treatment option, we may be able to thwart issues such as adherence and persistence that plague our current medical management protocols.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38421290/", "endSection": "abstract"}, {"offsetInBeginSection": 355, "offsetInEndSection": 531, "text": "In this comprehensive narrative review, we delve into the current body of literature that explores the utility of SLT across a wide spectrum of scenarios and glaucoma subtypes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38421290/", "endSection": "abstract"}, {"offsetInBeginSection": 532, "offsetInEndSection": 686, "text": "We present evidence that provides valuable insight into the efficacy and benefits of SLT, positioning it as a viable option in the management of glaucoma.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38421290/", "endSection": "abstract"}, {"offsetInBeginSection": 814, "offsetInEndSection": 961, "text": "Despite the ample evidence supporting SLT's efficacy, some questions remain regarding its long-term effects and the potential need for retreatment.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38421290/", "endSection": "abstract"}, {"offsetInBeginSection": 962, "offsetInEndSection": 1117, "text": "This review aims to shed light on these aspects to guide clinicians in making informed decisions and tailoring treatment plans to individual patient needs.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38421290/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Intraocular pressure is the only modifiable risk factor for the development and progression of glaucoma.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38478513/", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 210, "text": "Raised intraocular pressure could cause progressive visual field loss and blindness if left uncontrolled.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38478513/", "endSection": "abstract"}, {"offsetInBeginSection": 211, "offsetInEndSection": 315, "text": "Adherence to ocular hypotensive medications is vital to prevent optic nerve damage and its consequences.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38478513/", "endSection": "abstract"}, {"offsetInBeginSection": 538, "offsetInEndSection": 618, "text": "Out of the 68 patients recruited, 56 PACG patients fulfilled the study criteria.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38099577/", "endSection": "abstract"}, {"offsetInBeginSection": 619, "offsetInEndSection": 667, "text": "The mean age of the participants was 58.5 years.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38099577/", "endSection": "abstract"}]}, {"body": "What is IL-35?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38290255/", "https://pubmed.ncbi.nlm.nih.gov/37878703/", "https://pubmed.ncbi.nlm.nih.gov/38225757/", "https://pubmed.ncbi.nlm.nih.gov/34995813/", "https://pubmed.ncbi.nlm.nih.gov/37464473/", "https://pubmed.ncbi.nlm.nih.gov/37988561/", "https://pubmed.ncbi.nlm.nih.gov/35034554/", "https://pubmed.ncbi.nlm.nih.gov/34929655/", "https://pubmed.ncbi.nlm.nih.gov/38203575/", "https://pubmed.ncbi.nlm.nih.gov/37737467/"], "ideal_answer": "IL-35 is a cytokine that belongs to the IL-12 family. It is an immunosuppressive and anti-inflammatory cytokine secreted mainly by regulatory cells. IL-35 has therapeutic and diagnostic potential in cancer and autoimmune diseases.", "exact_answer": "IL-35 is a cytokine that belongs to the IL-12 family. It is an immunosuppressive and anti-inflammatory cytokine secreted mainly by regulatory cells. IL-35 has therapeutic and diagnostic potential in cancer and autoimmune diseases.", "type": "summary", "id": "65f5a319c4010b4d78000016", "snippets": [{"offsetInBeginSection": 526, "offsetInEndSection": 663, "text": "IL-35, the newest member of the IL-12 family, is an immunosuppressive and anti-inflammatory cytokine secreted mainly by regulatory cells.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38290255/", "endSection": "abstract"}, {"offsetInBeginSection": 775, "offsetInEndSection": 868, "text": "IL-35 appears to hold therapeutic and diagnostic potential in cancer and autoimmune diseases.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38290255/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Interleukins are secreted proteins that regulate immune responses.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37878703/", "endSection": "abstract"}, {"offsetInBeginSection": 273, "offsetInEndSection": 419, "text": "Within the IL-12 family, IL-35 remains particularly ill-characterized on a molecular level despite its key role in autoimmune diseases and cancer.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37878703/", "endSection": "abstract"}, {"offsetInBeginSection": 788, "offsetInEndSection": 930, "text": "Together, our study reveals IL-12\u03b1 and EBI3, the subunits of IL-35, to be functionally active anti-inflammatory immune molecules on their own.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37878703/", "endSection": "abstract"}, {"offsetInBeginSection": 449, "offsetInEndSection": 538, "text": "IL-35 increases the number of megakaryocyte colony-forming units through the Akt pathway.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38225757/", "endSection": "abstract"}, {"offsetInBeginSection": 539, "offsetInEndSection": 660, "text": "The level of bone marrow IL-35 is reduced in ITP patients, and the decreased level of IL-35 may inhibit megakaryopoiesis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38225757/", "endSection": "abstract"}, {"offsetInBeginSection": 1080, "offsetInEndSection": 1211, "text": "Iguratimod promotes megakaryocyte development and differentiation by elevating the expression of IL-35 receptors on megakaryocytes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38225757/", "endSection": "abstract"}, {"offsetInBeginSection": 1212, "offsetInEndSection": 1318, "text": "Iguratimod improves response rates and reduces bleeding symptoms in corticosteroid-resistant ITP patients.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38225757/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Cytokines interact closely with each other and play a crucial role in the progression of sepsis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/34995813/", "endSection": "abstract"}]}, {"body": "What is the cause of Leigh syndrome?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/36042640/", "https://pubmed.ncbi.nlm.nih.gov/37974220/", "https://pubmed.ncbi.nlm.nih.gov/38046674/", "https://pubmed.ncbi.nlm.nih.gov/38316835/", "https://pubmed.ncbi.nlm.nih.gov/37861028/", "https://pubmed.ncbi.nlm.nih.gov/36064416/", "https://pubmed.ncbi.nlm.nih.gov/36056365/", "https://pubmed.ncbi.nlm.nih.gov/38243972/", "https://pubmed.ncbi.nlm.nih.gov/37936209/", "https://pubmed.ncbi.nlm.nih.gov/38217609/"], "ideal_answer": "Leigh syndrome is caused by various genetic mutations that affect mitochondrial function, leading to impaired energy production and neurodegeneration. These mutations can involve genes related to mitochondrial DNA or nuclear DNA, resulting in deficiencies in oxidative phosphorylation and the accumulation of toxic metabolites. The exact cause of Leigh syndrome can vary among individuals, with over 110 different genes implicated in its development.", "exact_answer": [["Leigh syndrome can have various causes, including genetic mutations in mitochondrial genes, such as NDUFS7, PNPT1, ECHS1, and MRPS34."]], "type": "factoid", "id": "6451007857b1c7a315000093", "snippets": [{"offsetInBeginSection": 260, "offsetInEndSection": 353, "text": "A 24-day-old full-term male infant presented with a 2-day history of lip cyanosis when crying", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36042640/", "endSection": "abstract"}, {"offsetInBeginSection": 170, "offsetInEndSection": 259, "text": "The study design was approved by the ethics review board of Shenzhen Children's Hospital.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36042640/", "endSection": "abstract"}, {"offsetInBeginSection": 421, "offsetInEndSection": 461, "text": "After birth, the patient was fed poorly.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36042640/", "endSection": "abstract"}, {"offsetInBeginSection": 462, "offsetInEndSection": 606, "text": "A recurrent decrease in peripheral oxygen saturation and difficulty in weaning from mechanical ventilation during hospitalization were observed.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36042640/", "endSection": "abstract"}, {"offsetInBeginSection": 732, "offsetInEndSection": 900, "text": "His lactic acid level increased markedly, and repeat MRI showed symmetrical abnormal signal areas in the bilateral basal ganglia and brainstem with disease progression.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36042640/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Leigh syndrome, an inherited neurometabolic disorder, is estimated to be the most common pediatric manifestation of mitochondrial disease.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37974220/", "endSection": "abstract"}, {"offsetInBeginSection": 139, "offsetInEndSection": 242, "text": "No treatments are currently available for Leigh syndrome due to many hurdles in drug discovery efforts.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37974220/", "endSection": "abstract"}, {"offsetInBeginSection": 243, "offsetInEndSection": 422, "text": "Leigh syndrome causal variants span over 110 different genes and likely lead to both unique and shared biochemical alterations, often resulting in overlapping phenotypic features.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37974220/", "endSection": "abstract"}, {"offsetInBeginSection": 423, "offsetInEndSection": 559, "text": "The mechanisms by which pathogenic variants in mitochondrial genes alter cellular phenotype to promote disease remain poorly understood.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37974220/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Two Jack-Russell Terrier \u00d7 Chihuahua mixed-breed littermates with Leigh syndrome were investigated.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38316835/", "endSection": "abstract"}]}, {"body": "What is the main cause of spillover events?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/31137254/", "https://pubmed.ncbi.nlm.nih.gov/37295151/", "https://pubmed.ncbi.nlm.nih.gov/36031675/", "https://pubmed.ncbi.nlm.nih.gov/32834333/", "https://pubmed.ncbi.nlm.nih.gov/26825428/", "https://pubmed.ncbi.nlm.nih.gov/33291635/", "https://pubmed.ncbi.nlm.nih.gov/36814938/", "https://pubmed.ncbi.nlm.nih.gov/36992358/", "https://pubmed.ncbi.nlm.nih.gov/21711553/", "https://pubmed.ncbi.nlm.nih.gov/18048040/"], "ideal_answer": "The main cause of spillover events is the transmission of pathogens from animals to humans, often due to close contact or consumption of infected animals or their products.", "exact_answer": [["The main cause of spillover events is the introduction of pathogens from animals to humans, often through close contact or consumption of infected animals or their products."]], "type": "factoid", "id": "65f8447fc4010b4d78000043", "snippets": [{"offsetInBeginSection": 1196, "offsetInEndSection": 1341, "text": "Outbreak event data and their causative viruses should be explored biologically and epidemiologically to possibly predict future outbreak events.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/31137254/", "endSection": "abstract"}, {"offsetInBeginSection": 747, "offsetInEndSection": 906, "text": "We then evaluate the carbon market's risk level and spillover effects using combined econometric methods and explore their application in portfolio management.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37295151/", "endSection": "abstract"}, {"offsetInBeginSection": 907, "offsetInEndSection": 1132, "text": "We report three main findings. First, based on our sample of 3217 observations between 2008 and 2022, five factors influencing carbon market risk emerged from the FCM, including OIL, COAL, SP500ENERGY, SPCLEANENERGY, and GPR.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37295151/", "endSection": "abstract"}, {"offsetInBeginSection": 1133, "offsetInEndSection": 1305, "text": "Second, we find a notable rise in risk spillover from GPR to EUA during the Russia-Ukraine conflict and an escalation of total cross-market spillover during extreme events.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37295151/", "endSection": "abstract"}, {"offsetInBeginSection": 1306, "offsetInEndSection": 1474, "text": "Third, our study presents new evidence on the hedging effect for EUA of the SP500ENERGY before the Russia-Ukraine conflict and of the SPCLEANENERGY during the conflict.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37295151/", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 246, "text": "We obtain a state-dependent linear optimal trading strategy, which makes the equilibrium price tractable.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32834333/", "endSection": "abstract"}, {"offsetInBeginSection": 516, "offsetInEndSection": 579, "text": "The model also generates contagion between uncorrelated assets.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32834333/", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 821, "text": "These results are consistent with the main puzzling features observed during market crashes, namely abrupt and asymmetric price movements that are not driven by major news events but coupled with a spillover effect between unrelated markets.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32834333/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "The main lesson from the 2015 Ebola outbreak is that we need to increase global preparedness to better deal with zoonotic disease outbreaks.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26825428/", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 312, "text": "Yet, it might be a more efficient strategy to prevent such zoonotic spillover events in the first place through conservation measures to protect biodiversity and wildlife.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26825428/", "endSection": "abstract"}]}, {"body": "is carotenodermia caused by an excess of lycopene in the diet?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/9830271/", "https://pubmed.ncbi.nlm.nih.gov/10748650/"], "ideal_answer": "No, carotenodermia is not caused by an excess of lycopene in the diet. Carotenodermia is a condition characterized by the accumulation of carotenoids, including beta-carotene, in the skin, leading to a yellow-orange discoloration. Lycopene is a specific type of carotenoid found in tomatoes and other red fruits and vegetables. While excessive intake of lycopene-rich foods may contribute to a temporary discoloration of the skin, it is not the primary cause of carotenodermia. In the given context, the woman's skin color changed to orange-yellow due to excessive intake of carotene-rich seaweed, not lycopene. After discontinuing the seaweed consumption, her skin color returned to normal.", "exact_answer": "no", "type": "yesno", "id": "65ef83acdffffb9b6b000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Carotenodermia may arise from excessive dietary intake of carotene containing foods.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9830271/", "endSection": "abstract"}, {"offsetInBeginSection": 85, "offsetInEndSection": 188, "text": "We reported a 22-year-old woman who had eaten excessive amount of carotene-rich seaweed to lose weight.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9830271/", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 280, "text": "Her skin color changed to orange-yellow, and her serum beta-carotene was 573 micrograms/dl.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9830271/", "endSection": "abstract"}, {"offsetInBeginSection": 281, "offsetInEndSection": 356, "text": "After stopping the ingestion of seaweed, her skin color returned to normal.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/9830271/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Carotenoids are essential pigments in vegetal photosynthetic processes, but they also have important biological functions in animal physiology: beta carotene in particular represents provitamin A.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/10748650/", "endSection": "abstract"}, {"offsetInBeginSection": 197, "offsetInEndSection": 380, "text": "The accumulation of carotenoids in a man results in a cutaneous hyperpigmentation very similar to jaundice: usually this happens in vegetarian subjects after an excessive food eating.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/10748650/", "endSection": "abstract"}]}, {"body": "What type of DMD can golodirsen be used for?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/30171533/", "https://pubmed.ncbi.nlm.nih.gov/34569969/", "https://pubmed.ncbi.nlm.nih.gov/30171536/"], "ideal_answer": "Golodirsen can be used for Duchenne muscular dystrophy (DMD) patients who are amenable to exon 53 skipping.", "exact_answer": [["Golodirsen can be used for Duchenne muscular dystrophy (DMD) patients who are amenable to exon 53 skipping."]], "type": "factoid", "id": "64179034690f196b5100002b", "snippets": [{"offsetInBeginSection": 576, "offsetInEndSection": 707, "text": "Exon inclusion for SMA employs an AON targeting an intronic splice silencer site to include an exon which is otherwise spliced out.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30171536/", "endSection": "abstract"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1274, "text": "A major challenge in exon skipping and exon inclusion is the difficulty in designing effective AONs.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30171536/", "endSection": "abstract"}, {"offsetInBeginSection": 1374, "offsetInEndSection": 1472, "text": "We will discuss the design of effective AONs for exon skipping and exon inclusion in this chapter.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30171536/", "endSection": "abstract"}]}, {"body": "What is the indication for Alirocumab?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/28277798/", "https://pubmed.ncbi.nlm.nih.gov/35052871/", "https://pubmed.ncbi.nlm.nih.gov/35052831/", "https://pubmed.ncbi.nlm.nih.gov/26785741/", "https://pubmed.ncbi.nlm.nih.gov/26892118/", "https://pubmed.ncbi.nlm.nih.gov/27250613/", "https://pubmed.ncbi.nlm.nih.gov/30704246/", "https://pubmed.ncbi.nlm.nih.gov/33599896/", "https://pubmed.ncbi.nlm.nih.gov/26886466/", "https://pubmed.ncbi.nlm.nih.gov/36484754/"], "ideal_answer": "The indication for Alirocumab is for patients who have high cardiovascular risk from established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia and who are unable to achieve LDL-C targets with maximally tolerated dose of statins with or without other lipid-lowering drugs.", "exact_answer": [["The indication for Alirocumab is for patients with high cardiovascular risk from established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who are unable to achieve LDL-C targets with maximally tolerated dose of statins with or without other lipid-lowering drugs."]], "type": "factoid", "id": "65f70b9cc4010b4d7800001c", "snippets": [{"offsetInBeginSection": 477, "offsetInEndSection": 692, "text": "The safety profile appears very promising from the relatively short term studies that have been completed but there are some remaining concerns about long term risks of neurocognitive events and developing diabetes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28277798/", "endSection": "abstract"}, {"offsetInBeginSection": 693, "offsetInEndSection": 909, "text": "Expert opinion: The profound reduction in LDL-C with alirocumab is most likely to translate into cardiovascular benefits in the ODYSSEY OUTCOMES trial and is unlikely in itself to result in any major adverse effects.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28277798/", "endSection": "abstract"}, {"offsetInBeginSection": 910, "offsetInEndSection": 1295, "text": "The high cost and the current lack of long-term safety and efficacy data will restrict the use of alirocumab to patients who have high cardiovascular risk from established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia and who are unable to achieve LDL-C targets with maximally tolerated dose of statins with or without other lipid-lowering drugs.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28277798/", "endSection": "abstract"}, {"offsetInBeginSection": 1296, "offsetInEndSection": 1376, "text": "When further data become available, these indications are likely to be expanded.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28277798/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35052871/", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 842, "text": "A total of 21 participants underwent the first and second investigation. Among these, two participants only received alirocumab twice and 19 patients completed the trial per protocol.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35052871/", "endSection": "abstract"}, {"offsetInBeginSection": 843, "offsetInEndSection": 892, "text": "All of them had atherosclerotic vascular disease.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35052871/", "endSection": "abstract"}, {"offsetInBeginSection": 369, "offsetInEndSection": 462, "text": "A total of 24 patients with an indication for treatment with PCSK9 antibodies were recruited.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35052831/", "endSection": "abstract"}, {"offsetInBeginSection": 1032, "offsetInEndSection": 1081, "text": "All of them had atherosclerotic vascular disease.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35052831/", "endSection": "abstract"}, {"offsetInBeginSection": 214, "offsetInEndSection": 349, "text": "Alirocumab has been shown to lower low density lipoprotein cholesterol by 45-62% with a safety profile generally comparable to placebo.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/26785741/", "endSection": "abstract"}]}, {"body": "Concizumab is used for which diseases?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/37646676/", "https://pubmed.ncbi.nlm.nih.gov/35955419/", "https://pubmed.ncbi.nlm.nih.gov/30614620/", "https://pubmed.ncbi.nlm.nih.gov/36051064/", "https://pubmed.ncbi.nlm.nih.gov/31517711/", "https://pubmed.ncbi.nlm.nih.gov/38481077/", "https://pubmed.ncbi.nlm.nih.gov/30146094/", "https://pubmed.ncbi.nlm.nih.gov/22563084/", "https://pubmed.ncbi.nlm.nih.gov/35521735/", "https://pubmed.ncbi.nlm.nih.gov/32955428/"], "ideal_answer": "Concizumab is used for the treatment of hemophilia, specifically in patients with hemophilia A or B who have inhibitors.", "exact_answer": [["Hemophilia"]], "type": "list", "id": "65cfad2d1930410b13000014", "snippets": [{"offsetInBeginSection": 439, "offsetInEndSection": 566, "text": "Homeostatic therapies consist in replacement and nonreplacement treatments or in the administration of antifibrinolytic agents.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35955419/", "endSection": "abstract"}, {"offsetInBeginSection": 567, "offsetInEndSection": 656, "text": "Rebalancing products reestablish hemostasis by inhibiting natural anticoagulant pathways.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35955419/", "endSection": "abstract"}, {"offsetInBeginSection": 657, "offsetInEndSection": 786, "text": "These agents include monoclonal antibodies, such as concizumab and marstacimab, which target the tissue factor pathway inhibitor.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35955419/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Essentials Hemophilia patients on concizumab prophylaxis may need rFVIIa to treat breakthrough bleeds.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30614620/", "endSection": "abstract"}, {"offsetInBeginSection": 188, "offsetInEndSection": 305, "text": "Until recently, patients relied upon the administration of factor concentrates to prevent or treat bleeding episodes.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36051064/", "endSection": "abstract"}, {"offsetInBeginSection": 541, "offsetInEndSection": 610, "text": "Novel non-factor therapies may offer a solution to these unmet needs.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36051064/", "endSection": "abstract"}, {"offsetInBeginSection": 859, "offsetInEndSection": 978, "text": "We review the available trial data, unanswered questions and challenges associated with these new treatment modalities.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36051064/", "endSection": "abstract"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1156, "text": "Finally, we provide practical management algorithms to aid the general haematologist when faced with a patient receiving emicizumab who requires surgery or may develop bleeding.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36051064/", "endSection": "abstract"}, {"offsetInBeginSection": 2, "offsetInEndSection": 103, "text": "The development of inhibitors continues to be the most important complication in severe hemophilia A.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/31517711/", "endSection": "abstract"}, {"offsetInBeginSection": 251, "offsetInEndSection": 568, "text": "In this paper, we review the prophylactic treatments carried out in the last two decades with the two available bypassing agents and the results of the clinical trials carried out with the new molecules under investigation or already licensed for the prevention of hemorrhagic episodes in hemophilia, like emicizumab.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/31517711/", "endSection": "abstract"}]}, {"body": "What is DEXTR", "documents": ["https://pubmed.ncbi.nlm.nih.gov/34920276/", "https://pubmed.ncbi.nlm.nih.gov/14062075/", "https://pubmed.ncbi.nlm.nih.gov/12043962/", "https://pubmed.ncbi.nlm.nih.gov/37015575/"], "ideal_answer": "DEXTR is an abbreviation for Dextran, which is a complex carbohydrate derived from sucrose. It is commonly used in medicine as a plasma volume expander and to prevent blood clotting during surgery. Dextran can also be used as a drug carrier in targeted drug delivery systems.", "exact_answer": "DEXTR is an abbreviation for Dextran, which is a type of polysaccharide. It is commonly used as a plasma volume expander in medical settings. Dextran can increase blood volume and improve circulation in certain clinical situations.", "type": "summary", "id": "65f37871c4010b4d7800000a", "snippets": []}, {"body": "Is measles immunisation the best public health approach to reduce incidence of measles worldwide?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/27727285/", "https://pubmed.ncbi.nlm.nih.gov/32652940/", "https://pubmed.ncbi.nlm.nih.gov/17100668/"], "ideal_answer": "Measles immunization is one of the most effective public health approaches to reduce the incidence of measles worldwide. Routine vaccination supplemented by planned campaigns is the core of current measles control efforts. However, large outbreaks can still occur, even with control measures in place. Supplementing routine immunization with mass vaccination campaigns triggered by low levels of measles immunity or incident cases can help limit the size of outbreaks. Simulation studies have shown that case- or serosurvey-triggered campaigns can prevent a significant number of measles cases. Therefore, while measles immunization is crucial, a comprehensive approach that includes routine vaccination and targeted campaigns is the best strategy to reduce the incidence of measles worldwide.", "exact_answer": "yes", "type": "yesno", "id": "65f84d20c4010b4d7800004a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Routine vaccination supplemented by planned campaigns occurring at 2-5 y intervals is the core of current measles control and elimination efforts.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27727285/", "endSection": "abstract"}, {"offsetInBeginSection": 147, "offsetInEndSection": 237, "text": "Yet, large, unexpected outbreaks still occur, even when control measures appear effective.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27727285/", "endSection": "abstract"}, {"offsetInBeginSection": 492, "offsetInEndSection": 766, "text": "Measles incidence was simulated using stochastic age-structured epidemic models in settings conducive to high or low measles incidence, roughly reflecting demographic contexts and measles vaccination coverage of four heterogeneous countries: Nepal, Niger, Yemen, and Zambia.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27727285/", "endSection": "abstract"}, {"offsetInBeginSection": 767, "offsetInEndSection": 823, "text": "Uncertainty in underlying vaccination rates was modeled.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27727285/", "endSection": "abstract"}, {"offsetInBeginSection": 824, "offsetInEndSection": 977, "text": "Scenarios with case- or serosurvey-triggered campaigns reaching 20% of the susceptible population were compared to scenarios without triggered campaigns.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27727285/", "endSection": "abstract"}, {"offsetInBeginSection": 1368, "offsetInEndSection": 1461, "text": "Triggered campaigns reduce the highest cumulative incidence seen in simulations by up to 80%.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/27727285/", "endSection": "abstract"}, {"offsetInBeginSection": 96, "offsetInEndSection": 275, "text": "The U.S. was certified measles-free in 2000, but the number of measles cases has increased in recent years breaking the record of the nationwide annual number of cases since 1992.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32652940/", "endSection": "abstract"}, {"offsetInBeginSection": 1703, "offsetInEndSection": 1887, "text": "For building-level interventions, schools with ductless-with-air-filter and ductless-without-air-filter systems have the lowest and highest transmission risks of measles, respectively.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32652940/", "endSection": "abstract"}, {"offsetInBeginSection": 1888, "offsetInEndSection": 2139, "text": "Finally, our simulation showed that infection control strategies could cut the average number of infected cases among all students in half when a combination of advanced air filtration, ventilation, and purification was adopted in the modeled schools.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32652940/", "endSection": "abstract"}, {"offsetInBeginSection": 1237, "offsetInEndSection": 1381, "text": "Combinations of engineering control measures and public health interventions could moderately contain influenza strains with an R0 as high as 4.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/17100668/", "endSection": "abstract"}]}, {"body": "What types of glucosteroids are used for the management of Duchenne muscular dystrophy?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/112945/", "https://pubmed.ncbi.nlm.nih.gov/15820437/", "https://pubmed.ncbi.nlm.nih.gov/5830478/"], "ideal_answer": "Glucocorticoids, specifically prednisone and deflazacort, are commonly used for the management of Duchenne muscular dystrophy (DMD). These glucocorticoids have been shown to improve muscle strength and function, delay the progression of muscle weakness, and prolong ambulation in patients with DMD.", "exact_answer": [["Corticosteroids"]], "type": "list", "id": "64414bdb57b1c7a315000058", "snippets": []}, {"body": "What is an Albatross plot used for?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/28453179/", "https://pubmed.ncbi.nlm.nih.gov/29693517/", "https://pubmed.ncbi.nlm.nih.gov/23194019/", "https://pubmed.ncbi.nlm.nih.gov/33908885/", "https://pubmed.ncbi.nlm.nih.gov/32423407/", "https://pubmed.ncbi.nlm.nih.gov/28978562/", "https://pubmed.ncbi.nlm.nih.gov/37835583/", "https://pubmed.ncbi.nlm.nih.gov/31918756/", "https://pubmed.ncbi.nlm.nih.gov/33375705/", "https://pubmed.ncbi.nlm.nih.gov/33915947/"], "ideal_answer": "An Albatross plot is used as a novel graphical tool to present the results of diversely reported studies in a systematic review. It allows for the visualization of the direction of effect observed in each study, providing a comprehensive overview of the findings and facilitating the identification of sources of heterogeneity across studies.", "exact_answer": [["An Albatross plot is used to present the results of diversely reported studies in a systematic review."]], "type": "factoid", "id": "65f37997c4010b4d7800000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Meta-analyses combine the results of multiple studies of a common question.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28453179/", "endSection": "abstract"}, {"offsetInBeginSection": 76, "offsetInEndSection": 181, "text": "Approaches based on effect size estimates from each study are generally regarded as the most informative.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28453179/", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 407, "text": "However, these methods can only be used if comparable effect sizes can be computed from each study, and this may not be the case due to variation in how the studies were done or limitations in how their results were reported.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28453179/", "endSection": "abstract"}, {"offsetInBeginSection": 408, "offsetInEndSection": 611, "text": "Other methods, such as vote counting, are then used to summarize the results of these studies, but most of these methods are limited in that they do not provide any indication of the magnitude of effect.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28453179/", "endSection": "abstract"}, {"offsetInBeginSection": 815, "offsetInEndSection": 955, "text": "The plot allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28453179/", "endSection": "abstract"}, {"offsetInBeginSection": 956, "offsetInEndSection": 1110, "text": "This is achieved by drawing contours showing the range of effect sizes that might lead to each P value for given sample sizes, under simple study designs.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/28453179/", "endSection": "abstract"}, {"offsetInBeginSection": 530, "offsetInEndSection": 647, "text": "Three episodes of threat and escape were probably added to the albatross episode later, along with an unhappy ending.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/29693517/", "endSection": "abstract"}, {"offsetInBeginSection": 719, "offsetInEndSection": 968, "text": "Although it does have some of the pelvic limb features of grebes and cormorants, the femur of Gansus is more gracile and is thus more consistent with an albatross-like shallow-diving mode of life than a strong foot-propelled diving movement pattern.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/23194019/", "endSection": "abstract"}, {"offsetInBeginSection": 432, "offsetInEndSection": 562, "text": "A multi-database search was used to identify original clinical and preclinical research articles examining RAGE expression in PCa.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37835583/", "endSection": "abstract"}, {"offsetInBeginSection": 563, "offsetInEndSection": 648, "text": "After screening and review, nine clinical and six preclinical articles were included.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/37835583/", "endSection": "abstract"}]}, {"body": "What is the vector for coxiella burnetii transmission?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/33406079/", "https://pubmed.ncbi.nlm.nih.gov/32059686/", "https://pubmed.ncbi.nlm.nih.gov/32141019/", "https://pubmed.ncbi.nlm.nih.gov/10530457/", "https://pubmed.ncbi.nlm.nih.gov/35190334/", "https://pubmed.ncbi.nlm.nih.gov/31589748/", "https://pubmed.ncbi.nlm.nih.gov/12737547/", "https://pubmed.ncbi.nlm.nih.gov/33878245/", "https://pubmed.ncbi.nlm.nih.gov/33957987/", "https://pubmed.ncbi.nlm.nih.gov/11775317/"], "ideal_answer": "The vector for Coxiella burnetii transmission is primarily through inhalation of infectious aerosols, although ticks have also been suggested as potential vectors.", "exact_answer": [["Ticks"]], "type": "factoid", "id": "65f039fdc4010b4d78000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Q fever is a widespread zoonotic disease caused by the intracellular bacterium Coxiella burnetii.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33406079/", "endSection": "abstract"}, {"offsetInBeginSection": 98, "offsetInEndSection": 245, "text": "While transmission is primarily but not exclusively airborne, ticks are usually thought to act as vectors on the basis of early microscopy studies.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33406079/", "endSection": "abstract"}, {"offsetInBeginSection": 246, "offsetInEndSection": 425, "text": "However, recent observations revealed that endosymbionts of ticks have been commonly misidentified as C. burnetii, calling the importance of tick-borne transmission into question.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33406079/", "endSection": "abstract"}, {"offsetInBeginSection": 426, "offsetInEndSection": 564, "text": "In this study, we re-evaluated the vector competence of the African soft tick Ornithodoros moubata for an avirulent strain of C. burnetii.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33406079/", "endSection": "abstract"}, {"offsetInBeginSection": 808, "offsetInEndSection": 1093, "text": "We observed typical traits associated with vector competence: The exposure to an infected blood meal resulted in viable and persistent infections in ticks, trans-stadial transmissions of infection from nymphs to adults and the ability of adult ticks to transmit infectious C. burnetii.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/33406079/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "The bacterium Coxiella burnetii is the etiological agent of Q fever and is mainly transmitted via inhalation of infectious aerosols.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32059686/", "endSection": "abstract"}, {"offsetInBeginSection": 133, "offsetInEndSection": 275, "text": "DNA of C. burnetii is frequently detected in ticks, but the role of ticks as vectors in the epidemiology of this agent is still controversial.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32059686/", "endSection": "abstract"}, {"offsetInBeginSection": 943, "offsetInEndSection": 1209, "text": "Coxiella burnetii DNA was detected in the feces of both tick species during and after feeding on blood containing 10 These findings show that transstadial transmission of C. burnetii occurs in I. ricinus and confirm that I. ricinus is a potential vector for Q fever.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32059686/", "endSection": "abstract"}, {"offsetInBeginSection": 1210, "offsetInEndSection": 1354, "text": "Transmission from both tick species might occur by inhalation of feces containing high amounts of viable C. burnetii rather than via tick bites.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32059686/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Q fever is a widespread zoonosis caused by Coxiella burnetii, an obligate intracellular bacterium, which humans usually acquire through the inhalation of infected dust from subclinically infected mammals.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/10530457/", "endSection": "abstract"}]}, {"body": "Can valproate be used during pregnancy?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38182639/", "https://pubmed.ncbi.nlm.nih.gov/35863137/", "https://pubmed.ncbi.nlm.nih.gov/38260618/", "https://pubmed.ncbi.nlm.nih.gov/38203562/", "https://pubmed.ncbi.nlm.nih.gov/38165339/", "https://pubmed.ncbi.nlm.nih.gov/38223363/", "https://pubmed.ncbi.nlm.nih.gov/37867487/", "https://pubmed.ncbi.nlm.nih.gov/38340680/", "https://pubmed.ncbi.nlm.nih.gov/38335859/", "https://pubmed.ncbi.nlm.nih.gov/38232647/"], "ideal_answer": "Valproate should generally be avoided during pregnancy due to its teratogenic effects. It has been associated with an increased risk of major congenital malformations and adverse neurodevelopmental outcomes in offspring. However, in certain cases where the benefits outweigh the risks, valproate may be used under close monitoring and with informed consent. It is important to discuss the potential risks and benefits with a healthcare provider before considering the use of valproate during pregnancy.", "exact_answer": "no", "type": "yesno", "id": "65d12b451930410b13000031", "snippets": [{"offsetInBeginSection": 827, "offsetInEndSection": 1049, "text": "An equal awareness is warranted that developmental delay in the context of VPA exposure in pregnancy does not necessarily constitute a diagnosis of FVSD but that other competing diagnostic hypotheses have to be considered.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/35863137/", "endSection": "abstract"}, {"offsetInBeginSection": 228, "offsetInEndSection": 306, "text": "However, in pregnancy, it seems to be the most teratogenic antiepileptic drug.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38203562/", "endSection": "abstract"}, {"offsetInBeginSection": 307, "offsetInEndSection": 374, "text": "Among the proven effects are congenital malformations in about 10%.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38203562/", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 647, "text": "These effects are dose related; daily doses below 600 mg have a limited teratogenic potential.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38203562/", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 732, "text": "VPA, when added to other anti-seizure medications, increases the malformations rate.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38203562/", "endSection": "abstract"}, {"offsetInBeginSection": 733, "offsetInEndSection": 891, "text": "It induces malformations even when taken for indications other than epilepsy, adding to the data that epilepsy is not responsible for the teratogenic effects.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38203562/", "endSection": "abstract"}, {"offsetInBeginSection": 892, "offsetInEndSection": 1006, "text": "VPA increases the rate of neurodevelopmental problems causing reduced cognitive abilities and language impairment.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38203562/", "endSection": "abstract"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1289, "text": "High doses of folic acid administered prior to and during pregnancy might alleviate some of the teratogenic effect of VPA and other AEDs.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38203562/", "endSection": "abstract"}, {"offsetInBeginSection": 1290, "offsetInEndSection": 1479, "text": "Several teratogenic mechanisms are proposed for VPA, but the most important mechanisms seem to be its effects on the metabolism of folate, SAMe and histones, thus affecting DNA methylation.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38203562/", "endSection": "abstract"}, {"offsetInBeginSection": 1480, "offsetInEndSection": 1565, "text": "VPA crosses the human placenta and was found at higher concentrations in fetal blood.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38203562/", "endSection": "abstract"}]}, {"body": "What are common side effects of the progesterone-only pill (POP)?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/38393800/", "https://pubmed.ncbi.nlm.nih.gov/3140975/", "https://pubmed.ncbi.nlm.nih.gov/33989805/", "https://pubmed.ncbi.nlm.nih.gov/9926590/", "https://pubmed.ncbi.nlm.nih.gov/12284489/", "https://pubmed.ncbi.nlm.nih.gov/1886418/", "https://pubmed.ncbi.nlm.nih.gov/4180710/"], "ideal_answer": "Common side effects of the progesterone-only pill (POP) include irregular menstrual bleeding, spotting, breast tenderness, headache, nausea, and mood changes.", "exact_answer": [["Common side effects of the progesterone-only pill (POP) include:"], ["1. Irregular menstrual bleeding or spotting"], ["2. Headaches"], ["3. Breast tenderness"], ["4. Nausea"]], "type": "list", "id": "65f847c5c4010b4d78000046", "snippets": [{"offsetInBeginSection": 1226, "offsetInEndSection": 1359, "text": "For patients using norethindrone progestin-only pills, changing to drospirenone progesterone-only pills may help reduce the bleeding.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/38393800/", "endSection": "abstract"}, {"offsetInBeginSection": 754, "offsetInEndSection": 879, "text": "The fear of side effects was an important reason why women did not use the combined pill, being cited by 22 out of 134 women.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/3140975/", "endSection": "abstract"}]}, {"body": "What is Primary Diffuse Meningeal Melanomatosis?", "documents": ["https://pubmed.ncbi.nlm.nih.gov/36412389/", "https://pubmed.ncbi.nlm.nih.gov/20220448/", "https://pubmed.ncbi.nlm.nih.gov/12533338/", "https://pubmed.ncbi.nlm.nih.gov/32004738/", "https://pubmed.ncbi.nlm.nih.gov/30496931/", "https://pubmed.ncbi.nlm.nih.gov/28126183/", "https://pubmed.ncbi.nlm.nih.gov/35166475/", "https://pubmed.ncbi.nlm.nih.gov/31690266/", "https://pubmed.ncbi.nlm.nih.gov/28413547/", "https://pubmed.ncbi.nlm.nih.gov/17330185/"], "ideal_answer": "Primary Diffuse Meningeal Melanomatosis (PDMM) is an extremely rare tumor originating from the melanocytes in the leptomeninges, which are the thin membranes that cover the brain and spinal cord. It is one of the recognized primary melanocytic tumors of the central nervous system. PDMM can clinically mimic various other conditions and is characterized by diffuse meningeal growth and dark coloration due to high melanin content.", "exact_answer": "Primary Diffuse Meningeal Melanomatosis (PDMM) is an extremely rare tumor originating from the melanocytes in the leptomeninges, which are the thin membranes that cover the brain and spinal cord. It is one of the recognized primary melanocytic tumors of the central nervous system. PDMM can clinically mimic various other conditions and is characterized by diffuse meningeal growth and dark coloration due to high melanin content.", "type": "summary", "id": "65d129621930410b1300002e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Meningeal melanomatosis is an infrequent tumor originating from the melanocytes in the leptomeninges and one of the recognized primary melanocytic tumors of the central nervous system.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/36412389/", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "Primary diffuse meningeal melanomatosis can clinically mimic a wide variety of other conditions, including lymphoma, leukemia, neurosarcoidosis, metastatic carcinoma, acute disseminated encephalomyelitis, subacute meningitis, viral encephalitis, and idiopathic hypertrophic cranial pachymeningitis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/20220448/", "endSection": "abstract"}, {"offsetInBeginSection": 299, "offsetInEndSection": 372, "text": "We report on a young patient with primary diffuse meningeal melanomatosis", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/20220448/", "endSection": "abstract"}, {"offsetInBeginSection": 270, "offsetInEndSection": 515, "text": "CT revealed hydrocephalus with effacement of the cerebral convexity sulci and abnormal contrast enhancement in the right sylvian and frontoparietal fissures, whereas MR imaging showed diffuse marked dural and leptomeningeal contrast enhancement.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/12533338/", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 230, "text": "A 21-year-old man presented with recurrent seizure and impaired memory.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32004738/", "endSection": "abstract"}, {"offsetInBeginSection": 231, "offsetInEndSection": 371, "text": "Cranial magnetic resonance imaging showed obvious brain atrophy with bilateral extensive meningeal enhancement in the supratentorial region.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32004738/", "endSection": "abstract"}, {"offsetInBeginSection": 493, "offsetInEndSection": 586, "text": "Microscopic examination revealed invasion of pigment into the Virchow-Robin space and cortex.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32004738/", "endSection": "abstract"}, {"offsetInBeginSection": 817, "offsetInEndSection": 921, "text": "Pathohistologic results of biopsied meninges confirmed the diagnosis of diffuse meningeal melanomatosis.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/32004738/", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 216, "text": "We report a rare case of PDLM without evidence of a primary focus.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30496931/", "endSection": "abstract"}, {"offsetInBeginSection": 335, "offsetInEndSection": 400, "text": "In the reported case, making the diagnosis of PDLM was difficult.", "beginSection": "abstract", "document": "https://pubmed.ncbi.nlm.nih.gov/30496931/", "endSection": "abstract"}]}]}
